BioMedLib Search Engine
[ goto HOMEPAGE ]
Search the biomedical literature, for the most relevant articles.
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
aids related non hodgkin's lymphoma 2005:2010[pubdate] *count=100
176 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
aids related non hodgkin's lymphoma
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 176
1.
Metta H, Corti M, Maranzana A, Schtirbu R, Narbaitz M, De Dios Soler M:
Unusual case of plasmablastic non-Hodgkin's lymphoma located in the liver. First case reported in an AIDS patient.
Ann Hepatol
; 2009 Jul-Sep;8(3):242-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Unusual case of plasmablastic
non
-
Hodgkin's lymphoma
located in the liver. First case reported in an
AIDS
patient.
Plasmablastic
lymphoma
is a rare and a relatively new entity that was first described in the jaws and the oral cavity of HIV-
AIDS
patients.
We report a case of plasmablastic
lymphoma
involving the liver in an
AIDS
patient.
Plasmablastic
lymphoma
is considered a diffuse large B-cell
lymphoma
with a unique phenotype and predilection for the oral cavity.
[MeSH-major]
Acquired Immunodeficiency Syndrome / complications. Liver Neoplasms / diagnosis.
Lymphoma
,
AIDS
-
Related
/ diagnosis.
Lymphoma
, Large B-Cell, Diffuse / diagnosis.
Lymphoma
,
Non
-
Hodgkin
/ diagnosis
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19841505.001).
[ISSN]
1665-2681
[Journal-full-title]
Annals of hepatology
[ISO-abbreviation]
Ann Hepatol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Mexico
[Chemical-registry-number]
0 / Interferon Regulatory Factors; 0 / Syndecan-1; 0 / interferon regulatory factor-4
2.
Bolarinwa RA, Ndakotsu MA, Oyekunle AA, Salawu L, Akinola NO, Durosinmi MA:
AIDS-related lymphomas in Nigeria.
Braz J Infect Dis
; 2009 Oct;13(5):359-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
AIDS
-
related
lymphomas in Nigeria.
Aggressive
non
-
Hodgkin's lymphoma
(
NHL
), including primary central nervous system (CNS)
lymphoma
, lymphoblastic
lymphoma
and
non
-endemic Burkitt's
lymphoma
have been recognized as
AIDS
-defining cancers in most developed countries.
However, HIV/
AIDS
epidemics appear not to have been associated with higher incidence of lymphomas in Africa.
We therefore carried out this study to highlight the significance or otherwise of HIV/
AIDS
epidemics in the pathogenesis of lymphomas in a population of Nigerians with the disease.
Patients with a histological diagnosis of malignant chronic lymphoproliferative diseases {
non
-
Hodgkin
lymphoma
(
NHL
), chronic lymphocytic leukaemia (CLL), Burkitt's
lymphoma
(BL) and
Hodgkin
lymphoma
(HL)} at the Obafemi Awolowo University Teaching Hospitals' Complex, Ile-Ife from January 1993 to August 2008 were noted.
Those patients confirmed to be HIV/
AIDS
positive among the cohort with lymphomas were retrospectively studied using their clinical case notes.
A total of 391 patients were histologically confirmed to have
lymphoma
{
NHL
-109, (27.9%); CLL-76, (19.4%); BL-178, (45.5%) and HL-28, (7.2%)} during the study period.
Six of these, five males and one female, ages 24-60 (median = 37.5) years, had
NHL
while another three, all females (age 50 - 68 years; median = 56 years) had CLL.
Patients with
NHL
presented at advanced stage of the disease (at least clinical stage IIIb), and all those with CLL presented at stage C of the International Working Party Classification.
All the HIV-positive patients with
NHL
succumbed to the disease within one to three weeks of admission into the hospital.
The prevalence of
AIDS
-
related
lymphomas is 2.3% compared to 4.4% found in the general population.
However, it is interesting that no single case of
AIDS
-associated BL was seen, despite the fact that Burkitt's
lymphoma
is endemic in this part of the world.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ epidemiology
Genetic Alliance.
consumer health - AIDS-HIV
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20428636.001).
[ISSN]
1678-4391
[Journal-full-title]
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
[ISO-abbreviation]
Braz J Infect Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Brazil
3.
Caimi PF, Barr PM, Berger NA, Lazarus HM:
Non-Hodgkin's lymphoma in the elderly.
Drugs Aging
; 2010 Mar 01;27(3):211-38
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Non
-
Hodgkin's lymphoma
in the elderly.
The expansion of older population segments and the continuous increase in the incidence of
non
-
Hodgkin's lymphoma
(
NHL
) makes this group of neoplasms an important and growing problem.
Older
NHL
patients have increased risk of therapy-
related
toxicity as a result of age-
related
physiological changes and frequent co-morbidities.
The comprehensive geriatric assessment (CGA) is one multidisciplinary tool that has been applied successfully to older cancer patients and
aids
in identification of subjects who will or will not benefit from anti-neoplastic treatment.
Diffuse large B-cell
lymphoma
is an aggressive but potentially curable disease.
Highly selected individuals up to age 70 years may attain long-term survival benefit from autoHCT, although transplant-
related
mortality is higher than in younger patients.
[MeSH-major]
Aging / physiology. Antineoplastic Agents / therapeutic use.
Lymphoma
,
Non
-
Hodgkin
/ physiopathology.
Lymphoma
,
Non
-
Hodgkin
/ therapy
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Seniors' Health
.
Hazardous Substances Data Bank.
RITUXIMAB
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2005 Aug 1;23(22):5019-26
[
15983392.001
]
[Cites]
Blood. 2008 Jun 15;111(12 ):5486-95
[
18390837.001
]
[Cites]
Clin Pharmacokinet. 2003;42(9):779-91
[
12882586.001
]
[Cites]
Semin Oncol. 2002 Feb;29(1S2):25-29
[
28140088.001
]
[Cites]
Oncology (Williston Park). 2007 Aug;21(9):1104-10
[
17910313.001
]
[Cites]
Clin Pharmacokinet. 1996 Jul;31(1):47-64
[
8827399.001
]
[Cites]
N Engl J Med. 1993 Apr 8;328(14):1002-6
[
7680764.001
]
[Cites]
J Clin Oncol. 2007 Mar 1;25(7):787-92
[
17228021.001
]
[Cites]
J Clin Oncol. 2001 Jan 15;19(2):389-97
[
11208830.001
]
[Cites]
J Clin Oncol. 2004 Aug 1;22(15):3032-8
[
15210738.001
]
[Cites]
Best Pract Res Clin Haematol. 2005 Mar;18(1):81-95
[
15694186.001
]
[Cites]
Blood. 1990 Oct 1;76(7):1293-8
[
2207307.001
]
[Cites]
J Clin Oncol. 2005 Jun 20;23(18):4117-26
[
15867204.001
]
[Cites]
Blood. 2004 Aug 1;104(3):634-41
[
15016643.001
]
[Cites]
Cancer. 2008 May 15;112(10):2228-32
[
18338745.001
]
[Cites]
Eur J Haematol. 2008 Feb;80(2):127-32
[
18005385.001
]
[Cites]
Crit Rev Oncol Hematol. 2008 Oct;68 Suppl 1:S1-8
[
18752969.001
]
[Cites]
J Clin Oncol. 2006 Jul 1;24(19):3187-205
[
16682719.001
]
[Cites]
Eur J Cancer. 2003 May;39(7):870-80
[
12706355.001
]
[Cites]
J Clin Oncol. 2009 Jun 20;27(18):3036-43
[
19414675.001
]
[Cites]
J Clin Oncol. 1995 Jul;13(7):1726-33
[
7602362.001
]
[Cites]
J Clin Oncol. 2009 Aug 10;27(23):3822-9
[
19581539.001
]
[Cites]
Blood. 2002 Sep 1;100(5):1559-65
[
12176870.001
]
[Cites]
Curr Treat Options Oncol. 2006 Jul;7(4):285-94
[
16916489.001
]
[Cites]
Lancet Oncol. 2006 May;7(5):357-9
[
16648037.001
]
[Cites]
J Clin Oncol. 2004 Apr 15;22(8):1454-9
[
15024027.001
]
[Cites]
Blood. 2005 Feb 15;105(4):1417-23
[
15494430.001
]
[Cites]
Oncology (Williston Park). 2007 Sep;21(10):1191-8; discussion 1198-1208, 1210
[
17926798.001
]
[Cites]
Blood. 2005 May 15;105(10):3817-23
[
15687232.001
]
[Cites]
Crit Rev Oncol Hematol. 2000 Feb;33(2):119-28
[
10737373.001
]
[Cites]
Am J Geriatr Pharmacother. 2008 Aug;6(3):153-60
[
18775390.001
]
[Cites]
Cancer Control. 2007 Jan;14(1):44-56
[
17242670.001
]
[Cites]
Crit Rev Oncol Hematol. 2005 Sep;55(3):241-52
[
16084735.001
]
[Cites]
Ann Oncol. 2007 Jul;18(7):1216-23
[
17470451.001
]
[Cites]
J Clin Oncol. 2004 Nov 1;22(21):4302-11
[
15381684.001
]
[Cites]
Blood. 2006 Jan 1;107(1):265-76
[
16150940.001
]
[Cites]
Ann Oncol. 2009 Mar;20(3):520-5
[
19074748.001
]
[Cites]
Semin Hematol. 1999 Apr;36(2):115-27
[
10319380.001
]
[Cites]
J Clin Oncol. 2003 Nov 1;21(21):3918-27
[
14517188.001
]
[Cites]
Br J Haematol. 2005 May;129(3):366-72
[
15842660.001
]
[Cites]
Leuk Lymphoma. 2008;49 Suppl 1:43-51
[
18821432.001
]
[Cites]
J Clin Oncol. 2007 Jul 20;25(21):3158-67
[
17634496.001
]
[Cites]
Br J Haematol. 2009 May;145(3):344-9
[
19245430.001
]
[Cites]
J Clin Oncol. 2004 Aug 1;22(15):2982-4
[
15210737.001
]
[Cites]
Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 2:S43-9
[
18284715.001
]
[Cites]
Bull Cancer. 2008 May 28;95 FMC Onco:F79-83
[
18511372.001
]
[Cites]
N Engl J Med. 1995 Dec 7;333(23):1540-5
[
7477169.001
]
[Cites]
Leuk Lymphoma. 1999 Jul;34(3-4):273-85
[
10439364.001
]
[Cites]
J Clin Oncol. 2008 Jan 10;26(2):204-10
[
18182663.001
]
[Cites]
Am J Health Syst Pharm. 2007 Mar 15;64(6):652-60
[
17353576.001
]
[Cites]
J Clin Oncol. 2002 May 15;20(10 ):2453-63
[
12011122.001
]
[Cites]
N Engl J Med. 1992 Oct 22;327(17):1209-15
[
1406793.001
]
[Cites]
Blood. 2004 Sep 1;104(5):1258-65
[
15126323.001
]
[Cites]
J Clin Oncol. 2009 Mar 10;27(8):1209-13
[
19188674.001
]
[Cites]
J Clin Oncol. 2005 Jul 1;23(19):4390-8
[
15994148.001
]
[Cites]
J Clin Oncol. 2000 Apr;18(7):1412-22
[
10735888.001
]
[Cites]
Aging Clin Exp Res. 2005 Jun;17(3):181-5
[
16110729.001
]
[Cites]
J Clin Oncol. 2008 Sep 20;26(27):4473-9
[
18626004.001
]
[Cites]
Leukemia. 2007 Nov;21(11):2324-31
[
17637813.001
]
[Cites]
Bone Marrow Transplant. 2000 May;25(9):957-64
[
10800063.001
]
[Cites]
J Immunol. 2009 Jul 1;183(1):749-58
[
19535640.001
]
[Cites]
J Clin Oncol. 2006 May 1;24(13):2105-12
[
16606971.001
]
[Cites]
J Clin Oncol. 2008 Oct 1;26(28):4579-86
[
18662969.001
]
[Cites]
Cancer. 1983 Aug 1;52(3):393-8
[
6344979.001
]
[Cites]
J Clin Oncol. 2009 Apr 1;27(10):1607-14
[
19255334.001
]
[Cites]
Clin Geriatr Med. 1997 May;13(2):251-63
[
9115450.001
]
[Cites]
J Clin Oncol. 1997 Aug;15(8):2945-53
[
9256139.001
]
[Cites]
N Engl J Med. 1993 Sep 30;329(14):1046
[
8366915.001
]
[Cites]
Biol Blood Marrow Transplant. 2008 Dec;14(12):1323-33
[
19041053.001
]
[Cites]
Cochrane Database Syst Rev. 2008 Oct 08;(4):CD003189
[
18843642.001
]
[Cites]
J Clin Oncol. 2006 Aug 20;24(24):3880-6
[
16864854.001
]
[Cites]
J Clin Oncol. 2005 Mar 20;23(9):1984-92
[
15668467.001
]
[Cites]
Blood. 2006 Dec 15;108(13):4003-8
[
16946304.001
]
[Cites]
Haematologica. 2002 Jan;87(1):33-43
[
11801463.001
]
[Cites]
Blood. 2005 Apr 1;105(7):2677-84
[
15591112.001
]
[Cites]
Br J Haematol. 2008 Jun;142(2):149-65
[
18410453.001
]
[Cites]
J Clin Oncol. 2005 Aug 10;23(23):5347-56
[
15983389.001
]
[Cites]
J Clin Oncol. 2003 Sep 1;21(17):3214-9
[
12874269.001
]
[Cites]
Cancer. 1976 Oct;38(4):1484-93
[
791473.001
]
[Cites]
J Clin Oncol. 1986 Mar;4(3):295-305
[
3512783.001
]
[Cites]
Hematol Oncol. 1989 Sep-Oct;7(5):365-80
[
2670728.001
]
[Cites]
Ann Hematol. 2001 Jul;80(7):398-405
[
11529465.001
]
[Cites]
Blood. 2003 May 15;101(10):3840-8
[
12531794.001
]
[Cites]
J Am Geriatr Soc. 2001 Dec;49(12):1691-9
[
11844005.001
]
[Cites]
Br J Haematol. 2007 Jan;136(2):191-202
[
17073892.001
]
[Cites]
J Clin Oncol. 2005 Nov 20;23(33):8447-52
[
16230674.001
]
[Cites]
N Engl J Med. 2005 Mar 24;352(12):1197-205
[
15788496.001
]
[Cites]
J Clin Oncol. 2007 Jun 20;25(18):2554-9
[
17515573.001
]
[Cites]
Radiother Oncol. 1995 Sep;36(3):167-71
[
8532901.001
]
[Cites]
Blood. 2004 May 15;103(10):3684-8
[
14739217.001
]
[Cites]
Eur J Cancer. 2006 Oct;42(15):2433-53
[
16750358.001
]
[Cites]
Clin Lymphoma. 2001 Jun;2(1):47-56
[
11707870.001
]
[Cites]
Leuk Lymphoma. 2008;49 Suppl 1:59-66
[
18821434.001
]
[Cites]
Blood. 2004 Oct 15;104(8):2269-71
[
15166030.001
]
[Cites]
Blood. 1994 Oct 15;84(8):2726-32
[
7919385.001
]
[Cites]
Semin Oncol. 1993 Feb;20(1):43-9
[
8475409.001
]
[Cites]
Cancer. 2004 Oct 15;101(8):1835-42
[
15386331.001
]
[Cites]
Ann Oncol. 2007 Jan;18(1):116-21
[
16971665.001
]
[Cites]
Br J Haematol. 2003 Aug;122(3):413-23
[
12877668.001
]
[Cites]
J Clin Oncol. 1994 Jun;12(6):1169-76
[
8201379.001
]
[Cites]
Blood. 2004 Aug 1;104(3):626-33
[
14982884.001
]
[Cites]
Blood. 1999 Jul 1;94(1):33-8
[
10381495.001
]
[Cites]
J Clin Oncol. 2006 Jul 1;24(19):3121-7
[
16754935.001
]
[Cites]
Ann Oncol. 2006 Sep;17 (9):1418-23
[
16766582.001
]
[Cites]
Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6
[
2456618.001
]
[Cites]
N Engl J Med. 1998 Sep 24;339(13):900-5
[
9744975.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1219-27
[
11728680.001
]
[Cites]
Expert Rev Anticancer Ther. 2008 Oct;8(10):1651-8
[
18925856.001
]
[Cites]
Blood. 2005 Dec 1;106(12):3725-32
[
16123223.001
]
[Cites]
Ann Oncol. 2008 Jul;19(7):1327-30
[
18349031.001
]
[Cites]
J Clin Oncol. 2005 Feb 1;23(4):667-75
[
15613697.001
]
[Cites]
Lancet. 2003 Aug 16;362(9383):516-22
[
12932382.001
]
[Cites]
Ann Intern Med. 2002 Jan 15;136(2):144-52
[
11790067.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):928-34
[
16243446.001
]
[Cites]
Eur J Cancer. 2008 Mar;44(4):579-87
[
18242077.001
]
[Cites]
J Clin Oncol. 2007 May 20;25(15):1986-92
[
17420513.001
]
[Cites]
J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301
[
16985248.001
]
[Cites]
Cancer. 2003 Dec 15;98(12):2630-5
[
14669282.001
]
[Cites]
Cancer Invest. 2007 Dec;25(8):766-75
[
18058474.001
]
[Cites]
J Clin Oncol. 2008 Jul 1;26(19):3159-65
[
18591554.001
]
[Cites]
Ann Oncol. 2008 Jun;19 Suppl 4:iv60-2
[
18519407.001
]
[Cites]
Cancer Control. 2003 Nov-Dec;10(6):487-99
[
14652525.001
]
[Cites]
J Clin Oncol. 2003 Jun 15;21(12):2407-14
[
12805341.001
]
[Cites]
N Engl J Med. 1998 Jul 2;339(1):21-6
[
9647875.001
]
[Cites]
Cancer Control. 1996 Oct;3(5 Suppl 1):5-14
[
10765230.001
]
[Cites]
J Clin Oncol. 1997 Mar;15(3):1110-7
[
9060552.001
]
[Cites]
Blood. 2004 Nov 1;104(9):2667-74
[
15238420.001
]
[Cites]
J Natl Cancer Inst. 2007 May 2;99(9):706-14
[
17470738.001
]
[Cites]
Bone Marrow Transplant. 2001 Mar;27(6):593-9
[
11319588.001
]
[Cites]
J Clin Oncol. 2005 Feb 1;23(4):676-84
[
15613699.001
]
[Cites]
Nephron. 1976;16(1):31-41
[
1244564.001
]
[Cites]
J Clin Oncol. 2005 Feb 20;23(6):1088-95
[
15657401.001
]
[Cites]
J Clin Oncol. 2002 Dec 15;20(24):4643-8
[
12488408.001
]
[Cites]
J Clin Oncol. 2006 Apr 1;24(10):1582-9
[
16575009.001
]
[Cites]
Lancet. 2009 Oct 31;374(9700):1512-20
[
19767089.001
]
[Cites]
J Clin Oncol. 2002 Oct 15;20(20):4261-7
[
12377971.001
]
[Cites]
J Clin Oncol. 1998 Jan;16(1):13-8
[
9440717.001
]
[Cites]
J Clin Oncol. 2005 Oct 1;23(28):7013-23
[
16145068.001
]
[Cites]
J Clin Oncol. 2005 May 20;23(15):3383-9
[
15908650.001
]
[Cites]
Ann Oncol. 1995 Mar;6(3):257-62
[
7612491.001
]
[Cites]
J Clin Oncol. 1996 Apr;14(4):1282-90
[
8648385.001
]
[Cites]
Clin Cancer Res. 2008 Jan 1;14(1):309-17
[
18172283.001
]
[Cites]
Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix
[
18954744.001
]
[Cites]
Hematol Oncol Clin North Am. 2008 Oct;22(5):1037-49, x-xi
[
18954750.001
]
[Cites]
Blood. 1997 May 1;89(9):3129-35
[
9129015.001
]
[Cites]
J Clin Oncol. 1995 Oct;13(10):2530-9
[
7595704.001
]
[Cites]
Semin Oncol. 2003 Feb;30(1S2):9-15
[
28140221.001
]
[Cites]
J Clin Oncol. 2009 Mar 10;27(8):1202-8
[
19204203.001
]
[Cites]
Blood. 2004 Nov 15;104(10):3064-71
[
15284112.001
]
[Cites]
Cancer Control. 2007 Jan;14(1):7-12
[
17242666.001
]
[Cites]
J Clin Oncol. 1998 Jul;16(7):2352-8
[
9667250.001
]
[Cites]
Leuk Lymphoma. 2009 Jan;50(1):47-53
[
19152172.001
]
[Cites]
Cancer. 2005 Nov 1;104(9):1998-2005
[
16206252.001
]
[Cites]
Ann Hematol. 2007 Feb;86(2):95-100
[
17031689.001
]
[Cites]
Nat Rev Cancer. 2009 Sep;9(9):675-81
[
19701243.001
]
[Cites]
Curr Opin Oncol. 2008 Sep;20(5):502-8
[
19106651.001
]
[Cites]
Bone Marrow Transplant. 2007 Nov;40(10):973-8
[
17873917.001
]
[Cites]
Cancer. 1997 Oct 1;80(7):1302-10
[
9317183.001
]
[Cites]
Blood. 2008 Feb 1;111(3):1094-100
[
18003886.001
]
[Cites]
Haematologica. 2008 Dec;93(12):1837-42
[
18838474.001
]
[Cites]
Blood. 2007 Mar 1;109(5):1857-61
[
17105812.001
]
[Cites]
Ann Intern Med. 1990 May 1;112(9):699-706
[
2334082.001
]
[Cites]
Drugs Aging. 2003;20(10):737-59
[
12875610.001
]
[Cites]
J Clin Oncol. 1989 Nov;7(11):1748-56
[
2681557.001
]
[Cites]
J Clin Oncol. 2002 Jan 15;20(2):494-502
[
11786579.001
]
[Cites]
Eur J Cancer. 1998 Feb;34(3):329-36
[
9640217.001
]
[Cites]
Gerontology. 1999 Sep-Oct;45(5):243-53
[
10460985.001
]
[Cites]
Blood. 1997 Jun 1;89(11):3909-18
[
9166827.001
]
[Cites]
Haematologica. 2006 Jan;91(1):11-6
[
16434365.001
]
[Cites]
J Clin Oncol. 2003 Aug 15;21(16):3051-9
[
12837807.001
]
[Cites]
J Clin Oncol. 1998 Mar;16(3):859-63
[
9508166.001
]
[Cites]
Ann Oncol. 1994;5 Suppl 2:67-71
[
7515649.001
]
[Cites]
Blood. 2006 Nov 15;108(10):3295-301
[
16873669.001
]
[Cites]
N Engl J Med. 1984 Dec 6;311(23):1471-5
[
6548796.001
]
[Cites]
Hematol Oncol Clin North Am. 2008 Oct;22(5):863-82, viii
[
18954741.001
]
[Cites]
N Engl J Med. 2002 Jan 24;346(4):235-42
[
11807147.001
]
[Cites]
J Clin Oncol. 1998 Jan;16(1):27-34
[
9440719.001
]
[Cites]
Semin Radiat Oncol. 2007 Jul;17(3):169-75
[
17591563.001
]
[Cites]
N Engl J Med. 2008 Aug 7;359(6):613-26
[
18687642.001
]
[Cites]
Blood. 2006 Oct 15;108(8):2540-4
[
16835383.001
]
[Cites]
J Clin Oncol. 2009 Mar 20;27(9):1492-501
[
19224851.001
]
[Cites]
J Clin Oncol. 2003 Jan 1;21(1):5-15
[
12506163.001
]
[Cites]
J Clin Oncol. 2004 Apr 15;22(8):1469-79
[
15084620.001
]
[Cites]
Ann Oncol. 1997 Jul;8(7):675-80
[
9296221.001
]
[Cites]
J Clin Oncol. 2006 Oct 20;24(30):4867-74
[
17001068.001
]
[Cites]
J Natl Cancer Inst. 2009 Feb 18;101(4):248-55
[
19211444.001
]
[Cites]
Blood. 2008 Oct 1;112(7):2687-93
[
18625886.001
]
[Cites]
Blood. 2001 Jan 1;97(1):101-6
[
11133748.001
]
[Cites]
Blood. 2002 Jun 15;99(12 ):4336-42
[
12036859.001
]
[Cites]
Lancet Neurol. 2009 Jun;8(6):581-92
[
19446277.001
]
[Cites]
Blood Rev. 2009 May;23(3):137-42
[
18951668.001
]
[Cites]
Cancer Invest. 2006 Oct;24(6):593-600
[
16982464.001
]
[Cites]
Cancer. 2006 Oct 1;107(7):1530-41
[
16933332.001
]
[Cites]
Cancer Control. 2002 May-Jun;9(3):203-11
[
12060818.001
]
[Cites]
Blood. 2001 Jan 15;97(2):404-9
[
11154216.001
]
[Cites]
J Clin Oncol. 2003 Aug 15;21(16):3041-50
[
12915593.001
]
[Cites]
J Clin Oncol. 1998 Aug;16(8):2825-33
[
9704735.001
]
[Cites]
Lancet Oncol. 2006 May;7(5):379-91
[
16648042.001
]
[Cites]
J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51
[
10922409.001
]
[Cites]
Cancer. 2002 Apr 1;94(7):2015-23
[
11932904.001
]
[Cites]
J Clin Oncol. 2008 Mar 20;26(9):1544-52
[
18285605.001
]
[Cites]
J Clin Oncol. 2002 Feb 1;20(3):770-5
[
11821460.001
]
[Cites]
Lancet Oncol. 2008 Feb;9(2):105-16
[
18226581.001
]
[Cites]
J Clin Oncol. 1998 Dec;16(12):3803-9
[
9850025.001
]
[Cites]
Blood. 2009 Apr 23;113(17):3896-902
[
19144985.001
]
[Cites]
J Clin Oncol. 2009 Feb 1;27(4):511-8
[
19075279.001
]
[Cites]
J Clin Oncol. 2008 Oct 20;26(30):4952-7
[
18606983.001
]
[Cites]
Blood. 2009 Apr 30;113(18):4144-52
[
19168784.001
]
[Cites]
J Clin Oncol. 2002 Aug 1;20(15):3262-9
[
12149300.001
]
(PMID = 20210368.001).
[ISSN]
1179-1969
[Journal-full-title]
Drugs & aging
[ISO-abbreviation]
Drugs Aging
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
New Zealand
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
Advertisement
4.
Epeldegui M, Breen EC, Hung YP, Boscardin WJ, Detels R, Martínez-Maza O:
Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS-NHL diagnosis.
AIDS
; 2007 Nov 12;21(17):2265-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes
AIDS
-
NHL
diagnosis.
Non
-
Hodgkin's
B cell
lymphoma
(
NHL
) is a common cancer in HIV infection.
Many
NHL
are thought to result from errors in class switch recombination and/or somatic hypermutation, processes that occur in germinal center B cells, and require the activity of activation induced cytidine deaminase (AID).
Since
NHL
is a common cancer in HIV infection, and expression of AID could contribute to the development of
NHL
, we hypothesized that AID expression would be elevated in those who went on to develop
AIDS
-associated
NHL
(
AIDS
-
NHL
).
AID mRNA levels were measured by TaqMan RT-PCR in peripheral blood mononuclear cells, obtained prior to
AIDS
-
NHL
diagnosis, from 16 HIV-infected subjects who developed
AIDS
-
NHL
, and from control subjects (
AIDS
but no
NHL
, and HIV-negative subjects).
PBMC AID expression was markedly elevated in those who developed
AIDS
-
NHL
, when compared to
AIDS
and HIV-negative controls.
Additionally, AID expression was seen to differ depending on
NHL
subtype, with the highest levels of expression seen in those who developed Burkitt's
lymphoma
.
[MeSH-major]
B-Lymphocytes / enzymology. Cytidine Deaminase / genetics. Gene Expression Regulation, Viral.
Lymphoma
,
AIDS
-
Related
/ enzymology.
Lymphoma
, B-Cell / enzymology
Genetic Alliance.
consumer health - AIDS-HIV
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18090274.001).
[ISSN]
0269-9370
[Journal-full-title]
AIDS (London, England)
[ISO-abbreviation]
AIDS
[Language]
eng
[Grant]
United States / NIAID NIH HHS / AI / AI28697; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888
[Publication-type]
Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / RNA, Viral; EC 3.5.4.5 / Cytidine Deaminase
5.
Simonelli C, Tedeschi R, Gloghini A, Talamini R, Bortolin MT, Berretta M, Spina M, Morassut S, Vaccher E, De Paoli P, Carbone A, Tirelli U:
Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.
J Med Virol
; 2009 May;81(5):888-96
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Plasma HHV-8 viral load in HHV-8-
related
lymphoproliferative disorders associated with HIV infection.
Patients with Multicentric Castleman Disease and HHV-8-
related lymphoma
diagnosed and treated from April 1987 to June 2004 were included in the study.
Nine patients with Multicentric Castleman disease, and 16 with HHV-8-
related
lymphomas (13 primary effusion lymphomas and 3 solid lymphomas), were diagnosed and treated out of 327 HIV-
related non
-
Hodgkin's
lymphomas.
Nine patients with primary effusion
lymphoma
were treated with a CHOP-like regimen (Cyclophosphamide, Prednisone anthracyclines, Vinca alkaloids, Bleomycin, Etoposide) and HAART; 1 with etoposide and HAART, 1 with HAART alone.
The patients with solid
lymphoma
underwent CHOP-like chemotherapy.
Patients with Multicentric Castleman disease showed lower median values of HHV-8 viral load and longer overall survival compared with HHV-8-
related
lymphomas.
In the univariate analysis, HHV-8-
related lymphoma
, HHV-8 viral load >40,000 cp/ml and performance status >2 were associated with an increased risk of death.
Multivariate analysis confirmed the diagnosis of
lymphoma
as an independent predictor of shorter survival.
[MeSH-major]
HIV Infections / complications. Herpesviridae Infections / complications. Herpesvirus 8, Human / physiology.
Lymphoma
,
AIDS
-
Related
/ drug therapy. Lymphoproliferative Disorders / complications. Viral Load
[MeSH-minor]
Adult. Aged. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. DNA, Viral / blood. Female. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / diagnosis. Giant Lymph Node Hyperplasia / drug therapy. Giant Lymph Node Hyperplasia / virology. Humans.
Lymphoma
/ complications.
Lymphoma
/ diagnosis.
Lymphoma
/ drug therapy.
Lymphoma
/ virology.
Lymphoma
, Primary Effusion / complications.
Lymphoma
, Primary Effusion / diagnosis.
Lymphoma
, Primary Effusion / drug therapy.
Lymphoma
, Primary Effusion / virology. Male. Middle Aged. Prognosis. Survival Analysis. Survival Rate. Treatment Outcome. Young Adult
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 Wiley-Liss, Inc.
(PMID = 19319955.001).
[ISSN]
1096-9071
[Journal-full-title]
Journal of medical virology
[ISO-abbreviation]
J. Med. Virol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / DNA, Viral
6.
Aissani B, Ogwaro KM, Shrestha S, Tang J, Breen EC, Wong HL, Jacobson LP, Rabkin CS, Ambinder RF, Martinez-Maza O, Kaslow RA:
The major histocompatibility complex conserved extended haplotype 8.1 in AIDS-related non-Hodgkin lymphoma.
J Acquir Immune Defic Syndr
; 2009 Oct 1;52(2):170-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The major histocompatibility complex conserved extended haplotype 8.1 in
AIDS
-
related non
-
Hodgkin
lymphoma
.
BACKGROUND: Two single nucleotide polymorphisms (SNPs) in adjacent genes, lymphotoxin alpha (LTA +252G, rs909253 A>G) and tumor necrosis factor (TNF -308A, rs1800629 G>A), form the G-A haplotype repeatedly associated with increased risk of
non
-
Hodgkin
lymphoma
(
NHL
) in individuals uninfected with HIV-1.
OBJECTIVE: We aimed to determine whether the reported association of the G-A haplotype of LTA-TNF with
non
-
AIDS
NHL
also occurs with
AIDS
-
related
NHL
.
METHODS: SNPs in LTA and TNF and in 6 other genes nearby were typed in 140
non
-Hispanic European American pairs of
AIDS
-
NHL
cases and matched controls selected from HIV-infected men in the Multicenter
AIDS
Cohort Study.
RESULTS: The G-A haplotype and a 4-SNP haplotype in the neighboring gene cluster (rs537160 (A) rs1270942 (G), rs2072633 (A), and rs6467 (C)) were associated with
AIDS
-
NHL
(odds ratio = 2.7, 95% confidence interval: 1.5 to 4.8, P = 0.0009; and odds ratio = 3.2, 95% confidence interval: 1.6 to 6.6, P = 0.0008; respectively).
CONCLUSION: The CEH 8.1-specific haplotype association of MHC class III variants with
AIDS
-
NHL
closely resembles that observed for
non
-
AIDS
NHL
.
Corroboration of an MHC determinant of
AIDS
and
non
-
AIDS
NHL
alike would imply an important pathogenetic mechanism common to both.
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Curr Opin Pharmacol. 2004 Aug;4(4):314-20
[
15251122.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195-9
[
9096369.001
]
[Cites]
Lancet. 1990 Apr 21;335(8695):927-30
[
1970024.001
]
[Cites]
Lancet. 1991 Apr 6;337(8745):805-9
[
1672911.001
]
[Cites]
Hum Immunol. 1992 Aug;34(4):242-52
[
1464552.001
]
[Cites]
AIDS. 2000 Jan 28;14(2):133-40
[
10708283.001
]
[Cites]
Blood. 2000 Oct 15;96(8):2730-4
[
11023505.001
]
[Cites]
Biometrics. 1999 Dec;55(4):997-1004
[
11315092.001
]
[Cites]
Eur J Cancer. 2001 Jul;37(10):1316-9
[
11423263.001
]
[Cites]
Hum Hered. 2002;53(2):79-91
[
12037407.001
]
[Cites]
Science. 2002 Jun 21;296(5576):2225-9
[
12029063.001
]
[Cites]
Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70
[
12108891.001
]
[Cites]
Blood. 2002 Oct 15;100(8):3037-40
[
12351419.001
]
[Cites]
Genome Res. 2004 Jun;14(6):1176-87
[
15140828.001
]
[Cites]
J Hered. 1995 Sep-Oct;86(5):409-11
[
7560877.001
]
[Cites]
Mol Biol Evol. 1995 Sep;12(5):921-7
[
7476138.001
]
[Cites]
Transplantation. 1995 Nov 27;60(10):1113-7
[
7482718.001
]
[Cites]
J Neuroimmunol. 1995 Dec 31;63(2):143-7
[
8550811.001
]
[Cites]
Clin Exp Immunol. 1996 Mar;103(3):391-6
[
8608636.001
]
[Cites]
J Neuroimmunol. 1997 Feb;72(2):149-53
[
9042107.001
]
[Cites]
Blood. 1998 May 15;91(10):3574-81
[
9572991.001
]
[Cites]
Clin Exp Immunol. 1998 Sep;113(3):401-6
[
9737669.001
]
[Cites]
Immunol Rev. 1999 Feb;167:257-74
[
10319267.001
]
[Cites]
Bioinformatics. 2005 Jan 15;21(2):263-5
[
15297300.001
]
[Cites]
J Natl Cancer Inst. 2005 Mar 16;97(6):425-32
[
15770006.001
]
[Cites]
J Med Virol. 2005 Jul;76(3):302-10
[
15902698.001
]
[Cites]
Nat Genet. 2005 Nov;37(11):1217-23
[
16244653.001
]
[Cites]
J Clin Oncol. 2005 Nov 20;23(33):8414-21
[
16293872.001
]
[Cites]
J Infect Dis. 2006 Jan 1;193(1):16-26
[
16323127.001
]
[Cites]
Lancet Oncol. 2006 Jan;7(1):27-38
[
16389181.001
]
[Cites]
Eur J Cancer. 2006 Apr;42(6):745-50
[
16517151.001
]
[Cites]
Br J Haematol. 2006 May;133(3):293-300
[
16643431.001
]
[Cites]
Diabetes. 2006 May;55(5):1265-9
[
16644681.001
]
[Cites]
Genomics. 2006 May;87(5):561-71
[
16434165.001
]
[Cites]
Blood. 2006 May 15;107(10):4101-8
[
16449530.001
]
[Cites]
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W621-5
[
16845085.001
]
[Cites]
Cancer Res. 2006 Oct 1;66(19):9771-80
[
17018637.001
]
[Cites]
Genes Chromosomes Cancer. 2007 May;46(5):500-7
[
17311253.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8
[
17337643.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4
[
17337646.001
]
[Cites]
Cancer Res. 2007 May 15;67(10):5042-54
[
17510437.001
]
[Cites]
Tissue Antigens. 2008 Jan;71(1):16-26
[
17971052.001
]
[Cites]
Immunogenetics. 2008 Jan;60(1):1-18
[
18193213.001
]
[Cites]
Int J Immunogenet. 2008 Jun;35(3):179-92
[
18397301.001
]
[Cites]
Carcinogenesis. 2007 Mar;28(3):704-12
[
17056605.001
]
[Cites]
Am J Epidemiol. 1987 Aug;126(2):310-8
[
3300281.001
]
(PMID = 19654554.001).
[ISSN]
1944-7884
[Journal-full-title]
Journal of acquired immune deficiency syndromes (1999)
[ISO-abbreviation]
J. Acquir. Immune Defic. Syndr.
[Language]
ENG
[Grant]
United States / NIAID NIH HHS / AI / U01 AI035042; United States / NCI NIH HHS / CA / R01 CA073475-03; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NCI NIH HHS / CA / R01 CA073475; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NCI NIH HHS / CA / R01 CA106168-01A1; United States / NCI NIH HHS / CA / CA106168-01A1; United States / NCI NIH HHS / CA / P50-CA96888; United States / NCI NIH HHS / CA / R01 CA106168; United States / NCI NIH HHS / CA / CA073475-03; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NCI NIH HHS / CA / P50 CA096888-01; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NIAID NIH HHS / AI / P30 AI045008; United States / NIAID NIH HHS / AI / UO1-AI-35040,; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / P30 AI045008-01; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NCI NIH HHS / CA / R01-CA106168; United States / NIAID NIH HHS / AI / AI045008-01; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NCI NIH HHS / CA / CA096888-01; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NCI NIH HHS / CA / P50 CA096888; United States / NIAID NIH HHS / AI / P30 AI 045008; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NCI NIH HHS / CA / R01-CA73475
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / HLA Antigens; 0 / Lymphotoxin-alpha; 0 / Tumor Necrosis Factor-alpha
[Other-IDs]
NLM/ NIHMS250460; NLM/ PMC3015185
7.
Knysz B, Kuliszkiewicz-Janus M, Jeleń M, Podlasin R, Gładysz A:
Non-Hodgkin's lymphoma as a rare manifestation of immune reconstitution disease in HIV-1 positive patients.
Postepy Hig Med Dosw (Online)
; 2006;60:547-51
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Non
-
Hodgkin's lymphoma
as a rare manifestation of immune reconstitution disease in HIV-1 positive patients.
IRS can develop within weeks to months after cART is commenced and the time is
related
to the type of the disease.
There are but scant reports concerning IRS-
NHL
(
non
-
Hodgkin's lymphoma
) in HIV-1 positive subjects.
We observed 4 (33%) cases of IRS-
NHL
out of 12 patients in whom
NHL
was diagnosed.
The diagnosis of
NHL
was established at a mean time of 36 weeks after cART was introduced and 20 weeks after the CD4 T cell increase was achieved.
This may indicate that the immune reconstitution as a result of cART was a predisposing factor for the development of
NHL
in our patients.
IRS-
NHL
should be suspected in any case of lymphadenopathy, generalized or limited to the abdomen or periphery, which develops after immune recovery due to potent cART within a few months.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
HIV InSite.
treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17060896.001).
[ISSN]
1732-2693
[Journal-full-title]
Postepy higieny i medycyny doswiadczalnej (Online)
[ISO-abbreviation]
Postepy Hig Med Dosw (Online)
[Language]
ENG
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Poland
[Chemical-registry-number]
0 / Anti-HIV Agents
8.
Steingass SK:
Hematopoietic cell transplantation in non-Hodgkin's lymphoma.
Semin Oncol Nurs
; 2006 May;22(2):107-16
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Hematopoietic cell transplantation in
non
-
Hodgkin's lymphoma
.
OBJECTIVE: To explore the role and outcomes using hematopoietic cell transplantation (HCT) as a treatment option with aggressive, follicular, mantle, T-cell, and HIV
related non
-
Hodgkin's lymphoma
(
NHL
).
CONCLUSION: High-dose chemotherapy and/or radiation therapy followed by HCT has been used to overcome resistance to standard-dose therapy and has been explored over the past 40 years and has shown long-term survival of approximately 10% to 50% in patients with relapsed or refractory
lymphoma
.
[MeSH-major]
Hematopoietic Stem Cell Transplantation.
Lymphoma
,
Non
-
Hodgkin
/ therapy
[MeSH-minor]
Humans.
Lymphoma
,
AIDS
-
Related
/ nursing.
Lymphoma
,
AIDS
-
Related
/ therapy.
Lymphoma
, Follicular / nursing.
Lymphoma
, Follicular / therapy.
Lymphoma
, Mantle-Cell / nursing.
Lymphoma
, Mantle-Cell / therapy.
Lymphoma
, T-Cell / nursing.
Lymphoma
, T-Cell / therapy. Transplantation Conditioning / adverse effects. Transplantation Conditioning / nursing
Genetic Alliance.
consumer health - Transplantation
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16720233.001).
[ISSN]
0749-2081
[Journal-full-title]
Seminars in oncology nursing
[ISO-abbreviation]
Semin Oncol Nurs
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
46
9.
Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D:
Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.
Blood
; 2005 Nov 1;106(9):3166-74
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to
AIDS
-
related non
-
Hodgkin
lymphoma
.
We previously observed a loss of Epstein-Barr virus (EBV)-specific CD8+ T cells in subjects progressing to EBV-
related non
-
Hodgkin
lymphoma
(
NHL
), correlating with loss of CD4+ T cells.
The aim of the present study was to determine the role of EBV-specific CD4+ T cells in the development of
NHL
during chronic HIV infection.
To this end, CD4+ and CD8+ memory T cells, capable of both proliferation and subsequent interferon gamma (IFNgamma) production, directed against a latent (Epstein-Barr virus nuclear antigen 1 [EBNA1]) and a lytic (BamH fragment Z left frame 1 [BZLF1]) EBV antigen were studied longitudinally in 9 progressors to
NHL
, 4 progressors to
non
-EBV-
related AIDS
, and 4 slow progressors to
AIDS
.
However, whereas latent antigen EBNA1-specific CD4+ T cells were lost well before diagnosis in all subjects who developed an
AIDS
-
related
NHL
(and EBNA1-specific CD8+ T cells were significantly lower compared with the other groups), these cells were better preserved in progressors to
non
-EBV-
related
disease and slow progressors.
Loss of EBNA1-specific T-cell immunity thus might be important for progression to
NHL
.
Interestingly, BZLF1-specific T cells were not lost in all progressors to
NHL
, suggesting a different function of these cells in the surveillance of EBV-infected B cells.
[MeSH-major]
CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Epstein-Barr Virus Nuclear Antigens / immunology. Immunologic Memory / immunology.
Lymphoma
,
AIDS
-
Related
/ immunology.
Lymphoma
,
Non
-
Hodgkin
/ complications.
Lymphoma
,
Non
-
Hodgkin
/ immunology
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
Genetic Alliance.
consumer health - HIV
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16014568.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens
10.
Tirwomwe JF, Rwenyonyi CM, Muwazi LM, Besigye B, Mboli F:
Oral manifestations of HIV/AIDS in clients attending TASO clinics in Uganda.
Clin Oral Investig
; 2007 Sep;11(3):289-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Oral manifestations of HIV/
AIDS
in clients attending TASO clinics in Uganda.
A total of 514 subjects aged 18 to 58 years (mean 42 years) were randomly recruited from five The
AIDS
Support Organization (TASO) clinics in Uganda.
Non
-
Hodgkin's lymphoma
, atypical ulcers, necrotizing periodontitis, and hairy leucoplakia were least frequently observed in the subjects.
[MeSH-minor]
AIDS
-
Related
Opportunistic Infections / epidemiology. Adolescent. Adult. Burning Mouth Syndrome / epidemiology. Candidiasis, Oral / epidemiology. Cheilitis / epidemiology. Cross-Sectional Studies. Female. Gingivitis, Necrotizing Ulcerative / epidemiology. Humans. Leukoplakia, Hairy / epidemiology.
Lymphoma
,
AIDS
-
Related
/ epidemiology.
Lymphoma
,
Non
-
Hodgkin
/ epidemiology. Male. Middle Aged. Oral Ulcer / epidemiology. Periodontitis / epidemiology. Prevalence. Sex Factors. Uganda / epidemiology. Xerostomia / epidemiology
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - Mouth Disorders
.
HIV InSite.
treatment guidelines - Serious Bacterial (Pediatric)
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Oral Dis. 2002;8 Suppl 2:34-9
[
12164657.001
]
[Cites]
Rev Panam Salud Publica. 2003 Aug;14(2):112-8
[
14577934.001
]
[Cites]
West Afr J Med. 2002 Jan-Mar;21(1):9-11
[
12081356.001
]
[Cites]
AIDS Patient Care STDS. 2002 Oct;16(10):479-86
[
12437859.001
]
[Cites]
Oral Dis. 2002;8 Suppl 2:110-4
[
12164643.001
]
[Cites]
Oral Dis. 2006 Nov;12(6):537-42
[
17054765.001
]
[Cites]
Cent Afr J Med. 1998 Feb;44(2):31-4
[
9675968.001
]
[Cites]
Medicine (Baltimore). 2003 Jan;82(1):39-50
[
12544709.001
]
[Cites]
J Oral Pathol Med. 1990 May;19(5):232-4
[
2359042.001
]
[Cites]
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Jun;87(6):708-13
[
10397663.001
]
[Cites]
Adv Dent Res. 2006 Apr 01;19(1):106-17
[
16672560.001
]
[Cites]
Trop Med Int Health. 1999 May;4(5):349-54
[
10402970.001
]
[Cites]
Oral Dis. 2002;8 Suppl 2:136-43
[
12164647.001
]
[Cites]
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Mar;89(3):299-304
[
10710453.001
]
[Cites]
Qual Life Res. 2002 Feb;11(1):57-70
[
12003056.001
]
[Cites]
Oral Dis. 2002;8 Suppl 2:80-7
[
12164666.001
]
[Cites]
J Oral Pathol Med. 1999 Apr;28(4):173-7
[
10235371.001
]
[Cites]
Med Oral Patol Oral Cir Bucal. 2004;9 Suppl:153-7; 148-53
[
15580133.001
]
[Cites]
AIDS Patient Care STDS. 2000 Dec;14(12):627-35
[
11119429.001
]
[Cites]
J Oral Pathol Med. 1998 Apr;27(4):176-9
[
9563573.001
]
(PMID = 17476537.001).
[ISSN]
1432-6981
[Journal-full-title]
Clinical oral investigations
[ISO-abbreviation]
Clin Oral Investig
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
11.
Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, Katzmann JA, Rajkumar SV, Engels EA:
Circulating serum free light chains as predictive markers of AIDS-related lymphoma.
J Clin Oncol
; 2010 Feb 10;28(5):773-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Circulating serum free light chains as predictive markers of
AIDS
-
related lymphoma
.
PURPOSE HIV-infected persons have an elevated risk of developing
non
-
Hodgkin's lymphoma
(
NHL
); this risk remains increased in the era of effective HIV therapy.
We evaluated serum immunoglobulin (Ig) proteins as predictors of
NHL
risk among HIV-infected individuals.
PATIENTS AND METHODS By using three cohorts of HIV-infected persons (from 1982 to 2005), we identified 66 individuals who developed
NHL
and 225 matched (by cohort, sex, ethnicity, age, and CD4 count), HIV-infected,
lymphoma
-free controls who had available stored prediagnostic blood samples.
Results The kappa and lambda FLCs were both significantly higher in patients (eg, in 2- to 5-year window: median kappa, 4.24 v 3.43 mg/dL; median lambda, 4.04 v 3.09 mg/dL) and strongly predicted
NHL
in a dose-response manner up to 2 to 5 years before diagnosis/selection (eg,
NHL
risk 3.76-fold higher with kappa concentration at least 2.00 times the upper limit of normal, and 8.13-fold higher with lambda concentration at least 2.00 times the upper limit of normal compared with normal levels).
M proteins were detected in only two patients with
NHL
(3%) and in nine controls (4%), and they were not significantly associated with
NHL
risk.
CONCLUSION Elevated FLCs may represent sensitive markers of polyclonal B-cell activation and dysfunction and could be useful for identifying HIV-infected persons at increased
NHL
risk.
[MeSH-major]
Biomarkers, Tumor / blood. Immunoglobulin kappa-Chains / blood. Immunoglobulin lambda-Chains / blood.
Lymphoma
,
AIDS
-
Related
/ immunology
Genetic Alliance.
consumer health - AIDS-HIV
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Rev Immunol. 2009 Apr;9(4):235-45
[
19319142.001
]
[Cites]
Ann Rheum Dis. 2009 Jan;68(1):89-93
[
18375535.001
]
[Cites]
Blood. 2009 May 28;113(22):5412-7
[
19179464.001
]
[Cites]
J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84
[
20418723.001
]
[Cites]
AIDS. 2000 Jan 28;14(2):133-40
[
10708283.001
]
[Cites]
JAMA. 2001 Apr 4;285(13):1736-45
[
11277828.001
]
[Cites]
Blood. 2001 May 1;97(9):2900-2
[
11313287.001
]
[Cites]
N Engl J Med. 2002 Feb 21;346(8):564-9
[
11856795.001
]
[Cites]
Clin Chem. 2002 Sep;48(9):1437-44
[
12194920.001
]
[Cites]
Blood. 2003 Nov 15;102(10):3759-64
[
12881316.001
]
[Cites]
Curr HIV Res. 2004 Jan;2(1):11-21
[
15053337.001
]
[Cites]
AIDS Read. 2004 Jul;14(7):372-4, 377-9
[
15282866.001
]
[Cites]
N Engl J Med. 2004 Oct 7;351(15):1548-63
[
15470219.001
]
[Cites]
N Engl J Med. 1983 Aug 25;309(8):453-8
[
6224088.001
]
[Cites]
JAMA. 1987 Jan 16;257(3):331-4
[
3491911.001
]
[Cites]
Clin Chem. 1987 Sep;33(9):1697-8
[
3621592.001
]
[Cites]
Clin Chem. 1989 Feb;35(2):338-9
[
2914402.001
]
[Cites]
N Engl J Med. 1989 Oct 26;321(17):1141-8
[
2477702.001
]
[Cites]
Br J Haematol. 1993 May;84(1):151-5
[
8101720.001
]
[Cites]
Int J Cancer. 1997 Nov 27;73(5):645-50
[
9398040.001
]
[Cites]
Leukemia. 1997 Dec;11(12):2150-6
[
9447834.001
]
[Cites]
Int J Cancer. 2005 Jun 10;115(2):296-300
[
15688390.001
]
[Cites]
Blood. 2005 Aug 1;106(3):812-7
[
15855274.001
]
[Cites]
Haemophilia. 2005 Sep;11(5):516-28
[
16128897.001
]
[Cites]
N Engl J Med. 2006 Mar 30;354(13):1362-9
[
16571879.001
]
[Cites]
Tumour Biol. 2006;27(4):187-94
[
16651853.001
]
[Cites]
AIDS. 2006 Aug 1;20(12):1645-54
[
16868446.001
]
[Cites]
Curr Opin Oncol. 2006 Sep;18(5):444-8
[
16894291.001
]
[Cites]
Clin Infect Dis. 2006 Nov 1;43(9):1198-205
[
17029142.001
]
[Cites]
Ann Rheum Dis. 2007 Jan;66(1):23-7
[
16569685.001
]
[Cites]
J Natl Cancer Inst. 2007 Jun 20;99(12):962-72
[
17565153.001
]
[Cites]
Lancet. 2007 Jul 7;370(9581):59-67
[
17617273.001
]
[Cites]
JAMA. 2008 Aug 6;300(5):555-70
[
18677028.001
]
[Cites]
N Engl J Med. 2009 Apr 30;360(18):1815-26
[
19339714.001
]
(PMID = 20048176.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / / Z01 CP010150-08; United States / NCI NIH HHS / CA / P01 CA062242; United States / NCI NIH HHS / CA / CA 107476; United States / NCI NIH HHS / CA / R01 CA107476; United States / NCI NIH HHS / CA / CA 62242
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains
[Other-IDs]
NLM/ PMC2834393
12.
Jacomet C, Lesens O, Villemagne B, Darcha C, Tournilhac O, Henquell C, Cormerais L, Gourdon F, Peigue-Lafeuille H, Travade P, Beytout J, Laurichesse H:
[Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
Med Mal Infect
; 2006 Mar;36(3):157-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Non Hodgkin's
and
Hodgkin's
lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
[Transliterated title]
Lymphomes
non
hodgkiniens et hodgkiniens et infection VIH: fréquence, pronostic et reconstitution immune sous trithérapie antirétrovirale; CHU de Clermont-Ferrand, 1991-2003.
OBJECTIVES: The authors had for aim to identify cases of
non Hodgkin's
(
NHL
) and
Hodgkin's
(HL) lymphomas in HIV1-infected patients to assess 1) their incidence, before and after 1996, 2) the clinical features and outcome under treatment together with the survival rate of the patients, 3) the immune reconstitution of
lymphoma
-free patients under HAART.
PATIENTS AND METHODS: A retrospective study was made of HIV1-infected patients managed at the Clermont-Ferrand University Hospital from 1991 to 2003 for the diagnosis and treatment of HIV1-
related
lymphomas.
RESULTS: Forty-one patients were included: 35
NHL
and 6 HL giving a cumulative incidence rate estimate from 2.4% between 1991 and 1996 to 3.4% between 1997 and 2003 while other opportunistic diseases were decreasing.
A high proportion of aggressive and disseminated disease was observed among
NHL
cases.
Complete remission was achieved in 17 (49%) and 5 (83%)
NHL
and HL cases respectively.
The mean survival was 109+/-54 months and was correlated with CD4 cell count at
lymphoma
diagnosis (univariate analysis).
Immune restoration in
lymphoma
-free patients under HAART is poor.
[MeSH-major]
Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. HIV-1.
Hodgkin
Disease / epidemiology.
Lymphoma
,
AIDS
-
Related
/ epidemiology.
Lymphoma
,
Non
-
Hodgkin
/ epidemiology
[MeSH-minor]
AIDS
-
Related
Opportunistic Infections / epidemiology. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Cohort Studies. Female. France / epidemiology. Hospitals, University / statistics & numerical data. Humans. Incidence. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
HIV InSite.
treatment guidelines - Palliative Care of Patients with HIV
.
HIV InSite.
treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16503104.001).
[ISSN]
0399-077X
[Journal-full-title]
Médecine et maladies infectieuses
[ISO-abbreviation]
Med Mal Infect
[Language]
fre
[Publication-type]
English Abstract; Journal Article
[Publication-country]
France
13.
Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sanchez MJ, Garau I, Non-Hodgkin's Lymphoma Working Group:
Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain.
Ann Oncol
; 2010 May;21 Suppl 3:iii90-96
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Attenuation of the epidemic increase in
non
-
Hodgkin's
lymphomas in Spain.
BACKGROUND: Attenuation of the epidemic increase in
non
-
Hodgkin's lymphoma
(
NHL
) incidence has recently been reported in the USA and Nordic European countries.
After two decades of steadily increasing
NHL
, this study sought to ascertain whether a similar stabilisation might have taken place in Spain in recent years.
PATIENTS AND METHODS:
NHL
cases were drawn from 13 population-based Spanish cancer registries with a record of at least 10 years of uninterrupted registration during the period 1975-2004.
RESULTS: A total of 21 335
NHL
cases (11 531 male and 9804 female) were identified.
CONCLUSIONS: In Spain,
NHL
incidence levelled off in 1996 after a sharp increase during the 1970s and 1980s.
This stabilisation is, partially at least, linked to the decrease in incidence of
AIDS
-
related
lymphomas among young adults.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20427366.001).
[ISSN]
1569-8041
[Journal-full-title]
Annals of oncology : official journal of the European Society for Medical Oncology
[ISO-abbreviation]
Ann. Oncol.
[Language]
ENG
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Investigator]
Dorronsorro M; Giraldo P; Díaz García JM; Gutiérrez G; Gutiérrez L; Pérez de Rada E
14.
Widney DP, Gui D, Popoviciu LM, Said JW, Breen EC, Huang X, Kitchen CM, Alcantar JM, Smith JB, Detels R, Martínez-Maza O:
Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma.
AIDS Res Treat
; 2010;2010:164586
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in
Aids
-Associated
Non
-
Hodgkin's Lymphoma
.
CXCL13/CXCR5 are expressed, and may play a role, in some
non
-
AIDS
-associated B cell tumors.
Objective. To determine if CXCL13/CXCR5 are associated with
AIDS
-
related non
-
Hodgkin's lymphoma
(
AIDS
-
NHL
).
Methods. Serum CXCL13 levels were measured by ELISA in 46 subjects who developed
AIDS
-
NHL
in the Multicenter
AIDS
Cohort Study and in controls.
The expression or function of CXCL13 and CXCR5 was examined on primary
AIDS
-
NHL
specimens or
AIDS
-
NHL
cell lines.
Results. Serum CXCL13 levels were significantly elevated in the
AIDS
-
NHL
group compared to controls.
All primary
AIDS
-
NHL
specimens showed CXCR5 expression and most also showed CXCL13 expression.
AIDS
-
NHL
cell lines expressed CXCR5 and showed chemotaxis towards CXCL13.
Conclusions. CXCL13/CXCR5 are expressed in
AIDS
-
NHL
and could potentially be involved in its biology.
CXCL13 may have potential as a biomarker for
AIDS
-
NHL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Pathol. 2008 Aug;215(4):431-44
[
18561120.001
]
[Cites]
J Neuroimmunol. 2008 Jul 31;198(1-2):106-12
[
18539341.001
]
[Cites]
Blood. 2009 May 7;113(19):4604-13
[
19228923.001
]
[Cites]
Am J Epidemiol. 1987 Aug;126(2):310-8
[
3300281.001
]
[Cites]
J Clin Oncol. 1993 Jun;11(6):1099-107
[
8099121.001
]
[Cites]
Blood. 1994 Feb 15;83(4):1067-78
[
8111047.001
]
[Cites]
Cell. 1996 Dec 13;87(6):1037-47
[
8978608.001
]
[Cites]
Blood. 1997 Jul 15;90(2):520-5
[
9226150.001
]
[Cites]
J Exp Med. 1998 Feb 16;187(4):655-60
[
9463416.001
]
[Cites]
Nature. 1998 Feb 19;391(6669):799-803
[
9486651.001
]
[Cites]
Oncology (Williston Park). 2001 Apr;15(4):439-48; discussion 448-9
[
11346932.001
]
[Cites]
Curr Opin Oncol. 2002 Sep;14(5):528-32
[
12192272.001
]
[Cites]
Ophthalmology. 2003 Feb;110(2):421-6
[
12578791.001
]
[Cites]
Tumour Biol. 2003 Mar-Apr;24(2):82-93
[
12853703.001
]
[Cites]
Breast Dis. 2004;20:137-43
[
15687714.001
]
[Cites]
J Natl Cancer Inst. 1991 May 15;83(10):695-701
[
2023270.001
]
[Cites]
Blood. 1995 Jun 15;85(12):3423-30
[
7780129.001
]
[Cites]
Biochem Biophys Res Commun. 1997 Jun 27;235(3):576-81
[
9207199.001
]
[Cites]
Blood. 1999 Mar 15;93(6):1838-42
[
10068655.001
]
[Cites]
Blood Rev. 1999 Sep;13(3):147-50
[
10527266.001
]
[Cites]
Immunology. 2000 Feb;99(2):266-71
[
10692046.001
]
[Cites]
Immunity. 2000 Feb;12(2):121-7
[
10714678.001
]
[Cites]
Immunol Rev. 2000 Aug;176:181-93
[
11043777.001
]
[Cites]
Biochem Biophys Res Commun. 2001 Mar 30;282(2):369-75
[
11401467.001
]
[Cites]
Eur J Cancer. 2001 Jul;37(10):1270-5
[
11423258.001
]
[Cites]
Cancer Res. 2001 Jul 1;61(13):5028-37
[
11431337.001
]
[Cites]
Blood. 2002 Jan 1;99(1):207-12
[
11756173.001
]
[Cites]
Nature. 2002 Mar 7;416(6876):94-9
[
11882900.001
]
[Cites]
Cancer Res. 2002 Jun 1;62(11):3106-12
[
12036921.001
]
[Cites]
J Leukoc Biol. 2002 Jul;72(1):1-8
[
12101256.001
]
[Cites]
Blood. 2003 Feb 1;101(3):815-21
[
12393412.001
]
[Cites]
J Virol. 2003 Feb;77(3):2271-5
[
12525664.001
]
[Cites]
Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86
[
12626353.001
]
[Cites]
Blood. 2004 Jul 15;104(2):502-8
[
15001469.001
]
[Cites]
Blood. 2004 Oct 1;104(7):1952-60
[
15213097.001
]
[Cites]
Int J Dev Biol. 2004;48(5-6):489-96
[
15349823.001
]
[Cites]
AIDS. 2005 Oct 14;19(15):1711-2
[
16184051.001
]
[Cites]
J Interferon Cytokine Res. 2005 Nov;25(11):702-6
[
16318584.001
]
[Cites]
Acta Neuropathol. 2007 Sep;114(3):271-6
[
17641901.001
]
[Cites]
Blood. 2007 Nov 1;110(9):3316-25
[
17652619.001
]
[Cites]
Immunity. 2007 Aug;27(2):190-202
[
17723214.001
]
[Cites]
J Clin Pathol. 2007 Dec;60(12):1365-72
[
18042692.001
]
[Cites]
Blood. 2008 Mar 15;111(6):3200-10
[
18184868.001
]
[Cites]
Blood. 2008 Dec 1;112(12):4401-10
[
18780835.001
]
(PMID = 21490903.001).
[ISSN]
2090-1259
[Journal-full-title]
AIDS research and treatment
[ISO-abbreviation]
AIDS Res Treat
[Language]
ENG
[Grant]
United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCI NIH HHS / CA / R01 CA073475; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA057152; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC3065842
15.
Lu TH, Chang HJ, Chen LS, Chu MH, Ou NM, Jen I:
Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan.
J Formos Med Assoc
; 2006 Jul;105(7):604-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Changes in causes of death and associated conditions among persons with HIV/
AIDS
after the introduction of highly active antiretroviral therapy in Taiwan.
To assess the pattern of change in the causes of death among HIV/
AIDS
patients in Taiwan after the introduction of highly active antiretroviral therapy (HAART), national HIV/
AIDS
registry data were linked with cause of death and health insurance claims data from 1994 to 2002 for analysis.
Although HIV/
AIDS
remained the leading underlying cause of death among HIV/
AIDS
patients during the study period (552/752 = 73.4%), an increased proportion of deaths was due to
non
-HIV/
AIDS
causes (other infectious diseases, cancers, liver diseases, etc.) after the introduction of HAART in 1997.
Most
AIDS
-
related
conditions associated with death (cryptococcosis, cachexia/wasting, dementia/encephalopathy, etc.) decreased in frequency from 1998-2000 to 2001-2002.
Nonetheless, some
AIDS
-
related
conditions associated with death remained stable or increased in frequency, such as candidiasis, tuberculosis, and
non
-
Hodgkin's lymphoma
.
More effort is required to address the mental health of HIV/
AIDS
patients as a part of therapy.
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
HIV InSite.
treatment guidelines - Non-ARV Adverse Events
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16877243.001).
[ISSN]
0929-6646
[Journal-full-title]
Journal of the Formosan Medical Association = Taiwan yi zhi
[ISO-abbreviation]
J. Formos. Med. Assoc.
[Language]
ENG
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Singapore
16.
Wood C, Harrington W Jr:
AIDS and associated malignancies.
Cell Res
; 2005 Nov-Dec;15(11-12):947-52
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
AIDS
and associated malignancies.
AIDS
associated malignancies (ARL) is a major complication associated with
AIDS
patients upon immunosuppression.
Malignancies that were found to have high incidence in HIV-infected individuals are Kaposi's sarcoma (KS),
Hodgkin's
disease (HD) and
non
-
Hodgkin's lymphoma
(
NHL
).
The incidence of
NHL
has increased nearly 200 fold in HIV-positive patients, and accounts for a greater percentage of
AIDS
defining illness in the US and Europe since the advent of HAART therapy.
These
AIDS related
lymphomas are distinct from their counterparts seen in HIV-1 seronegative patients.
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16354573.001).
[ISSN]
1001-0602
[Journal-full-title]
Cell research
[ISO-abbreviation]
Cell Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA082274; United States / NCI NIH HHS / CA / CA76958; United States / NICHD NIH HHS / HD / HD39620; United States / NCRR NIH HHS / RR / RR15635
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
[Publication-country]
China
[Number-of-references]
60
17.
Kaaya EE, Castaños-Velez E, Ekman M, Mwakigonja A, Carneiro P, Lema L, Kitinya J, Linde A, Biberfeld P:
AIDS and non AIDS-related malignant lymphoma in Tanzania.
Afr Health Sci
; 2006 Jun;6(2):69-75
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
AIDS
and
non AIDS
-
related
malignant
lymphoma
in Tanzania.
BACKGROUND: Malignant
lymphoma
(ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as
AIDS
-defining tumors.
In Africa the frequency of
AIDS
-
related lymphoma
(ARL) is rare and the findings are controversial.
Both retrospective and prospective
lymphoma
cases were classified according to the revised European-American (REAL) classification.
OBJECTIVES: To determine the frequency and type of
AIDS
and
non
-
AIDS related
malignant
lymphoma
in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.
The tumors were classified as Burkitt's (6), diffuse large cell (10), precursor-B lymphoblastic (1) and
Hodgkin's
disease (5) from HIV positive and negative patients.
Ten (40%) high grade ML and three
Hodgkin's lymphoma
from HIV patients had HHV-8 DNA.
These findings were not
related
to age, sex or type of
lymphoma
.
There was no association of HHV-8 with the
lymphoma
cells.
[MeSH-major]
Lymphoma
/ epidemiology.
Lymphoma
/ pathology.
Lymphoma
,
AIDS
-
Related
/ epidemiology
[MeSH-minor]
Adolescent. Adult. Aged. Biopsy, Needle. Burkitt
Lymphoma
/ epidemiology. Burkitt
Lymphoma
/ pathology. Child. Child, Preschool. Developing Countries. Female. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification.
Hodgkin
Disease / epidemiology.
Hodgkin
Disease / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Incidence.
Lymphoma
,
Non
-
Hodgkin
/ epidemiology.
Lymphoma
,
Non
-
Hodgkin
/ pathology. Male. Middle Aged. Polymerase Chain Reaction. Registries. Retrospective Studies. Risk Assessment. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Survival Analysis. Tanzania / epidemiology. Young Adult
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Natl Cancer Inst Monogr. 1998;(23):79-88
[
9709308.001
]
[Cites]
Br J Cancer. 1997;75(11):1704-7
[
9184191.001
]
[Cites]
CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264
[
16020424.001
]
[Cites]
Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11
[
16091217.001
]
[Cites]
Br J Haematol. 2005 Sep;130(5):662-70
[
16115121.001
]
[Cites]
Scand J Infect Dis. 1994;26(6):749-52
[
7747100.001
]
[Cites]
Int J Cancer. 1995 May 16;61(4):574-9
[
7759163.001
]
[Cites]
Blood. 1995 Aug 15;86(4):1276-80
[
7632932.001
]
[Cites]
Blood. 1995 Oct 1;86(7):2708-14
[
7670109.001
]
[Cites]
Lancet. 1995 Sep 23;346(8978):799-802
[
7674745.001
]
[Cites]
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305
[
7552491.001
]
[Cites]
AIDS. 2002 Mar 8;16(4):597-603
[
11873003.001
]
[Cites]
J Med Virol. 2002 Oct;68(2):264-7
[
12210417.001
]
[Cites]
Lancet Oncol. 2003 Feb;4(2):110-9
[
12573353.001
]
[Cites]
Rev Clin Exp Hematol. 2003 Dec;7(4):375-405
[
15129649.001
]
[Cites]
MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5
[
2989677.001
]
[Cites]
N Engl J Med. 1985 Dec 19;313(25):1564-71
[
2999595.001
]
[Cites]
Lancet. 1991 Apr 6;337(8745):805-9
[
1672911.001
]
[Cites]
J Histochem Cytochem. 1991 Jun;39(6):741-8
[
1709656.001
]
[Cites]
Blood. 1994 Sep 1;84(5):1361-92
[
8068936.001
]
[Cites]
Science. 1994 Dec 16;266(5192):1865-9
[
7997879.001
]
[Cites]
N Engl J Med. 1995 May 4;332(18):1186-91
[
7700311.001
]
[Cites]
Science. 1995 Apr 28;268(5210):582-3
[
7725108.001
]
[Cites]
Nat Med. 1995 Jul;1(7):707-8
[
7585156.001
]
[Cites]
Nat Med. 1995 Dec;1(12):1274-8
[
7489408.001
]
[Cites]
J Virol. 1996 Jan;70(1):549-58
[
8523568.001
]
[Cites]
N Engl J Med. 1996 Jan 25;334(4):272-3
[
8532016.001
]
[Cites]
Arch Intern Med. 1996 Jan 22;156(2):202-4
[
8546554.001
]
[Cites]
Br J Haematol. 1995 Dec;91(4):918-20
[
8547139.001
]
[Cites]
Am J Clin Pathol. 1996 Feb;105(2):221-9
[
8607449.001
]
[Cites]
Blood. 1996 May 1;87(9):3903-9
[
8611719.001
]
[Cites]
Nat Med. 1996 Aug;2(8):918-24
[
8705863.001
]
[Cites]
Nat Med. 1996 Aug;2(8):925-8
[
8705864.001
]
[Cites]
J Mol Med (Berl). 1995 Dec;73(12):603-9
[
8825757.001
]
[Cites]
AIDS. 1996 Aug;10(9):951-8
[
8853727.001
]
[Cites]
J Virol. 1997 Mar;71(3):2505-11
[
9032391.001
]
[Cites]
J Mol Diagn. 2005 Feb;7(1):17-27
[
15681470.001
]
(PMID = 16916294.001).
[ISSN]
1729-0503
[Journal-full-title]
African health sciences
[ISO-abbreviation]
Afr Health Sci
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Uganda
[Other-IDs]
NLM/ PMC1831982
18.
Dhir AA, Sawant SP:
Malignancies in HIV: the Indian scenario.
Curr Opin Oncol
; 2008 Sep;20(5):517-21
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PURPOSE OF REVIEW: India has the second largest number of HIV/
AIDS
patients in the world; however, studies done in the area of HIV-
related
malignancies are few.
With the availability of highly active antiretroviral therapy and treatment and prevention of opportunistic infections, an increase in life expectancy of HIV-infected individuals and an increase in HIV-
related
malignancies is expected.
The purpose of this review is to put forth the Indian scenario of HIV-
related
malignancies.
RECENT FINDINGS: About 2.5 million Indians have HIV/
AIDS
.
Non
-
Hodgkin's lymphoma
and cervical cancer were found to occur in a higher proportion among the HIV-infected individuals in India as compared with
non
-HIV-infected individuals.
The incidence of
AIDS
-
related
primary central nervous system
lymphoma
is low in India.
Amongst the
non
-
AIDS
defining cancers anal cancer, testicular cancer,
Hodgkin's
disease, colon cancer and certain head and neck cancer sites in men and vaginal cancers among women were found to occur more frequently.
As India is a large country and geographically and culturally diverse, large-scale studies need to be done linking the regional cancer centres with the
AIDS
centres across the country to evaluate the exact burden of HIV-
related
malignancies.
[MeSH-major]
HIV Infections / complications.
Lymphoma
,
AIDS
-
Related
/ etiology. Neoplasms / etiology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19106653.001).
[ISSN]
1531-703X
[Journal-full-title]
Current opinion in oncology
[ISO-abbreviation]
Curr Opin Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
37
19.
Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D:
AIDS-related malignancies: state of the art and therapeutic challenges.
J Clin Oncol
; 2008 Oct 10;26(29):4834-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
AIDS
-
related
malignancies: state of the art and therapeutic challenges.
Despite the impact of combination antiretroviral therapy (cART) on HIV-
related
mortality, malignancy remains an important cause of death in the current era.
Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and
non
-
Hodgkin's lymphoma
,
non
-
AIDS
-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as
Hodgkin's lymphoma
, anal cancer, lung cancer, hepatocarcinoma, and many others.
Special considerations of these
AIDS
-
related
and
non
-
AIDS
-
related
malignancies and their clinical and therapeutic aspects constitute the subject of this review.
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18591544.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
99
20.
Noy A:
Update in HIV lymphoma.
Curr Opin Oncol
; 2006 Sep;18(5):449-55
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Update in HIV
lymphoma
.
Lymphoma
is the most common HIV-associated malignancy in these countries.
RECENT FINDINGS: Investigators continue to demonstrate that HIV-associated
non
-
Hodgkin's lymphoma
remains a significant problem, even in the era of highly active antiretroviral therapy.
The majority of work has been in diffuse large B-cell
lymphoma
, with infusional therapy remaining promising, and rituximab an area of investigation.
Biological insights have been gained into the spectrum of HIV-associated
non
-
Hodgkin's lymphoma
and
Hodgkin's
disease, and include further work on virological co-infections.
SUMMARY: The outcome for individuals infected with HIV and developing
non
-
Hodgkin's lymphoma
and
Hodgkin's
disease continues to improve as insights into the pathophysiology and treatment advance.
[MeSH-major]
Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
,
AIDS
-
Related
/ drug therapy
Genetic Alliance.
consumer health - HIV
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16894292.001).
[ISSN]
1040-8746
[Journal-full-title]
Current opinion in oncology
[ISO-abbreviation]
Curr Opin Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Anti-Retroviral Agents
[Number-of-references]
45
21.
Serrano D, Miralles P, Balsalobre P, Díez-Martin JL, Berenguer J:
Hematopoietic stem cell transplantation in patients infected with HIV.
Curr HIV/AIDS Rep
; 2010 Aug;7(3):175-84
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Several studies have reported the feasibility, safety, and efficacy of autologous HSCT as rescue or consolidation treatment for
non
-
Hodgkin's
and
Hodgkin's lymphoma
in HIV-infected patients.
[MeSH-major]
Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hematopoietic Stem Cell Transplantation / methods.
Lymphoma
,
AIDS
-
Related
/ therapy
[MeSH-minor]
Hodgkin
Disease / complications.
Hodgkin
Disease / therapy. Humans.
Lymphoma
,
Non
-
Hodgkin
/ complications.
Lymphoma
,
Non
-
Hodgkin
/ therapy. Transplantation Conditioning / methods. Treatment Outcome
Genetic Alliance.
consumer health - Transplantation
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Exp Hematol. 2005 Apr;33(4):487-94
[
15781340.001
]
[Cites]
J Infect Dis. 2000 Jan;181(1):148-57
[
10608761.001
]
[Cites]
Blood. 1996 Nov 1;88(9):3329-35
[
8896397.001
]
[Cites]
Transplantation. 2006 Jun 27;81(12):1658-61
[
16794531.001
]
[Cites]
Cancer. 1994 May 1;73(9):2400-7
[
8168044.001
]
[Cites]
Med Clin (Barc). 2008 Mar 8;130(8):300-11
[
18358123.001
]
[Cites]
N Engl J Med. 2004 Mar 25;350(13):1287-95
[
15044639.001
]
[Cites]
Lancet. 1993 Apr 24;341(8852):1051-4
[
8096958.001
]
[Cites]
Blood. 2009 Aug 13;114(7):1306-13
[
19451551.001
]
[Cites]
Exp Hematol. 2002 Mar;30(3):279-84
[
11882366.001
]
[Cites]
Blood. 2009 Jun 4;113(23):6011-4
[
19307667.001
]
[Cites]
Biol Blood Marrow Transplant. 2009 Jul;15(7):864-71
[
19539219.001
]
[Cites]
Bone Marrow Transplant. 2010 Mar;45(3):584-6
[
19617906.001
]
[Cites]
N Engl J Med. 1997 Jun 5;336(23):1641-8
[
9171066.001
]
[Cites]
Clin Infect Dis. 2000 Mar;30(3):504-10
[
10722435.001
]
[Cites]
AIDS. 2002 Apr 12;16(6):865-76
[
11919488.001
]
[Cites]
J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):422-8
[
18434957.001
]
[Cites]
Blood. 2009 Jun 4;113(23):5737-42
[
19336755.001
]
[Cites]
Leuk Lymphoma. 2008 Jun;49(6):1155-60
[
18452074.001
]
[Cites]
Curr Opin Oncol. 2007 Sep;19(5):446-51
[
17762569.001
]
[Cites]
AIDS Read. 2004 Jul;14(7):372-4, 377-9
[
15282866.001
]
[Cites]
N Engl J Med. 2009 Feb 12;360(7):692-8
[
19213682.001
]
[Cites]
J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):289-90
[
10969356.001
]
[Cites]
AIDS. 2002 Sep 27;16(14):1973-6
[
12351963.001
]
[Cites]
Biol Blood Marrow Transplant. 2011 Apr;17(4):586-7
[
19892025.001
]
[Cites]
N Engl J Med. 1987 Jun 11;316(24):1493-8
[
3295541.001
]
[Cites]
Haematologica. 2004 Sep;89(9):1100-8
[
15377471.001
]
[Cites]
Biol Blood Marrow Transplant. 2008 May;14(5):601-2
[
18410904.001
]
[Cites]
Bone Marrow Transplant. 2005 Aug;36(3):261-2
[
15908966.001
]
[Cites]
Curr Opin HIV AIDS. 2009 Jan;4(1):27-34
[
19339937.001
]
[Cites]
J Clin Oncol. 2009 May 1;27(13):2192-8
[
19332732.001
]
[Cites]
J Natl Cancer Inst. 2007 Jun 20;99(12):962-72
[
17565153.001
]
[Cites]
Blood. 2002 Jan 15;99(2):698-701
[
11781257.001
]
[Cites]
J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73
[
17117144.001
]
[Cites]
AIDS Res Hum Retroviruses. 2000 Oct 10;16(15):1471-9
[
11054260.001
]
[Cites]
Curr Opin HIV AIDS. 2009 Jan;4(1):11-5
[
19339935.001
]
[Cites]
Blood. 2008 Oct 15;112(8):3484-7
[
18698002.001
]
[Cites]
J Virol. 1999 Nov;73(11):9089-97
[
10516015.001
]
[Cites]
Haematologica. 2007 Apr;92(4):e56-8
[
17562594.001
]
[Cites]
Blood. 1998 Feb 1;91(3):907-15
[
9446651.001
]
[Cites]
Ann Intern Med. 1988 May;108(5):744-53
[
3358573.001
]
[Cites]
Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66
[
18158962.001
]
[Cites]
Blood. 2005 Jan 15;105(2):874-8
[
15388574.001
]
[Cites]
AIDS. 2009 Jun 1;23(9):1069-76
[
19417577.001
]
(PMID = 20549392.001).
[ISSN]
1548-3576
[Journal-full-title]
Current HIV/AIDS reports
[ISO-abbreviation]
Curr HIV/AIDS Rep
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
22.
Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B:
Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
Oncogene
; 2005 Dec 8;24(55):8114-27
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Rituximab (chimeric anti-CD20) sensitizes B-
NHL
cell lines to Fas-induced apoptosis.
Rituximab (chimeric anti-CD20 monoclonal antibodies) is currently being used in the treatment of B
non
-
Hodgkin's lymphoma
(
NHL
).
We have recently reported that rituximab triggers and modifies various intracellular signaling pathways in
NHL
B-cell lines, resulting in reverting the chemoresistant phenotype to a sensitive phenotype.
This study investigated whether rituximab also modifies intracellular signaling pathways resulting in the sensitization of
NHL
cells to Fas-induced apoptosis.
Treatment of the Fas-resistant
NHL
cell lines (2F7, Ramos and Raji) with rituximab sensitized the cells to CH-11 (FasL agonist mAb)-induced apoptosis and synergy was achieved.
These findings provide a novel mechanism of rituximab-mediated activity by sensitizing
NHL
cells to Fas-induced apoptosis.
[MeSH-major]
Antibodies, Monoclonal / pharmacology. Antigens, CD95 / immunology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects.
Lymphoma
, B-Cell / pathology
[MeSH-minor]
Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Burkitt
Lymphoma
/ pathology. Cell Line, Tumor. Cell Survival / drug effects. Enzyme Inhibitors / pharmacology. Gene Expression Regulation, Neoplastic. Humans. Imidazoles / pharmacology.
Lymphoma
,
AIDS
-
Related
. NF-kappa B / pharmacology. Pyridines / pharmacology. Rituximab. Transcription, Genetic / drug effects. p38 Mitogen-Activated Protein Kinases / metabolism
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
RITUXIMAB
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16103877.001).
[ISSN]
0950-9232
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
eng
[Grant]
United States / NIAID NIH HHS / AI / AI28697; United States / FIC NIH HHS / TW / D43 TW00013-14
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Imidazoles; 0 / NF-kappa B; 0 / Pyridines; 0 / SB 203580; 4F4X42SYQ6 / Rituximab; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
23.
Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF:
Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.
HIV Med
; 2005 Jan;6(1):21-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system
non
-
Hodgkin's lymphoma
in
AIDS
patients.
Central nervous system (CNS)
lymphoma
should always be considered because it is an important cause of morbidity and mortality.
RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS
lymphoma
.
This advantage suggests that, in case of negative flow cytometry results, disorders other than
non
-
Hodgkin's lymphoma
should be strongly considered.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ diagnosis. Meningeal Neoplasms / diagnosis
[MeSH-minor]
Adult. Burkitt
Lymphoma
/ cerebrospinal fluid. Burkitt
Lymphoma
/ diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity
Genetic Alliance.
consumer health - AIDS-HIV
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15670248.001).
[ISSN]
1464-2662
[Journal-full-title]
HIV medicine
[ISO-abbreviation]
HIV Med.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
England
24.
Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr:
Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
J Clin Oncol
; 2010 Nov 20;28(33):4935-44
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Second malignancy risks after
non
-
Hodgkin's lymphoma
and chronic lymphocytic leukemia: differences by
lymphoma
subtype.
PURPOSE: Previous studies have shown increased risks of second malignancies after
non
-
Hodgkin's lymphoma
(
NHL
) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by
lymphoma
subtype.
PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic
lymphoma
(SLL), diffuse large B-cell
lymphoma
(DLBCL), or follicular
lymphoma
(FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.
RESULTS: Among patients without HIV/
AIDS
-
related lymphoma
, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).
Patients with HIV/
AIDS
-
related lymphoma
(n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).
CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among
lymphoma
subtypes contribute to the patterns of second malignancy risk.
Elucidating these patterns may provide etiologic clues to
lymphoma
as well as to the second malignancies.
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33
[
15824165.001
]
[Cites]
Am J Epidemiol. 2010 Feb 1;171(3):267-76
[
20047977.001
]
[Cites]
Br J Cancer. 2005 Jul 11;93(1):159-66
[
15970927.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6
[
16214923.001
]
[Cites]
N Engl J Med. 2005 Nov 17;353(20):2135-47
[
16291983.001
]
[Cites]
Lung Cancer. 2005 Dec;50(3):419-20
[
16125820.001
]
[Cites]
J Clin Oncol. 2006 Apr 1;24(10):1568-74
[
16520465.001
]
[Cites]
Cancer. 2006 Jul 1;107(1):108-15
[
16708354.001
]
[Cites]
Haematologica. 2006 Nov;91(11):1481-8
[
17043014.001
]
[Cites]
Leuk Lymphoma. 2006 Nov;47(11):2314-20
[
17107903.001
]
[Cites]
AIDS. 2007 Jan 11;21(2):207-13
[
17197812.001
]
[Cites]
Int J Cancer. 2007 Mar 1;120(5):1099-102
[
17131330.001
]
[Cites]
Cancer Causes Control. 2007 Mar;18(2):135-42
[
17235495.001
]
[Cites]
Int J Cancer. 2007 Jul 1;121(1):151-6
[
17351903.001
]
[Cites]
Blood. 2007 Jun 1;109(11):4617-26
[
17311989.001
]
[Cites]
Blood. 2007 Jul 15;110(2):695-708
[
17389762.001
]
[Cites]
Lancet. 2007 Jul 7;370(9581):59-67
[
17617273.001
]
[Cites]
Int J Cancer. 2008 Jan 1;122(1):144-54
[
17708556.001
]
[Cites]
Cancer Causes Control. 2008 Feb;19(1):43-50
[
17906957.001
]
[Cites]
Haematologica. 2008 Mar;93(3):398-404
[
18268277.001
]
[Cites]
Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8
[
18387498.001
]
[Cites]
Blood. 2008 Apr 15;111(8):4029-38
[
18263783.001
]
[Cites]
J Clin Oncol. 2008 Apr 10;26(11):1850-7
[
18347006.001
]
[Cites]
Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15
[
18402527.001
]
[Cites]
Int J Cancer. 2008 Jul 1;123(1):187-94
[
18435450.001
]
[Cites]
Expert Opin Pharmacother. 2008 Jun;9(9):1481-94
[
18518779.001
]
[Cites]
Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix
[
18954744.001
]
[Cites]
Blood. 2008 Dec 15;112(13):5150-60
[
18796628.001
]
[Cites]
Blood. 2009 Jan 29;113(5):1175-83
[
18971419.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2454-60
[
10561309.001
]
[Cites]
Cancer. 2001 Feb 15;91(4):874-80
[
11241258.001
]
[Cites]
J Clin Oncol. 2001 Mar 15;19(6):1610-8
[
11250989.001
]
[Cites]
J Natl Cancer Inst. 2002 Feb 6;94(3):182-92
[
11830608.001
]
[Cites]
Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24
[
11842384.001
]
[Cites]
J Clin Oncol. 2002 Sep 15;20(18):3878-84
[
12228208.001
]
[Cites]
Br J Cancer. 2003 Jan 13;88(1):74-8
[
12556962.001
]
[Cites]
Med Oncol. 2003;20(3):211-20
[
14514970.001
]
[Cites]
Eur J Cancer. 2004 Feb;40(3):383-9
[
14746857.001
]
[Cites]
Blood. 2004 Feb 15;103(4):1222-8
[
14576060.001
]
[Cites]
Cancer. 2004 May 1;100(9):1902-8
[
15112271.001
]
[Cites]
J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91
[
15247562.001
]
[Cites]
J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7
[
1512794.001
]
[Cites]
Eur J Haematol. 1994 Oct;53(4):218-22
[
7957806.001
]
[Cites]
J Natl Cancer Inst. 1995 Apr 5;87(7):524-30
[
7707439.001
]
[Cites]
J Clin Oncol. 1996 Feb;14(2):565-71
[
8636772.001
]
[Cites]
Int J Cancer. 1997 Nov 27;73(5):645-50
[
9398040.001
]
[Cites]
Cancer. 2005 Jan 15;103(2):216-28
[
15578683.001
]
[Cites]
N Engl J Med. 2009 Feb 12;360(7):659-67
[
19213679.001
]
[Cites]
J Natl Cancer Inst. 2009 Feb 18;101(4):248-55
[
19211444.001
]
[Cites]
J Clin Oncol. 2009 Feb 20;27(6):904-10
[
19114699.001
]
[Cites]
Nat Genet. 2009 Aug;41(8):873-5
[
19620980.001
]
[Cites]
J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30
[
19648510.001
]
[Cites]
Blood. 2005 Jun 15;105(12):4573-5
[
15741224.001
]
(PMID = 20940199.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
ENG
[Grant]
United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Other-IDs]
NLM/ PMC3020697
25.
Pereg D, Koren G, Lishner M:
The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy.
Haematologica
; 2007 Sep;92(9):1230-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The treatment of
Hodgkin's
and
non
-
Hodgkin's lymphoma
in pregnancy.
BACKGROUND AND OBJECTIVES:
Lymphoma
is the fourth most frequent malignancy diagnosed during pregnancy, occurring in approximately 1 over 6000 deliveries.
DESIGN AND METHODS: Its occurrence may increase due to the current trend to postpone pregnancy until later in life and the evidence suggested high incidence of
AIDS
-
related non
-
Hodgkin's lymphoma
in developing countries.
The relatively rare occurrence of pregnancy-associated
lymphoma
precludes the conduction of large, prospective studies to examine diagnostic, management and outcome issues.
In the vast majority of cases, when
lymphoma
is diagnosed during the first trimester, treatment with a standard chemotherapy regimen, following pregnancy termination should be recommended.
In the rare patients at low risk, such as those with stage 1
Hodgkin's lymphoma
or indolent
non
-Hodgkins
lymphoma
, therapy can be delayed until the end of the first trimester and of embryogenesis while keeping the patients under close observation.
INTERPRETATION AND CONCLUSIONS: When
lymphoma
is diagnosed during the second and third trimesters, evidence exists suggesting that full-dose chemotherapy can be administered safely without apparent increased risk of severe adverse fetal outcome.
[MeSH-major]
Hodgkin
Disease / therapy.
Lymphoma
,
Non
-
Hodgkin
/ therapy. Pregnancy Complications, Neoplastic / therapy
Genetic Alliance.
consumer health - Pregnancy
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
MedlinePlus Health Information.
consumer health - Tumors and Pregnancy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17666365.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Italy
[Number-of-references]
67
26.
Galceran J, Marcos-Gragera R, Soler M, Romaguera A, Ameijide A, Izquierdo A, Borràs J, de Sanjosé S, Casabona J:
Cancer incidence in AIDS patients in Catalonia, Spain.
Eur J Cancer
; 2007 Apr;43(6):1085-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cancer incidence in
AIDS
patients in Catalonia, Spain.
HIV infected people and
AIDS
patients develop cancer more frequently than the general population.
The objective of this study was to evaluate the risk of developing cancer among 15 to 69 year old
AIDS
patients from two geographic areas: Tarragona and Girona provinces, in north-eastern Spain.
We have studied invasive and in situ cancers (for all sites) among 1659
AIDS
patients from +/-5 years around the date of their
AIDS
diagnosis by matching the population-based Cancer Registries with the
AIDS
Registry covering these populations.
Compared with the general population, incidence of cancer among
AIDS
patients (invasive and in situ) increased 22.9 fold in men (n=142) and 21.0 fold in women (n=45).
High statistically significant SIRs were found for Kaposi's sarcoma (KS) (male, 486.4; female, 1030.0),
non
-
Hodgkin's lymphoma
(
NHL
) (male, 126.1; female, 192.8) and invasive cervical cancer (41.8).
High risks were also found for
Hodgkin's lymphoma
(31.1), liver cancer (29.4) and lung cancer (9.4) in men, and in situ cervical cancer (24.4) in women.
For all
non
-
AIDS
defining malignant neoplasms as a group SIRs were 3.4 in men and 2.5 in women.
Among men, homo/bisexuality was strongly
related
to risk of KS and
NHL
.
The rates of cervical cancer,
Hodgkin's lymphoma
, liver cancer and lung cancer were among the highest ever reported linked to HIV infection.
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17349785.001).
[ISSN]
0959-8049
[Journal-full-title]
European journal of cancer (Oxford, England : 1990)
[ISO-abbreviation]
Eur. J. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
27.
Jazirehi AR, Bonavida B:
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Oncogene
; 2005 Mar 24;24(13):2121-43
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in
non
-
Hodgkin's lymphoma
: implications in chemosensitization and therapeutic intervention.
The clinical application of rituximab (chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with chemotherapy, has significantly ameliorated the treatment outcome of patients with relapsed and refractory low-grade or follicular
non
-
Hodgkin's lymphoma
(
NHL
).
Monomeric rituximab chemosensitizes drug-resistant
NHL
cells via selective downregulation of antiapoptotic factors through the type II mitochondrial apoptotic pathway.
ARL (acquired immunodeficiency syndrome (
AIDS
)-
related lymphoma
) and
non
-ARL cell lines have been examined as in vitro model systems.
Rituximab upregulates Raf-1 kinase inhibitor protein (RKIP) expression in
non
-ARL cells.
Downmodulation of the ERK1/2 and NF-kappa B pathways inhibits the transcriptional activity of AP-1 and NF-kappa B transcription factors, respectively, both of which lead to the downregulation of Bcl-(xL) (Bcl-2
related
gene (long alternatively spliced variant of Bcl-x gene)) transcription and expression and sensitization to drug-induced apoptosis.
Rituximab-resistant B-
NHL
clones were generated to investigate the acquired resistance to rituximab-mediated signaling, and chemosensitization.
Studies presented herein also reveal several intracellular targets modified by rituximab, which can be exploited for therapeutic and prognostic purposes in the treatment of patients with rituximab- and drug-refractory
NHL
.
[MeSH-major]
Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use.
Lymphoma
,
Non
-
Hodgkin
/ drug therapy. Signal Transduction / drug effects
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
RITUXIMAB
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15789036.001).
[ISSN]
0950-9232
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Recombinant Fusion Proteins; 4F4X42SYQ6 / Rituximab
[Number-of-references]
250
28.
Sharma A, Bajpai J, Raina V, Mohanti BK:
HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
Indian J Cancer
; 2010 Jan-Mar;47(1):35-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HIV-associated
non
-
Hodgkin's lymphoma
: experience from a regional cancer center.
AIMS: To analyze clinical features and survival in HIV-associated
non
-
Hodgkin
lymphoma
(
NHL
) cases registered at Dr BRA Institute Rotary Cancer Hospital of AIIMS, New Delhi.
MATERIALS AND METHODS: We have retrospectively reviewed records of
NHL
patients registered, from January 2003 to July 2007 to analyze HIV-associated
NHL
.
RESULTS: Seven cases of HIV-associated
NHL
cases were identified.
Three cases had nodal
lymphoma
and four had extra nodal
lymphoma
.
No primary CNS (PCNSL)
lymphoma
was seen.
Six cases had high-grade
NHL
.
HIV infection was diagnosed as part of
NHL
work-up in five patients.
CONCLUSIONS: These
NHL
are of higher grade and advanced stage.
[MeSH-major]
HIV Infections / complications. HIV Infections / mortality.
Lymphoma
,
AIDS
-
Related
/ mortality.
Lymphoma
,
Non
-
Hodgkin
/ mortality.
Lymphoma
,
Non
-
Hodgkin
/ virology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Indian J Cancer. 2010 Jan-Mar;47(1):6-7
[
20071782.001
]
(PMID = 20071788.001).
[ISSN]
1998-4774
[Journal-full-title]
Indian journal of cancer
[ISO-abbreviation]
Indian J Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
29.
Marotta D, Sgambato A, Cerciello S, Magarelli N, Martini M, Larocca LM, Maccauro G:
Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature.
World J Surg Oncol
; 2008;6:111
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Soft tissue
non
-
Hodgkin
lymphoma
of shoulder in a HIV patient: a report of a case and review of the literature.
BACKGROUND: The risk of developing
lymphoma
is greatly increased in HIV infection.
HIV-
related
neoplastic processes that affect the musculoskeletal system include Kaposi's sarcoma and
non
-
Hodgkin's lymphoma
, the latter being mainly localized at lower extremities, spine and skull.
A final diagnosis of diffuse large B-cell
lymphoma
was made.
CONCLUSION: In this report, we present a case of diffuse large B-cell
lymphoma
localized in the soft tissue of the shoulder in a HIV infected patient.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ pathology.
Lymphoma
, Large B-Cell, Diffuse / pathology. Pregnancy Complications, Neoplastic / pathology. Pregnancy Outcome. Soft Tissue Neoplasms / pathology
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Tumors and Pregnancy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Med Interne (Paris). 2003 Dec;154(8):523-8
[
15037828.001
]
[Cites]
J Am Acad Dermatol. 2003 May;48(5 Suppl):S82-5
[
12734486.001
]
[Cites]
Radiology. 1980 Feb;134(2):521-3
[
7352243.001
]
[Cites]
Am J Surg Pathol. 1987 May;11(5):359-66
[
3578646.001
]
[Cites]
Br J Radiol. 1989 Jan;62(733):81
[
2914198.001
]
[Cites]
J Comput Assist Tomogr. 1995 May-Jun;19(3):455-9
[
7790558.001
]
[Cites]
Bol Asoc Med P R. 1995 Oct-Dec;87(10-12):158-61
[
8924158.001
]
[Cites]
Crit Rev Diagn Imaging. 1996 Sep;37(4):305-47
[
8894398.001
]
[Cites]
Clin Radiol. 1997 Mar;52(3):203-12
[
9091255.001
]
[Cites]
Radiol Clin North Am. 1997 Sep;35(5):1167-89
[
9298091.001
]
[Cites]
Am J Orthop (Belle Mead NJ). 1998 Feb;27(2):128-34
[
9506198.001
]
[Cites]
Semin Ultrasound CT MR. 1998 Apr;19(2):200-8
[
9567324.001
]
[Cites]
Blood. 1998 Aug 1;92(3):1011-9
[
9680371.001
]
[Cites]
Am J Surg Pathol. 1999 Jan;23(1):88-96
[
9888708.001
]
[Cites]
Clin Orthop Relat Res. 1999 Mar;(360):221-30
[
10101328.001
]
[Cites]
Leuk Lymphoma. 2006 Feb;47(2):329-32
[
16321866.001
]
[Cites]
Blood. 2006 Jan 1;107(1):13-20
[
16099881.001
]
[Cites]
Leukemia. 2007 Feb;21(2):207-14
[
17170731.001
]
[Cites]
AJR Am J Roentgenol. 2007 Jun;188(6):1443-5
[
17515361.001
]
[Cites]
J Am Acad Orthop Surg. 2002 Sep-Oct;10(5):312-20
[
12374482.001
]
[Cites]
Rev Chir Orthop Reparatrice Appar Mot. 2002 Sep;88(5):518-21
[
12399719.001
]
[Cites]
Leuk Lymphoma. 2002 Dec;43(12):2405-7
[
12613532.001
]
[Cites]
Skeletal Radiol. 2004 Jun;33(6):311-20
[
15127244.001
]
(PMID = 18939988.001).
[ISSN]
1477-7819
[Journal-full-title]
World journal of surgical oncology
[ISO-abbreviation]
World J Surg Oncol
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
England
[Number-of-references]
24
30.
Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ:
Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy.
J Neurol Neurosurg Psychiatry
; 2010 Nov;81(11):1288-91
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Of all patients, only two were females including one who had
non
-
Hodgkin's lymphoma
and was HIV negative.
[MeSH-major]
AIDS
-
Related
Opportunistic Infections / immunology.
AIDS
-
Related
Opportunistic Infections / mortality. JC Virus / immunology. Leukoencephalopathy, Progressive Multifocal / immunology. Leukoencephalopathy, Progressive Multifocal / mortality
[MeSH-minor]
Adult. Antibodies, Viral / blood. Antiretroviral Therapy, Highly Active. Female. Follow-Up Studies. Humans.
Lymphoma
,
Non
-
Hodgkin
/ mortality. Magnetic Resonance Imaging. Male. Middle Aged. Time Factors. Treatment Outcome
Genetic Alliance.
consumer health - Progressive multifocal leukoencephalopathy
.
MedlinePlus Health Information.
consumer health - HIV/AIDS and Infections
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurovirol. 2003 Jun;9(3):411-9
[
12775425.001
]
[Cites]
J Neurovirol. 2003;9 Suppl 1:88-92
[
12709878.001
]
[Cites]
N Engl J Med. 2004 Apr 29;350(18):1882-93
[
15115835.001
]
[Cites]
Brain. 2004 Sep;127(Pt 9):1970-8
[
15215217.001
]
[Cites]
Stroke. 1989 Jun;20(6):828
[
2728057.001
]
[Cites]
J Neurovirol. 1998 Feb;4(1):59-68
[
9531012.001
]
[Cites]
Science. 2004 Nov 19;306(5700):1380-3
[
15550673.001
]
[Cites]
N Engl J Med. 2005 Jul 28;353(4):414-6
[
15947082.001
]
[Cites]
J NeuroAIDS. 1996;1(4):79-88
[
16873181.001
]
[Cites]
Ann Neurol. 2006 Aug;60(2):162-73
[
16862584.001
]
[Cites]
J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):26-31
[
18667930.001
]
[Cites]
AIDS. 2008 Sep 12;22(14):1759-67
[
18753934.001
]
[Cites]
J Infect Dis. 2009 Jan 1;199(1):77-83
[
19007313.001
]
[Cites]
Virology. 2009 Jan 20;383(2):173-7
[
19062062.001
]
[Cites]
J Neurovirol. 2001 Aug;7(4):386-90
[
11517422.001
]
[Cites]
Clin Infect Dis. 2003 Apr 15;36(8):1047-52
[
12684918.001
]
[Cites]
J Neurovirol. 2003;9 Suppl 1:47-53
[
12709872.001
]
[Cites]
AIDS. 2003 Jul 4;17(10):1443-9
[
12824781.001
]
(PMID = 20710013.001).
[ISSN]
1468-330X
[Journal-full-title]
Journal of neurology, neurosurgery, and psychiatry
[ISO-abbreviation]
J. Neurol. Neurosurg. Psychiatry
[Language]
eng
[Grant]
United States / NINDS NIH HHS / NS / K24 NS 060950; United States / NIAID NIH HHS / AI / R01 NS/AI 041198; United States / NINDS NIH HHS / NS / NS 047029; United States / NINDS NIH HHS / NS / R01 NS041198; United States / NINDS NIH HHS / NS / R01 NS047029; United States / NINDS NIH HHS / NS / K24 NS060950
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Viral
[Other-IDs]
NLM/ NIHMS266515; NLM/ PMC3077967
31.
Gabriel I, Apperley J, Bower M, Chaidos A, Gazzard B, Giles C, Kew A, Nelson M, Kanfer E:
A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease.
AIDS
; 2008 Feb 19;22(4):539-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A 44-year-old man with relapsed HIV-associated stage IV nodular sclerosing
Hodgkin's
disease underwent high-dose therapy with autologous stem cell transplantation.
Autologous stem cell transplantation is safe in HIV patients and can achieve long-term durable remissions in
Hodgkin's
disease.
[MeSH-major]
Antiretroviral Therapy, Highly Active. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cell Transplantation / methods.
Hodgkin
Disease / therapy.
Lymphoma
,
AIDS
-
Related
/ therapy
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
Hazardous Substances Data Bank.
LOMUSTINE
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18301069.001).
[ISSN]
1473-5571
[Journal-full-title]
AIDS (London, England)
[ISO-abbreviation]
AIDS
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
32.
Dhir AA:
HIV-associated non-Hodgkin's lymphoma: how much do we know?
Indian J Cancer
; 2010 Jan-Mar;47(1):6-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HIV-associated
non
-
Hodgkin's lymphoma
: how much do we know?
[MeSH-major]
HIV Infections / complications.
Lymphoma
,
AIDS
-
Related
/ epidemiology.
Lymphoma
,
Non
-
Hodgkin
/ epidemiology.
Lymphoma
,
Non
-
Hodgkin
/ virology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Indian J Cancer. 2010 Jan-Mar;47(1):35-9
[
20071788.001
]
(PMID = 20071782.001).
[ISSN]
1998-4774
[Journal-full-title]
Indian journal of cancer
[ISO-abbreviation]
Indian J Cancer
[Language]
eng
[Publication-type]
Comment; Editorial
[Publication-country]
India
33.
Fleisch F, Reinhart WH, Brand B, Berger C:
Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma.
Swiss Med Wkly
; 2005 Apr 30;135(17-18):263-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of
non
-
Hodgkin's lymphoma
.
Immunocompromised patients are at risk of developing Epstein-Barr virus (EBV)-
related
lymphoproliferative disorders.
Quantitative determination of serum EBV DNA permits early diagnosis of an
AIDS
-
related non
-
Hodgkin's lymphoma
, and surveillance of treatment response and/or relapse, and thus may be a useful tool to monitor disease activity.
[MeSH-major]
DNA, Viral / blood. HIV Infections / virology. Herpesvirus 4, Human / isolation & purification.
Lymphoma
,
AIDS
-
Related
/ virology.
Lymphoma
,
Non
-
Hodgkin
/ virology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Zurich Open Access Repository and Archive.
Full text from
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15965829.001).
[ISSN]
1424-7860
[Journal-full-title]
Swiss medical weekly
[ISO-abbreviation]
Swiss Med Wkly
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Anti-HIV Agents; 0 / DNA, Viral; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
34.
Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST:
High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.
Leukemia
; 2005 May;19(5):851-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-
related
solid immunoblastic/plasmablastic diffuse large B-cell
lymphoma
.
Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion
lymphoma
(PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic
lymphoma
.
We here report a high incidence of KSHV infection in solid HIV-associated immunoblastic/plasmablastic
non
-
Hodgkin's
lymphomas (NHLs), in patients lacking effusions and without evidence of (prior) MCD.
Within a cohort of 99 HIV-
related
NHLs, 10 cases were found to be KSHV positive on the basis of immunostaining for KSHV LNA-1 as well as KSHV-specific polymerase chain reaction.
Our results indicate that KSHV infection is not restricted to PEL and MCD; it is also common (38%) in HIV-
related
solid immunoblastic/plasmablastic lymphomas.
[MeSH-major]
Giant Lymph Node Hyperplasia / virology. HIV Infections / virology. Herpesviridae Infections / virology. Herpesvirus 8, Human.
Lymphoma
,
AIDS
-
Related
/ virology.
Lymphoma
, Large B-Cell, Diffuse / virology. Sarcoma, Kaposi / virology
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - Kaposi's Sarcoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15744337.001).
[ISSN]
0887-6924
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
35.
Diamond C, Taylor TH, Im T, Anton-Culver H:
Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS.
Leuk Lymphoma
; 2006 Sep;47(9):1822-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Presentation and outcomes of systemic
non
-
Hodgkin's lymphoma
: a comparison between patients with acquired immunodeficiency syndrome (
AIDS
) treated with highly active antiretroviral therapy and patients without
AIDS
.
We used the San Diego/Orange County cancer registry to identify 64 cases of systemic
non
-
Hodgkin's lymphoma
(
NHL
) with
AIDS
who received highly active antiretroviral therapy (HAART) at the time of
NHL
diagnosis or thereafter and 64
NHL
controls without
AIDS
, matched on age, sex, race, time of
NHL
diagnosis (1994-1995 and 1996-1999), and hospital type (academic, large community, and small community).
Patients with
AIDS
-
related
NHL
who received HAART had high grade histology and baseline cytopenia and received reduced-dose chemotherapy more often than patients without
AIDS
.
However,
AIDS
patients who received HAART and chemotherapy had survival similar to
NHL
patients without
AIDS
, an improvement from the pre-HAART era.
Appropriate hematologic support, through growth factors, transfusions, and avoidance of drugs with hematologic toxicity, might allow full dosing of chemotherapy, and perhaps would further improve outcomes among patients with
AIDS
and
NHL
.
[MeSH-major]
Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy.
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
,
Non
-
Hodgkin
/ drug therapy
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17064995.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / 1K07 CA 096480
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
36.
Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D:
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
J Clin Oncol
; 2006 Sep 1;24(25):4123-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase II trial of CHOP plus rituximab in patients with HIV-associated
non
-
Hodgkin's lymphoma
.
PURPOSE: To evaluate the safety and efficacy of rituximab adjunction to the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed
AIDS
-
related non
-
Hodgkin's lymphoma
.
PATIENTS AND METHODS: HIV-seropositive patients with high-grade
lymphoma
of B-cell origin were eligible if they had no more than one of the following characteristics: CD4 cell count less than 100/microL, prior
AIDS
, or performance status less than 2.
Characteristics of patients were median age, 41 years; median CD4 cells, 172/microL; histology, diffuse large B-cell
lymphoma
(n = 42), immunoblastic (n = 2), Burkitt
lymphoma
(n = 16), and plasmablastic (n = 1); 42 patients with stage III to IV; International Prognostic Index 0 to 1 (n=31), and 2 to 3 (n = 27).
Eighteen patients died: 16 as a result of
lymphoma
, one as a result of infection, and one as a result of encephalitis.
CONCLUSION: Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with
AIDS
-
related non
-
Hodgkin's lymphoma
, without increasing the risk of life-threatening infections.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Hodgkin
Disease / drug therapy.
Lymphoma
,
AIDS
-
Related
/ drug therapy
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Clin Oncol. 2007 Feb 20;25(6):e6
[
17308260.001
]
[CommentIn]
J Clin Oncol. 2007 Feb 20;25(6):e7
[
17308261.001
]
(PMID = 16896005.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
37.
Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT, Swiss HIV Cohort Study:
Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Antivir Ther
; 2007;12(6):931-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Treatment and prognosis of
AIDS
-
related lymphoma
in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with
AIDS
-
related non
-
Hodgkin's lymphoma
.
METHODS: The study included 91 patients with
AIDS
-
related non
-
Hodgkin's lymphoma
from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain.
We extracted
AIDS
-
related non
-
Hodgkin's lymphoma
- and HIV-specific variables at the time of
lymphoma
diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database.
The effect of cART interruptions on
AIDS
-
related non
-
Hodgkin's lymphoma
prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count.
[MeSH-major]
Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy.
Lymphoma
,
AIDS
-
Related
/ drug therapy
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17926647.001).
[ISSN]
1359-6535
[Journal-full-title]
Antiviral therapy
[ISO-abbreviation]
Antivir. Ther. (Lond.)
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Anti-HIV Agents; 0 / Antineoplastic Agents
38.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM:
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.
Lancet
; 2007 Jul 7;370(9581):59-67
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Incidence of cancers in people with HIV/
AIDS
compared with immunosuppressed transplant recipients: a meta-analysis.
BACKGROUND: Only a few types of cancer are recognised as being directly
related
to immune deficiency in people with HIV/
AIDS
.
Our aim was to compare cancer incidence in population-based cohort studies of people with HIV/
AIDS
and people immunosuppressed after solid organ transplantation.
FINDINGS: Seven studies of people with HIV/
AIDS
(n=444,172) and five of transplant recipients (n=31 977) were included.
Most of these were cancers with a known infectious cause, including all three types of
AIDS
-defining cancer, all HPV-
related
cancers, as well as
Hodgkin's lymphoma
(HIV/
AIDS
meta-analysis SIR 11.03, 95% CI 8.43-14.4; transplant 3.89, 2.42-6.26), liver cancer (HIV/
AIDS
5.22, 3.32-8.20; transplant 2.13, 1.16-3.91), and stomach cancer (HIV/
AIDS
1.90, 1.53-2.36; transplant 2.04, 1.49-2.79).
Infection-
related
cancer will probably become an increasingly important complication of long-term HIV infection.
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Organ Transplantation
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Lancet. 2007 Jul 7;370(9581):6-7
[
17617251.001
]
(PMID = 17617273.001).
[ISSN]
1474-547X
[Journal-full-title]
Lancet (London, England)
[ISO-abbreviation]
Lancet
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Number-of-references]
30
39.
Balsalobre P, Díez-Martín JL, Re A, Michieli M, Ribera JM, Canals C, Rosselet A, Conde E, Varela R, Cwynarski K, Gabriel I, Genet P, Guillerm G, Allione B, Ferrant A, Biron P, Espigado I, Serrano D, Sureda A:
Autologous stem-cell transplantation in patients with HIV-related lymphoma.
J Clin Oncol
; 2009 May 1;27(13):2192-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Autologous stem-cell transplantation in patients with HIV-
related lymphoma
.
PURPOSE: Peripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-
related lymphoma
(HIV-Ly) has been reported as a safe and useful procedure.
RESULTS: Since 1999, 68 patients from 20 institutions (median age, 41 years; range, 29 to 62 years) were included, diagnosed with
non
-
Hodgkin's lymphoma
(
NHL
; n = 50) or
Hodgkin's lymphoma
(n = 18).
CI of relapse was 30.4% at 24 months, statistically
related
with not being in CR at ASCT (relative risk [RR] = 3.6),
NHL
histology other than diffuse large B-cell
lymphoma
(RR = 3.4), and use of more than two previous treatment lines (RR = 3).
CONCLUSION: Similarly to HIV-negative patients with
lymphoma
, ASCT is a useful treatment for patients with HIV-Ly and is associated with low NRM, mainly when performed in early stages and chemo-S disease.
[MeSH-major]
Hematopoietic Stem Cell Transplantation.
Lymphoma
,
AIDS
-
Related
/ therapy
Genetic Alliance.
consumer health - Transplantation
.
Genetic Alliance.
consumer health - HIV
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
J Clin Oncol. 2009 Jul 1;27(19):3263
(PMID = 19332732.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
40.
Engels EA, Pfeiffer RM, Landgren O, Moore RD:
Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era.
J Acquir Immune Defic Syndr
; 2010 May 1;54(1):78-84
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunologic and virologic predictors of
AIDS
-
related non
-
hodgkin
lymphoma
in the highly active antiretroviral therapy era.
HIV-infected persons treated with highly active antiretroviral therapy (HAART) continue to have elevated risk for
non
-
Hodgkin
lymphoma
(
NHL
).
We conducted a retrospective cohort study of
NHL
among patients at an urban HIV clinic (N = 3025).
Proportional hazards models identified immunologic and virologic predictors of
NHL
.
NHL
incidence declined over time.
NHL
risk increased with declining CD4 count (P trend < 0.0001) and increasing HIV viral load (P trend = 0.005).
In a multivariable model,
NHL
risk was independently associated with both current CD4 count (hazard ratios 7.7 and 3.8, respectively, for CD4 counts 0-99 and 100-249 vs. 250+ cells/mm(3); P trend < 0.0001) and prior time spent with a viral load above 5.00 log(10) copies/mL (hazard ratios of 3.4, 2.6, and 6.8, respectively, for 0.1-0.4, 0.5-1.4, and 1.5+ yr vs. 0 yr; P trend = 0.004).
Although serum globulin levels were elevated compared with the general population,
NHL
risk was unrelated to this B-cell activation marker (P = 0.39).
The association with high-level viremia could reflect detrimental effects on immune function
related
to incompletely effective HAART or direct effects on B cells.
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Curr HIV Res. 2004 Jan;2(1):11-21
[
15053337.001
]
[Cites]
Mod Pathol. 2003 May;16(5):424-9
[
12748248.001
]
[Cites]
J Clin Oncol. 2004 Jun 1;22(11):2177-83
[
15169806.001
]
[Cites]
N Engl J Med. 2004 Oct 7;351(15):1548-63
[
15470219.001
]
[Cites]
N Engl J Med. 1983 Aug 25;309(8):453-8
[
6224088.001
]
[Cites]
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
[
1361652.001
]
[Cites]
Eur J Haematol. 1995 Oct;55(4):245-50
[
7589342.001
]
[Cites]
Int J Cancer. 1997 Nov 27;73(5):645-50
[
9398040.001
]
[Cites]
J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17 Suppl 1:S38-41
[
9586651.001
]
[Cites]
Ann Intern Med. 1999 Aug 17;131(4):256-64
[
10454946.001
]
[Cites]
Int J Cancer. 1999 Nov 12;83(4):481-5
[
10508483.001
]
[Cites]
Tumour Biol. 2006;27(4):187-94
[
16651853.001
]
[Cites]
AIDS. 2006 Aug 1;20(12):1645-54
[
16868446.001
]
[Cites]
Curr Opin Oncol. 2006 Sep;18(5):444-8
[
16894291.001
]
[Cites]
Ann Rheum Dis. 2007 Jan;66(1):23-7
[
16569685.001
]
[Cites]
JAMA. 2007 Jun 6;297(21):2349-50
[
17551128.001
]
[Cites]
J Natl Cancer Inst. 2007 Jun 20;99(12):962-72
[
17565153.001
]
[Cites]
Lancet. 2007 Jul 7;370(9581):59-67
[
17617273.001
]
[Cites]
AIDS. 2008 Jan 11;22(2):301-6
[
18097233.001
]
[Cites]
Ann Intern Med. 2008 May 20;148(10):728-36
[
18490686.001
]
[Cites]
J Allergy Clin Immunol. 2008 Jul;122(1):12-9; quiz 20-1
[
18547629.001
]
[Cites]
J Infect Dis. 2009 Jul 1;200(1):79-87
[
19476437.001
]
[Cites]
AIDS. 2000 Jan 28;14(2):133-40
[
10708283.001
]
[Cites]
Am J Epidemiol. 2000 Nov 15;152(10):923-33
[
11092434.001
]
[Cites]
J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30
[
11078759.001
]
[Cites]
Blood. 2001 Dec 1;98(12):3406-12
[
11719381.001
]
[Cites]
AIDS. 2004 Mar 5;18(4):673-81
[
15090773.001
]
(PMID = 20418723.001).
[ISSN]
1944-7884
[Journal-full-title]
Journal of acquired immune deficiency syndromes (1999)
[ISO-abbreviation]
J. Acquir. Immune Defic. Syndr.
[Language]
ENG
[Grant]
United States / NIAAA NIH HHS / AA / R01 AA016893; United States / NIDA NIH HHS / DA / R01 DA011602; United States / NIDA NIH HHS / DA / K24 DA000432; United States / NIDA NIH HHS / DA / K24 DA000432-10; United States / NIDA NIH HHS / DA / DA011602-13; United States / NIAID NIH HHS / AI / U01 AI069918-05; United States / Intramural NIH HHS / / Z01 CP010150-08; United States / NIDA NIH HHS / DA / R01 DA11602; United States / NIAID NIH HHS / AI / U01 AI069918; United States / NIAAA NIH HHS / AA / R01 AA016893-01A2; United States / NIDA NIH HHS / DA / K24 DA00432; United States / NIDA NIH HHS / DA / R01 DA011602-13; United States / NIAAA NIH HHS / AA / R01 AA16893; United States / Intramural NIH HHS / / Z01 CP010150-09; United States / NIAID NIH HHS / AI / AI069918-05
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS152223; NLM/ PMC3078556
41.
Spina M, Simonelli C, Tirelli U:
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
J Clin Oncol
; 2007 Feb 20;25(6):e7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase II trial of CHOP plus rituximab in patients with HIV-associated
non
-
Hodgkin's lymphoma
.
[MeSH-major]
Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
,
Non
-
Hodgkin
/ drug therapy
Genetic Alliance.
consumer health - HIV
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
J Clin Oncol. 2006 Sep 1;24(25):4123-8
[
16896005.001
]
(PMID = 17308261.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Comment; Letter
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
42.
Pantanowitz L, Pihan G, Carbone A, Dezube BJ:
Differentiating HIV-associated non-Hodgkin's lymphomas with similar plasmacellular differentiation.
J HIV Ther
; 2009 Jun;14(2):24-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Differentiating HIV-associated
non
-
Hodgkin's
lymphomas with similar plasmacellular differentiation.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ pathology.
Lymphoma
,
Non
-
Hodgkin
/ pathology. Plasma Cells / pathology
[MeSH-minor]
Burkitt
Lymphoma
/ pathology. Cell Differentiation. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Humans.
Lymphoma
, Large B-Cell, Diffuse / pathology. Lymphoproliferative Disorders / pathology
Genetic Alliance.
consumer health - HIV
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19839364.001).
[ISSN]
1462-0308
[Journal-full-title]
Journal of HIV therapy
[ISO-abbreviation]
J HIV Ther
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Number-of-references]
123
43.
Chanan-Khan A, Holkova B, Goldenberg AS, Pavlick A, Demopoulos R, Takeshita K:
Non-Hodgkin's lymphoma presenting as a breast mass in patients with HIV infection: a report of three cases.
Leuk Lymphoma
; 2005 Aug;46(8):1189-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Non
-
Hodgkin's lymphoma
presenting as a breast mass in patients with HIV infection: a report of three cases.
Breast involvement with
non
-
Hodgkin's lymphoma
(
NHL
) is rare.
Patients with
AIDS
have an increased incidence of
NHL
, often with high-grade histology, extranodal presentation and aggressive clinical course.
Lymphoma
of the breast in patients with HIV-1 infection has not been reported.
We reviewed our tumor registry database of all
AIDS
-associated
NHL
and report on the clinical presentation and long-term outcome of 3 patients with
AIDS
who presented with lymphomatous involvement of the breast.
[MeSH-major]
Breast Neoplasms / complications. Breast Neoplasms, Male / complications. HIV Infections / complications.
Lymphoma
,
AIDS
-
Related
/ complications.
Lymphoma
,
Non
-
Hodgkin
/ complications
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16085561.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD
44.
Kestler MH, Gardner EM, Cohn DL:
Hepatic non-Hodgkin's lymphoma with lactic acidosis in HIV-infected patients: report of 2 cases.
J Int Assoc Physicians AIDS Care (Chic)
; 2010 Sep-Oct;9(5):301-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Hepatic
non
-
Hodgkin's lymphoma
with lactic acidosis in HIV-infected patients: report of 2 cases.
We report 2 patients with HIV-associated
non
-
Hodgkin's lymphoma
with massive hepatic involvement and lactic acidosis.
[MeSH-major]
Acidosis, Lactic / etiology. Liver Neoplasms / complications.
Lymphoma
,
AIDS
-
Related
/ complications
Genetic Alliance.
consumer health - Lactic Acidosis
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20739590.001).
[ISSN]
1545-1097
[Journal-full-title]
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)
[ISO-abbreviation]
J Int Assoc Physicians AIDS Care (Chic)
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
45.
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Chene G, Egger M:
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.
Antivir Ther
; 2009;14(8):1065-74
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Incidence and risk factors of HIV-
related non
-
Hodgkin's lymphoma
in the era of combination antiretroviral therapy: a European multicohort study.
BACKGROUND: Incidence and risk factors of HIV-associated
non
-
Hodgkin's lymphoma
(
NHL
) are not well defined in the era of combination antiretroviral therapy (cART).
Weibull random effects models were used to estimate hazard ratios (HRs) for developing systemic
NHL
and included CD4(+) T-cell counts and viral load as time-updated variables.
RESULTS: During the 212,042 person-years of follow-up, 521 patients were diagnosed with systemic
NHL
and 62 with primary brain
lymphoma
(PBL).
The incidence rate of systemic
NHL
was 463 per 100,000 person-years not on cART and 205 per 100,000 person-years in treated patients for a rate ratio of 0.44 (95% confidence interval [CI] 0.37-0.53).
Suppression of HIV-1 replication on cART (HR 0.60, 95% CI 0.44-0.81, comparing < or =500 with 10,000-99,999 copies/ml) and increases in CD4(+) T-cell counts (HR 0.30, 0.22-0.42, comparing > or =350 with 100-199 cells/microl) were protective; a history of Kaposi's sarcoma (HR 1.70, 1.08-2.68, compared to no history of
AIDS
), transmission through sex between men (HR 1.57, 1.19-2.08, compared with heterosexual transmission) and older age (HR 3.71, 2.37-5.80, comparing > or =50 with 16-29 years) were risk factors for systemic
NHL
.
CONCLUSIONS: The incidence rates of both systemic
NHL
and PBL were substantially reduced in patients on cART.
Timely initiation of therapy is key to the prevention of
NHL
in the era of cART.
[MeSH-major]
Anti-HIV Agents / therapeutic use. Brain Neoplasms / epidemiology. HIV Infections / complications.
Lymphoma
,
AIDS
-
Related
/ epidemiology.
Lymphoma
,
Non
-
Hodgkin
/ epidemiology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
HAL archives ouvertes.
Full text from
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
JAMA. 1999 Dec 15;282(23):2220-6
[
10605973.001
]
[Cites]
Blood. 2009 Feb 5;113(6):1213-24
[
18955561.001
]
[Cites]
J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30
[
11078759.001
]
[Cites]
JAMA. 2001 Apr 4;285(13):1736-45
[
11277828.001
]
[Cites]
AIDS. 2001 Aug 17;15(12):1483-91
[
11504980.001
]
[Cites]
Blood. 2001 Dec 1;98(12):3406-12
[
11719381.001
]
[Cites]
Br J Cancer. 2001 Nov 2;85(9):1298-303
[
11720464.001
]
[Cites]
Blood. 2002 Apr 1;99(7):2331-6
[
11895764.001
]
[Cites]
Lancet Oncol. 2003 Feb;4(2):110-9
[
12573353.001
]
[Cites]
Mod Pathol. 2003 May;16(5):424-9
[
12748248.001
]
[Cites]
AIDS. 2003 Jul 4;17(10):1521-9
[
12824790.001
]
[Cites]
J Clin Oncol. 2004 Jun 1;22(11):2177-83
[
15169806.001
]
[Cites]
Antivir Ther. 2004 Aug;9(4):631-3
[
15456095.001
]
[Cites]
Am J Surg Pathol. 2004 Nov;28(11):1401-16
[
15489644.001
]
[Cites]
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
[
1361652.001
]
[Cites]
Am J Epidemiol. 1994 Feb 15;139(4):362-8
[
8109570.001
]
[Cites]
Science. 1994 Dec 16;266(5192):1865-9
[
7997879.001
]
[Cites]
N Engl J Med. 1995 May 4;332(18):1186-91
[
7700311.001
]
[Cites]
AIDS. 1996 Feb;10(2):181-5
[
8838706.001
]
[Cites]
Int J Cancer. 1997 Nov 27;73(5):645-50
[
9398040.001
]
[Cites]
Arch Intern Med. 2005 Feb 28;165(4):416-23
[
15738371.001
]
[Cites]
Leukemia. 2005 May;19(5):851-5
[
15744337.001
]
[Cites]
CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264
[
16020424.001
]
[Cites]
Clin Infect Dis. 2006 Feb 1;42(3):411-7
[
16392091.001
]
[Cites]
J Clin Oncol. 2006 Sep 1;24(25):4123-8
[
16896005.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):377-80
[
17372233.001
]
[Cites]
J Natl Cancer Inst. 2007 Jun 20;99(12):962-72
[
17565153.001
]
[Cites]
AIDS. 2007 Sep 12;21(14):1957-63
[
17721103.001
]
[Cites]
Antivir Ther. 2007;12(6):931-9
[
17926647.001
]
[Cites]
J Clin Pathol. 2007 Dec;60(12):1350-7
[
18042691.001
]
[Cites]
AIDS. 2008 Jan 11;22(2):301-6
[
18097233.001
]
[Cites]
AIDS. 2008 Feb 19;22(4):489-96
[
18301061.001
]
[Cites]
Int J Cancer. 2008 Jul 1;123(1):187-94
[
18435450.001
]
[Cites]
Clin Infect Dis. 2008 Aug 1;47(3):410-7
[
18582203.001
]
[Cites]
AIDS. 2008 Jul 31;22(12):1463-73
[
18614870.001
]
[Cites]
JAMA. 2008 Aug 6;300(5):555-70
[
18677028.001
]
[Cites]
Clin Infect Dis. 2008 Nov 1;47(9):1209-15
[
18808357.001
]
[Cites]
J Clin Oncol. 2008 Oct 10;26(29):4834-42
[
18591544.001
]
[Cites]
J Intern Med. 2008 Dec;264(6):537-48
[
19017178.001
]
[Cites]
AIDS. 2009 Jan 2;23(1):41-50
[
19050385.001
]
[Cites]
Clin Infect Dis. 2009 Mar 1;48(5):633-9
[
19202627.001
]
[Cites]
AIDS. 2000 Jan 28;14(2):133-40
[
10708283.001
]
(PMID = 20032536.001).
[ISSN]
2040-2058
[Journal-full-title]
Antiviral therapy
[ISO-abbreviation]
Antivir. Ther. (Lond.)
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / G0700820
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Anti-HIV Agents
[Other-IDs]
NLM/ HALMS394577; NLM/ PMC2821596
[Investigator]
Antinori A; Bonnet F; Boué F; Brockmeyer N; Casabona J; Costagliola D; Dronda F; Obel N; Fätkenheuer G; Fisher M; Franceschi S; Gibb D; Le Moing V; Mocroft A; Nadal D; Touloumi G; Prins M; Raffi F; Roca B; Verbon A; Wolf T; Fortuny C; Bohlius J; Chakraborty R; Clifford G; Egger M; Franceschi S; May M; Minder C; Sterne J; Zwahlen M; Ellefson M; Kjaer J; Collin F; Colin C; Weller I; Costagliola D; Ledergerber B; Lundgren J; Chene G; Touloumi G; Warszawski J; Meyer L; Dabis F; Krause MM; Goujard C; Leport C; de Wolf F; Reiss P; Porter K; Dorrucci M; Sabin C; Gibb D; Del Amo J; Obel N; Thorne C; Mocroft A; Kirk O; Staszewski S; Perez-Hoyos S; Almeda J; Antinori A; Monforte Ad; de Martino M; Brockmeyer N; Fätkenheuer G; Ramos J; Battegay M; Mussini C; Tookey P; Casabona J; Miro JM; Castagna A; de Wit S; Torti C; Teira R; Garrido M; Dedes N; Sabin C; Phillips A; Furrer H; Kirk O; Egger M; Dabis F; Newell M; Sterne J; Telenti A; Pantazis N; Lechenadec J; Jérôme F; Tran L; Balestre E; Lanoy E; Couturier F; Rispens T; Gras LA; Bhaskaran K; Sabin C; Hill T; Judd A; Duong T; Sobrino P; Obel N; Thorne C; Kjaer J; Jennings B; Pérez-Hoyos S; Almeda J; Bonfigli S; Cozzi-Lepri A; Corvasce S; Adorni F; Ridolfo AL; Paraninfo G; Ramos JT; Keiser O; Borghi V; Masters J; Ortiga B; Salpietro S; Rickenbach M; Poll B; Garrido M
46.
Bonnet F, Jouvencel AC, Parrens M, Leon MJ, Cotto E, Garrigue I, Morlat P, Beylot J, Fleury H, Lafon ME:
A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma.
J Clin Virol
; 2006 Aug;36(4):258-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A longitudinal and prospective study of Epstein-Barr virus load in
AIDS
-
related non
-
Hodgkin
lymphoma
.
BACKGROUND: Epstein-Barr virus (EBV) may be causally associated with
non
-
Hodgkin
Lymphoma
(
NHL
) in HIV-infected patients.
OBJECTIVES: To compare EBV load in whole blood in
AIDS
-
NHL
patients, HIV
non
-
AIDS
patients and
non
-HIV-infected persons, and to prospectively measure EBV load in whole blood in
AIDS
-
NHL
patients.
RESULTS: We observed no statistical difference in EBV load between
AIDS
-
NHL
(3.69log(10) copies/mL [interquartile range (IQR): 2.89-4.27]) and HIV
non
-
AIDS
patients (3.08log(10) copies/mL [IQR: 1.29-3.57]) but
AIDS
-
NHL
patients had significantly higher EBV loads than HIV-negative controls (1.19log(10) copies/mL [IQR: 0.00-3.29]).
We noticed an inverse correlation between CD4+ lymphocytes count and EBV load in patients with
AIDS
-
NHL
(r(2)=0.41, P=0.01).
In the longitudinal study, the mean EBV load three months after
NHL
diagnosis decreased significantly (mean difference=-1.69log(10) copies/mL [95% confidence interval: -0.32; -3.04]; P=0.03) under chemotherapy but was still elevated in patients with relapses or no response to chemotherapy.
CONCLUSION: Although EBV load seems a suboptimal marker for the diagnosis of
AIDS
-
NHL
, we observed a significant decrease of EBV load in patients treated with chemotherapy and a strong association between
NHL
outcome and EBV load in whole blood.
[MeSH-major]
Acquired Immunodeficiency Syndrome / virology. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / immunology. Herpesvirus 4, Human / isolation & purification.
Lymphoma
,
AIDS
-
Related
/ virology
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16762591.001).
[ISSN]
1386-6532
[Journal-full-title]
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
[ISO-abbreviation]
J. Clin. Virol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DNA, Viral; 0 / RNA, Viral
47.
Diamond C, Taylor TH, Im T, Wallace M, Saven A, Anton-Culver H:
How valid is using cancer registries' data to identify acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma?
Cancer Causes Control
; 2007 Mar;18(2):135-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
How valid is using cancer registries' data to identify acquired immunodeficiency syndrome-
related non
-
Hodgkin's lymphoma
?
OBJECTIVE: We sought to determine the accuracy of cancer registry data regarding the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (
AIDS
) status of patients with
non
-
Hodgkin's lymphoma
(
NHL
).
METHODS: We used the population-based San Diego/Orange County cancer registry to identify 392 patients with HIV-
related
NHL
diagnosed 1994-1999.
After matching for age, sex, race, period of
NHL
diagnosis, and hospital type, we were able to find 324 corresponding patients among the remaining 4,863
NHL
patients diagnosed 1994-1999 (who did not have HIV infection according to cancer registry records).
CONCLUSION: Using cancer registry data to identify
AIDS
-
related
NHL
is a valid research practice.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ epidemiology.
Lymphoma
,
Non
-
Hodgkin
/ epidemiology. Medical Records / standards. Population Surveillance / methods. Registries / standards. SEER Program / standards
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17235495.001).
[ISSN]
0957-5243
[Journal-full-title]
Cancer causes & control : CCC
[ISO-abbreviation]
Cancer Causes Control
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / K07 CA96480
[Publication-type]
Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
48.
Sloand E:
Hematologic complications of HIV infection.
AIDS Rev
; 2005 Oct-Dec;7(4):187-96
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) has altered the natural history of human immunodeficiency virus (HIV) infection by decreasing the frequency of opportunistic infections and altering the expected frequency of hematologic complications and
AIDS
-
related
malignancies.
Hodgkin's
and
non
-
Hodgkin's lymphoma
are still problematic in patients with advanced disease with high viral loads.
[MeSH-minor]
Anemia / drug therapy. Anemia / etiology. Antiretroviral Therapy, Highly Active. Humans.
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
,
AIDS
-
Related
/ etiology. Neutropenia / drug therapy. Neutropenia / etiology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Blood Disorders
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16425959.001).
[ISSN]
1139-6121
[Journal-full-title]
AIDS reviews
[ISO-abbreviation]
AIDS Rev
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Spain
[Number-of-references]
105
49.
Lim ST, Levine AM:
Non-AIDS-defining cancers and HIV infection.
Curr HIV/AIDS Rep
; 2005 Aug;2(3):146-53
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Non
-
AIDS
-defining cancers and HIV infection.
With fewer patients now succumbing to infectious complications of
AIDS
, other HIV-
related
morbidities, such as malignancies, have become increasingly important.
Apart from Kaposi's sarcoma,
non
-
Hodgkin's lymphoma
, and cervical cancer, which are considered as
AIDS
-defining, several additional cancers, referred to as
non
-
AIDS
-defining cancers, are also statistically increased in HIV-infected persons.
These include
Hodgkin's
disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
Although immunosuppression is consistently associated with an increased risk of
AIDS
-
related
malignancies, the role of immunosuppression in the pathogenesis of
non
-
AIDS
- defining cancers is controversial.
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33
[
12679705.001
]
[Cites]
Sex Transm Dis. 2004 Feb;31(2):96-9
[
14743072.001
]
[Cites]
Eur J Epidemiol. 1995 Dec;11(6):609-14
[
8861842.001
]
[Cites]
Ann Thorac Surg. 2003 Feb;75(2):367-71
[
12607641.001
]
[Cites]
J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50
[
11035615.001
]
[Cites]
Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56
[
2022598.001
]
[Cites]
Lancet. 1998 Jun 20;351(9119):1833-9
[
9652666.001
]
[Cites]
J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8
[
9362158.001
]
[Cites]
AIDS. 2003 Feb 14;17(3):371-5
[
12556691.001
]
[Cites]
AIDS Care. 1996 Feb;8(1):5-14
[
8664369.001
]
[Cites]
Ann Oncol. 1993 Sep;4(8):635-41
[
8240994.001
]
[Cites]
J Clin Oncol. 1995 Oct;13(10):2540-6
[
7595705.001
]
[Cites]
Eur J Cancer. 2001 Jul;37(10):1276-87
[
11423259.001
]
[Cites]
AIDS. 1998 Mar 26;12(5):495-503
[
9543448.001
]
[Cites]
J Infect Dis. 1998 Feb;177(2):361-7
[
9466522.001
]
[Cites]
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9
[
9525431.001
]
[Cites]
JAMA. 1999 May 19;281(19):1822-9
[
10340370.001
]
[Cites]
J Clin Oncol. 1995 Nov;13(11):2705-11
[
7595728.001
]
[Cites]
Cancer. 2001 Dec 1;92(11):2739-45
[
11753946.001
]
[Cites]
Int J STD AIDS. 2001 Feb;12(2):100-2
[
11236097.001
]
[Cites]
J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30
[
11078759.001
]
[Cites]
Blood. 2002 Sep 15;100(6):1984-8
[
12200356.001
]
[Cites]
Am J Med. 1985 Feb;78(2):211-5
[
3918441.001
]
[Cites]
AIDS. 1999 May 7;13(7):839-43
[
10357384.001
]
[Cites]
AIDS. 2001 Nov 9;15(16):2157-64
[
11684935.001
]
[Cites]
J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85
[
15220706.001
]
[Cites]
JAMA. 2001 Apr 4;285(13):1736-45
[
11277828.001
]
[Cites]
N Engl J Med. 1998 Mar 26;338(13):853-60
[
9516219.001
]
[Cites]
J Clin Oncol. 2003 Sep 15;21(18):3447-53
[
12972519.001
]
[Cites]
Cancer. 1992 Jul 15;70(2):432-6
[
1617592.001
]
[Cites]
Cancer. 1990 May 15;65(10):2248-54
[
2346909.001
]
[Cites]
J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10
[
10995805.001
]
[Cites]
Ann Oncol. 1999 Feb;10(2):189-95
[
10093688.001
]
[Cites]
Cancer. 2000 Feb 1;88(3):563-9
[
10649248.001
]
[Cites]
Ann Oncol. 2003 Oct;14(10):1562-9
[
14504059.001
]
[Cites]
AIDS. 2002 May 24;16(8):1155-61
[
12004274.001
]
[Cites]
Ann Intern Med. 2003 Mar 18;138(6):453-9
[
12639077.001
]
[Cites]
J Clin Oncol. 1995 Jun;13(6):1391-7
[
7538557.001
]
[Cites]
J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50
[
15051794.001
]
[Cites]
Clin Infect Dis. 2003 Jul 15;37(2):292-8
[
12856222.001
]
[Cites]
Am J Med. 2000 Jun 1;108(8):634-41
[
10856411.001
]
[Cites]
Semin Oncol. 2000 Aug;27(4):480-8
[
10950375.001
]
[Cites]
Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010
[
8880192.001
]
[Cites]
Br J Cancer. 1998 Oct;78(7):966-70
[
9764592.001
]
[Cites]
Chest. 1993 Feb;103(2):410-3
[
8432128.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93
[
3928544.001
]
[Cites]
Blood. 1999 Apr 1;93(7):2319-26
[
10090942.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71
[
11058153.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5
[
9169819.001
]
[Cites]
Chest. 1998 Jan;113(1):154-61
[
9440583.001
]
[Cites]
Mutat Res. 1999 Oct 19;429(2):249-59
[
10526209.001
]
[Cites]
Eur J Cancer. 2000 Apr;36(6):754-8
[
10762748.001
]
[Cites]
J Clin Oncol. 2003 May 15;21(10):1922-7
[
12743144.001
]
[Cites]
Fundam Appl Toxicol. 1996 Aug;32(2):148-58
[
8921318.001
]
[Cites]
Mutagenesis. 2000 Sep;15(5):405-10
[
10970446.001
]
[Cites]
Int J Cancer. 2001 Dec 1;94(5):753-7
[
11745473.001
]
[Cites]
J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8
[
11744829.001
]
[Cites]
Ann Oncol. 1991 Feb;2 Suppl 2:201-5
[
1710920.001
]
[Cites]
Lung Cancer. 2002 Apr;36(1):9-14
[
11891027.001
]
[Cites]
Br J Cancer. 2003 Aug 4;89(3):457-9
[
12888811.001
]
[Cites]
Am J Surg Pathol. 1996 Dec;20(12):1520-4
[
8944046.001
]
[Cites]
Chest. 1992 Dec;102(6):1704-8
[
1446476.001
]
(PMID = 16091262.001).
[ISSN]
1548-3568
[Journal-full-title]
Current HIV/AIDS reports
[ISO-abbreviation]
Curr HIV/AIDS Rep
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
[Number-of-references]
64
50.
Sparano JA:
HIV-associated lymphoma: the evidence for treating aggressively but with caution.
Curr Opin Oncol
; 2007 Sep;19(5):458-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HIV-associated
lymphoma
: the evidence for treating aggressively but with caution.
PURPOSE OF THE REVIEW: The aim of this article is to review key reports regarding the biology and management of HIV-associated
lymphoma
during the past year.
RECENT FINDINGS: The use of highly active antiretroviral therapy (HAART) has been associated with a reduced risk of primary cerebral and systemic
non
-
Hodgkin's lymphoma
, a stable or slightly increased risk of
Hodgkin's lymphoma
, and improved prognosis for those who develop HIV-associated
non
-
Hodgkin's lymphoma
or
Hodgkin's lymphoma
.
Emerging evidence suggests that patients with HIV-associated
lymphoma
should be treated in a similar manner as immunocompetent patients with the same disease, especially if the CD4 count is 50-100 cells/mul or higher.
Use of the anti-CD20 monoclonal antibody rituximab in combination with chemotherapy appears to result in improved control of B-cell
lymphoma
, but may come at the expense of an increased risk of bacterial and viral infections.
SUMMARY: Although the evidence currently supports an aggressive and curative approach for the management of HIV-associated
lymphoma
, clinicians must be vigilant about implementing infection prophylaxis and promptly recognizing, diagnosing, and treating bacterial, parasitic, fungal, and viral infections that may occur as a consequence of therapy.
[MeSH-major]
HIV. HIV Infections / drug therapy.
Lymphoma
,
AIDS
-
Related
/ drug therapy
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Palliative Care of Patients with HIV
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17762571.001).
[ISSN]
1040-8746
[Journal-full-title]
Current opinion in oncology
[ISO-abbreviation]
Curr Opin Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
[Number-of-references]
39
51.
Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E:
Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
J Clin Oncol
; 2005 Jul 1;23(19):4372-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic factors and outcome of human herpesvirus 8-associated primary effusion
lymphoma
in patients with
AIDS
.
PURPOSE: Primary effusion
lymphoma
(PEL) is a rare high-grade B-cell
non
-
Hodgkin's lymphoma
associated with Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) infection, and is mostly observed in the course of HIV infection.
To date, no prognostic factor has been identified in this subset of
lymphoma
.
CONCLUSION: Based on a retrospective series of 28 patients, two prognostic factors were identified as being independently associated with impaired clinical outcome in HIV-
related
PEL--(1) a poor performance status and (2) the absence of HAART before PEL diagnosis.
[MeSH-major]
Antiretroviral Therapy, Highly Active. Herpesvirus 8, Human.
Lymphoma
,
AIDS
-
Related
/ mortality
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - Primary effusion lymphoma
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
HIV InSite.
treatment guidelines - Cardiac Cardiac Manifestations of HIV
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Clin Oncol. 2006 Jan 1;24(1):209; author reply 209-10
[
16382129.001
]
(PMID = 15994147.001).
[ISSN]
0732-183X
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
52.
Newton R, Carpenter L, Casabonne D, Beral V, Babiker A, Darbyshire J, Weller I, Weiss R, Kwan A, Bourboulia D, Munoz F, Lagos D, Boshoff C:
A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1.
Br J Cancer
; 2006 May 22;94(10):1504-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Antibody titres against Kaposi's sarcoma associated herpesvirus (KSHV or human herpesvirus 8 (HHV-8)) and Epstein-Barr virus (EBV) were examined in people who subsequently developed Kaposi's sarcoma and
non
-
Hodgkin's lymphoma
, within randomised controlled trials of antiretroviral therapy in adults infected with the human immunodeficiency virus-1 (HIV).
For each case of Kaposi's sarcoma (n=189) and each case of
non
-
Hodgkin's lymphoma
(n=67), which developed after randomisation, one control was randomly selected from other trial participants, after matching for age, sex, ethnicity, mode of HIV transmission, type of treatment received and period of follow-up.
Virtually, all cases and controls had anti-EBV antibodies detected and the OR for
non
-
Hodgkin's lymphoma
associated with a doubling of the anti-EBV antibody titre was estimated to increase by a multiplicative factor of 1.3 (95% CI 0.9-1.7, P=0.1).
Kaposi's sarcoma was not associated with antibody levels against EBV (P=0.4) and
non
-
Hodgkin's lymphoma
was not associated with antibodies against KSHV (latent P=0.3; lytic P=0.5).
In conclusion, among human immunodeficiency virus infected people, high levels of antibodies against KSHV latent and lytic antigens are strongly associated with subsequent risk of Kaposi's sarcoma but not
non
-
Hodgkin's lymphoma
.
Antibody titre to EBV does not appear to be strongly associated with subsequent risk of Kaposi's sarcoma or
non
-
Hodgkin's lymphoma
in HIV infected people.
[MeSH-major]
Antibodies, Viral / blood. HIV Infections / virology. HIV-1. Herpesvirus 4, Human / immunology. Herpesvirus 8, Human / immunology.
Lymphoma
,
AIDS
-
Related
/ virology. Sarcoma, Kaposi / virology
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - Kaposi's Sarcoma
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
AIDS. 2004 Feb 20;18(3):485-93
[
15090801.001
]
[Cites]
J Natl Cancer Inst. 1999 Sep 1;91(17):1468-74
[
10469747.001
]
[Cites]
AIDS. 1996 Jul;10(8):867-80
[
8828744.001
]
[Cites]
J Natl Cancer Inst Monogr. 1998;(23):1-6
[
9709294.001
]
[Cites]
Cancer Causes Control. 1993 May;4(3):187-93
[
8391336.001
]
[Cites]
Nature. 1978 Aug 24;274(5673):756-61
[
210392.001
]
[Cites]
Int J Cancer. 2003 Jan 10;103(2):226-32
[
12455037.001
]
[Cites]
Br J Cancer. 2003 Aug 4;89(3):502-4
[
12888820.001
]
[Cites]
Int J Cancer. 1991 Sep 30;49(3):387-93
[
1655660.001
]
[Cites]
Int J Cancer. 1999 Jul 2;82(1):1-5
[
10360811.001
]
[Cites]
J Clin Microbiol. 2002 Feb;40(2):325-9
[
11825937.001
]
[Cites]
J Virol. 1967 Oct;1(5):1045-51
[
4912237.001
]
[Cites]
Int J Cancer. 2003 Jan 10;103(2):233-40
[
12455038.001
]
[Cites]
Lancet. 1994 Apr 9;343(8902):871-81
[
7908356.001
]
[Cites]
J Natl Cancer Inst. 2001 Feb 7;93(3):194-202
[
11158187.001
]
[Cites]
Infect Agent Cancer. 2006 Sep 14;1:2
[
17150131.001
]
[Cites]
AIDS. 1998 Dec 24;12(18):2481-8
[
9875587.001
]
[Cites]
Lancet. 1996 Aug 3;348(9023):283-91
[
8709686.001
]
[Cites]
J Infect Dis. 2000 Jun;181(6):1940-9
[
10837173.001
]
(PMID = 16705315.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / G0800168; United Kingdom / Medical Research Council / / G8712499
[Publication-type]
Journal Article; Multicenter Study; Randomized Controlled Trial
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Viral; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / latent nuclear antigen (LNA)
[Other-IDs]
NLM/ PMC2361279
53.
Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Møller H, Bower M:
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
J Clin Oncol
; 2009 Feb 20;27(6):884-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Highly active antiretroviral therapy and the incidence of
non
-
AIDS
-defining cancers in people with HIV infection.
PURPOSE: The effect of highly active antiretroviral therapy (HAART) on the incidence of
non
-
AIDS
-defining cancers (NADCs) is unclear.
We investigated the effect of calendar period, HIV parameters, and immunologic and treatment-
related
factors on the incidence of these cancers using univariate and multivariate analyses.
Only the
non
-nucleoside reverse transcriptase inhibitors (NNRTIs) were associated with a significantly increased risk of NADCs (HR = 1.45; 95% CI, 1.01 to 2.08).
Much of this association was attributable to an increased risk of
Hodgkin's lymphoma
with NNRTIs (HR = 2.20; 95% CI, 1.03 to 4.69).
There may be an association between the use of NNRTIs and the development of
Hodgkin's lymphoma
.
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
HIV InSite.
treatment guidelines - Non-ARV Adverse Events
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19114688.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Anti-HIV Agents
54.
Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M:
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
Clin Infect Dis
; 2009 Apr 15;48(8):1138-51
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Variable impact on mortality of
AIDS
-defining events diagnosed during combination antiretroviral therapy: not all
AIDS
-defining conditions are created equal.
BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (
AIDS
)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy.
The greatest mortality hazard ratio was associated with
non
-
Hodgkin's lymphoma
(hazard ratio, 17.59; 95% confidence interval, 13.84-22.35) and progressive multifocal leukoencephalopathy (hazard ratio, 10.0; 95% confidence interval, 6.70-14.92).
Three groups of ADEs were identified on the basis of the ranked hazard ratios with bootstrapped confidence intervals: severe (
non
-
Hodgkin's lymphoma
and progressive multifocal leukoencephalopathy [hazard ratio, 7.26; 95% confidence interval, 5.55-9.48]), moderate (cryptococcosis, cerebral toxoplasmosis,
AIDS
dementia complex, disseminated Mycobacterium avium complex, and rare ADEs [hazard ratio, 2.35; 95% confidence interval, 1.76-3.13]), and mild (all other ADEs [hazard ratio, 1.47; 95% confidence interval, 1.08-2.00]).
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS and Infections
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
HIV InSite.
treatment guidelines - Mycobacterium avium Complex and Atypical Mycobacterial Infections in the Setting of HIV Infection
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet. 2002 Jul 13;360(9327):119-29
[
12126821.001
]
[Cites]
JAMA. 2003 May 21;289(19):2554-9
[
12759327.001
]
[Cites]
N Engl J Med. 2003 Nov 20;349(21):1993-2003
[
14627784.001
]
[Cites]
JAMA. 2004 Jul 14;292(2):180-9
[
15249567.001
]
[Cites]
Lancet. 1981 Sep 19;2(8247):598-600
[
6116083.001
]
[Cites]
N Engl J Med. 1981 Dec 10;305(24):1425-31
[
6272109.001
]
[Cites]
Ann Intern Med. 1985 Sep;103(3):402-3
[
2992336.001
]
[Cites]
JAMA. 1987 Sep 4;258(9):1143-5, 1149, 1153-4
[
3041060.001
]
[Cites]
Ann Intern Med. 1991 Aug 1;115(3):184-9
[
1676252.001
]
[Cites]
J Acquir Immune Defic Syndr. 1991;4(10):1059-71
[
1890600.001
]
[Cites]
JAMA. 1992 Nov 18;268(19):2662-6
[
1359163.001
]
[Cites]
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
[
1361652.001
]
[Cites]
BMJ. 1994 Apr 23;308(6936):1068-73
[
7909698.001
]
[Cites]
Stat Med. 1994 Oct 15-30;13(19-20):2107-25
[
7846414.001
]
[Cites]
AIDS. 1995 Jan;9(1):57-63
[
7893442.001
]
[Cites]
Arch Intern Med. 1995 Jul 24;155(14):1537-42
[
7605156.001
]
[Cites]
Int J Epidemiol. 1997 Apr;26(2):400-7
[
9169177.001
]
[Cites]
AIDS. 1998 Jan 1;12(1):29-33
[
9456252.001
]
[Cites]
Nat Med. 1998 Feb;4(2):208-14
[
9461195.001
]
[Cites]
Lancet. 1998 Feb 21;351(9102):543-9
[
9492772.001
]
[Cites]
Int J Epidemiol. 2005 Feb;34(1):121-30
[
15561752.001
]
[Cites]
AIDS. 2005 Mar 4;19(4):399-406
[
15750393.001
]
[Cites]
Infection. 2005 Feb;33(1):43-5
[
15750761.001
]
[Cites]
BMJ. 2005 Mar 12;330(7491):594-6
[
15761002.001
]
[Cites]
J Infect Dis. 2005 Sep 15;192(6):992-1002
[
16107951.001
]
[Cites]
Lancet. 2006 Mar 11;367(9513):817-24
[
16530575.001
]
[Cites]
N Engl J Med. 2006 Nov 30;355(22):2283-96
[
17135583.001
]
[Cites]
AIDS. 2007 May 31;21(9):1185-97
[
17502729.001
]
[Cites]
AIDS. 2007 Sep 12;21(14):1867-75
[
17721094.001
]
[Cites]
J Acquir Immune Defic Syndr. 2002 May 1;30(1):111-8
[
12048371.001
]
[Cites]
J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):451-8
[
11141245.001
]
[Cites]
J Infect Dis. 2002 Jan 15;185(2):178-87
[
11807691.001
]
[Cites]
J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):388-95
[
11917244.001
]
(PMID = 19275498.001).
[ISSN]
1537-6591
[Journal-full-title]
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
[ISO-abbreviation]
Clin. Infect. Dis.
[Language]
ENG
[Grant]
United States / NIAAA NIH HHS / AA / AA013566-08; United States / NIAAA NIH HHS / AA / U10 AA013566; United Kingdom / Medical Research Council / / G0700820; United States / NIAAA NIH HHS / AA / U10 AA013566-08
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Anti-HIV Agents
[Other-IDs]
NLM/ NIHMS264818; NLM/ PMC3032444
[Investigator]
Casabona J; Chêne G; Costagliola D; Dabis F; D'Arminio Monforte A; de Wolf F; Egger M; Fatkenheuer G; Gill J; Hogg R; Justice A; Kitahata M; Ledergerber B; Mocroft A; Phillips A; Reiss P; Saag M; Sabin C; Staszewski S; Weller I; May M; Harris R; Sterne J; Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Cotte L; De Truchis P; Duval X; Duvivier C; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Katlama C; Khuong MA; Lang JM; Lascaux AS; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard JL; Pavie J; Pialoux G; Pilorgé F; Poizot-Martin I; Pradier C; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard JP; Viget N; Pariente-Khayat A; Salomon V; Jacquemet N; Rivet A; Guiguet M; Kousignian I; Lanoy E; Lièvre L; Potard V; Selinger-Leneman H; Bouvet E; Crickx B; Ecobichon JL; Leport C; Picard-Dahan C; Yeni P; Tisne-Dessus D; Weiss L; Salmon D; Sicard D; Auperin I; Roudière L; Fior R; Delfraissy JF; Goujard C; Jung C; Lesprit P; Desplanque N; Meyohas MC; Picard O; Cadranel J; Mayaud C; Bricaire F; Herson S; Clauvel JP; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine JL; Trepo C; Ravaux I; Delmont JP; Moreau J; Gastaut JA; Retornaz F; Soubeyrand J; Allegre T; Blanc PA; Galinier A; Ruiz JM; Lepeu G; Granet-Brunello P; Esterni JP; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; May T; Rabaud C; Raffi F; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand MF; Yasdanpanah Y; Pradinaud R; Sobesky M; Contant M; Montroni M; Scalise G; Braschi MC; Riva A; Tirelli U; Martellotta F; Pastore G; Ladisa N; Suter F; Arici C; Chiodo F; Colangeli V; Fiorini C; Carosi G; Cristini G; Torti C; Minardi C; Bertelli D; Quirino T; Manconi PE; Piano P; Cosco L; Scerbo A; Vecchiet J; D'Alessandro M; Santoro D; Pusterla L; Carnevale G; Lorenzotti S; Viganò P; Mena M; Ghinelli F; Sighinolfi L; Leoncini F; Mazzotta F; Pozzi M; Lo Caputo S; Grisorio B; Ferrara S; Grima P; Grima PF; Pagano G; Cassola G; Alessandrini A; Piscopo R; Toti M; Trezzi M; Soscia F; Tacconi L; Orani A; Perini P; Scasso A; Vincenti A; Chiodera F; Castelli P; Scalzini A; Palvarini L; Moroni M; Lazzarin A; Rizzardini G; Caggese L; Cicconi P; Galli A; Merli S; Pastecchia C; Moioli MC; Esposito R; Mussini C; Abrescia N; Chirianni A; Izzo CM; Piazza M; De Marco M; Viglietti R; Manzillo E; Nappa S; Colomba A; Abbadessa V; Prestileo T; Mancuso S; Ferrari C; Pizzaferri P; Filice G; Minoli L; Bruno R; Novati S; Baldelli F; Camanni G; Petrelli E; Cioppi A; Alberici F; Ruggieri A; Menichetti F; Martinelli C; De Stefano C; La Gala A; Ballardini G; Rizzo E; Magnani G; Ursitti MA; Arlotti M; Ortolani P; Cauda R; Dianzani F; Ippolito G; Antinori A; Antonucci G; Ciardi M; Narciso P; Petrosillo N; Vullo V; De Luca A; Zaccarelli M; Acinapura R; De Longis P; Trotta MP; Noto P; Lichtner M; Capobianchi MR; Carletti F; Girardi E; Pezzotti P; Rezza G; Mura MS; Mannazzu M; Caramello P; Di Perri G; Orofino GC; Sciandra M; Grossi PA; Basilico C; Poggio A; Bottari G; Raise E; Ebo F; Pellizzer G; Buonfrate D; Resta F; Loso K; Cozzi Lepri A; Battegay M; Bernasconi E; Böni J; Bucher H; Bürgisser P; Cattacin S; Cavassini M; Dubs R; Elzi L; Erb P; Fischer M; Flepp M; Fontana A; Francioli P; Furrer H; Gorgievski M; Günthard H; Hirsch H; Hirschel B; Hösli I; Kahlert C; Kaiser L; Karrer U; Kind C; Klimkait T; Martinetti G; Martinez B; Müller N; Nadal D; Opravil M; Paccaud F; Pantaleo G; Rickenbach M; Rudin C; Schmid P; Schultze D; Schüpbach J; Speck R; Taffé P; Tarr P; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S; Gras LA; van Sighem AI; Smit C; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Branger J; Eeftinck Schattenkerk JK; Gisolf J; Godfried MH; Lange JM; Lettinga KD; van der Meer JT; Nellen FJ; van der Poll T; Ruys TA; Steingrover R; Vermeulen JN; Vrouenraets SM; van Vugt M; Wit FW; Kuijpers TW; Pajkrt D; Scherpbier HJ; van Eeden A; Brinkman K; van den Berk GE; Blok WL; Frissen PH; Roos JC; Schouten WE; Mulder JW; van Gorp EC; Wagenaar J; Veenstra J; Danner SA; Van Agtmael MA; Claessen FA; Perenboom RM; Rijkeboer A; van Vonderen MG; Richter C; van der Berg J; Vriesendorp R; Jeurissen FJ; Kauffmann RH; Pogány K; Bravenboer B; ten Napel CH; Kootstra GJ; Sprenger HG; van Assen S; van Leeuwen JT; Doedens R; Scholvinck EH; ten Kate RW; Soetekouw R; van Houte D; Polée MB; Kroon FP; van den Broek PJ; van Dissel JT; Schippers EF; Schreij G; van der Geest S; Lowe S; Verbon A; Koopmans PP; Van Crevel R; de Groot R; Keuter M; Post F; van der Ven AJ; Warris A; van der Ende ME; Gyssens IC; van der Feltz M; Nouwen JL; Rijnders BJ; de Vries TE; Driessen G; van der Flier M; Hartwig NG; Juttman JR; van Kasteren ME; Van de Heul C; Hoepelman IM; Schneider MM; Bonten MJ; Borleffs JC; Ellerbroek PM; Jaspers CA; Mudrikove T; Schurink CA; Gisolf EH; Geelen SP; Wolfs TF; Faber T; Tanis AA; Groeneveld PH; den Hollander JG; Duits AJ; Winkel K; Back NK; Bakker ME; Berkhout B; Jurriaans S; Zaaijer HL; Cuijpers T; Rietra PJ; Roozendaal KJ; Pauw W; van Zanten AP; Smits PH; von Blomberg BM; Savelkoul P; Pettersson A; Swanink CM; Franck PF; Lampe AS; Jansen CL; Hendriks R; Benne CA; Veenendaal D; Storm H; Weel J; van Zeijl JH; Kroes AC; Claas HC; Bruggeman CA; Goossens VJ; Galama JM; Melchers WJ; Poort YA; Doornum GJ; Niesters MG; Osterhaus AD; Schutten M; Buiting AG; Swaans CA; Boucher CA; Schuurman R; Boel E; Jansz AF; Veldkamp A; Beijnen JH; Huitema AD; Burger DM; Hugen PW; van Kan HJ; Losso M; Duran A; Vetter N; Karpov I; Vassilenko A; Mitsura VM; Suetnov O; Clumeck N; De Wit S; Poll B; Colebunders R; Kostov K; Begovac J; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Lundgren J; Benfield T; Kirk O; Gerstoft J; Katzenstein T; Hansen AB; Skinhøj P; Pedersen C; Oestergaard L; Zilmer K; Ristola M; Girard PM; Vanhems P; Rockstroh J; Schmidt R; van Lunzen J; Degen O; Stellbrink HJ; Bogner J; Kosmidis J; Gargalianos P; Xylomenos G; Perdios J; Panos G; Filandras A; Karabatsaki E; Sambattakou H; Banhegyi D; Mulcahy F; Yust I; Turner D; Burke M; Pollack S; Hassoun G; Maayan S; Chiesi A; Mazeu I; Pristera R; Gabbuti A; Montesarchio E; Gargiulo M; Iacomi F; Vlassi C; Finazzi R; Galli M; Ridolfo A; Rozentale B; Aldins P; Chaplinskas S; Hemmer R; Staub T; Bruun J; Maeland A; Ormaasen V; Knysz B; Gasiorowski J; Horban A; Prokopowicz D; Wiercinska-Drapalo A; Boron-Kaczmarska A; Pynka M; Beniowski M; Mularska E; Trocha H; Antunes F; Valadas E; Mansinho K; Maltez F; Duiculescu D; Rakhmanova A; Vinogradova E; Buzunova S; Jevtovic D; Mokrás M; Staneková D; González-Lahoz J; Soriano V; Martin-Carbonero L; Labarga P; Clotet B; Jou A; Conejero J; Tural C; Gatell JM; Miró JM; Domingo P; Gutierrez M; Mateo G; Sambeat MA; Karlsson A; Persson PO; Flamholc L; Boffi E; Kravchenko E; Chentsova N; Barton S; Johnson AM; Mercey D; Johnson MA; Murphy M; Weber J; Scullard G; Fisher M; Brettle R; Gatell J; Gazzard B; Friis-Møller N; Bannister W; Ellefson M; Borch A; Podlekareva D; Holkmann Olsen C; Kjaer J; Peters L; Reekie J; Raffanti S; Dieterch D; Becker S; Scarsella A; Fusco G; Most B; Balu R; Rana R; Beckerman R; Ising T; Fusco J; Irek R; Johnson B; Hirani A; DeJesus E; Pierone G; Lackey P; Irek C; Johnson A; Burdick J; Leon S; Arch J; Helm EB; Carlebach A; Müller A; Haberl A; Nisius G; Lennemann T; Stephan C; Bickel M; Mösch M; Gute P; Locher L; Lutz T; Klauke S; Knecht G; Khaykin P; Doerr HW; Stürmer M; Babacan E; von Hentig N; Beylot J; Dupon M; Longy-Boursier M; Pellegrin JL; Ragnaud JM; Salamon R; Thiébaut R; Lewden C; Lawson-Ayayi S; Dupon M; Mercié P; Moreau JF; Morlat P; Bernard N; Lacoste D; Malvy D; Neau D; Blaizeau MJ; Decoin M; Delveaux S; Hannapier C; Labarrère S; Lavignolle-Aurillac V; Uwamaliya-Nziyumvira B; Palmer G; Touchard D; Balestre E; Alioum A; Jacqmin-Gadda H; Bonarek M; Bonnet F; Coadou B; Gellie P; Nouts C; Bocquentin F; Dutronc H; Lafarie S; Aslan A; Pistonne T; Thibaut P; Vatan R; Chambon D; De La Taille C; Cazorla C; Ocho A; Viallard JF; Caubet O; Cipriano C; Lazaro E; Couzigou P; Castera L; Fleury H; Lafon ME; Masquelier B; Pellegrin I; Breilh D; Blanco P; Loste P; Caunègre L; Bonnal F; Farbos S; Ferrand M; Ceccaldi J; Tchamgoué S; De Witte S; Buy E; Alexander C; Barrios R; Braitstein P; Brumme Z; Chan K; Cote H; Gataric N; Geller J; Guillemi S; Harrigan PR; Harris M; Joy R; Levy A; Montaner J; Montessori V; Palepu A; Phillips E; Phillips P; Press N; Tyndall M; Wood E; Yip B; Bhagani S; Breen R; Byrne P; Carroll A; Cuthbertson Z; Dunleavy A; Geretti AM; Heelan B; Johnson M; Kinloch-de Loes S; Lipman M; Madge S; Marshall N; Nair D; Nebbia G; Prinz B; Shah S; Swader L; Tyrer M; Youle M; Chaloner C; Grabowska H; Holloway J; Puradiredja J; Ransom D; Tsintas R; Bansi L; Fox Z; Harris E; Hill T; Lampe F; Lodwick R; Smith C; Amoah E; Booth C; Clewley G; Garcia Diaz A; Gregory B; Janossy G; Labbett W; Thomas M; Read R; Krentz H; Beckthold B; Schmeisser N; Alquézar A; Esteve A; Podzamczer D; Murillas J; Romero A; Agustí C; Agüero F; Ferrer E; Riera M; Segura F; Navarro G; Force L; Vilaró J; Masabeu A; García I; Guadarrama M; Montoliu A; Ortega N; Lazzari E; Puchol E; Sanchez M; Blanco JL; Garcia-Alcaide F; Martinez E; Mallolas J; López-Dieguez M; García-Goez JF; Sirera G; Romeu J; Negredo E; Miranda C; Capitan MC; Olmo M; Barragan P; Saumoy M; Bolao F; Cabellos C; Peña C; Sala M; Cervantes M; Jose Amengual M; Navarro M; Penelo E; Barrufet P; Raper JL; Mugavero MJ; Willig JH; Schumacher J; Chang PW; Westfall AO; Cloud G; Lin HY; Acosta EP; Colette-Kempf M; Allison JJ; Pisu M
55.
Northup JK, Gadre SA, Ge Y, Lockhart LH, Velagaleti GV:
Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Eur J Haematol
; 2007 Feb;78(2):152-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The first case is that of a lymph node sample from a 40-yr-old
non
-
Hodgkin's lymphoma
(
NHL
) patient sent for determination of disease progress.
Hematologic studies showed no evidence of transformation to high-grade
NHL
(>15% blasts with rare mitotic figures).
Cytogenetic studies of lymph node showed multiple clonal abnormalities, most notably a der(18) from a t(14;18) which is associated with high-grade
NHL
.
After two cycles of chemotherapy with fludarabine, the patient did not show any clinical response, suggesting possible progression to high-grade
lymphoma
.
The second case is of a patient with a history of human immunodeficiency virus and blastic natural killer leukemia/
lymphoma
.
Hematologic studies of ascitic fluid classified the patient as having pleural effusion
lymphoma
whereas bone marrow analysis showed no malignancy.
Bone marrow cytogenetic studies showed multiple clonal abnormalities including a t(8;14), which is commonly associated with Burkitt's
lymphoma
(BL).
To our knowledge, this is the first case wherein a morphologically normal bone marrow showed presence of clonal abnormalities consistent with BL or Pleural effusion
lymphoma
.
[MeSH-major]
Burkitt
Lymphoma
/ genetics.
Lymphoma
,
AIDS
-
Related
/ genetics.
Lymphoma
, Follicular / genetics.
Lymphoma
,
Non
-
Hodgkin
/ genetics. Translocation, Genetic
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
FLUDARABINE
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VIDARABINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17313561.001).
[ISSN]
0902-4441
[Journal-full-title]
European journal of haematology
[ISO-abbreviation]
Eur. J. Haematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
56.
Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, López-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H, GESIDA Group, GELCAB Group:
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
Haematologica
; 2007 Feb;92(2):191-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-
related Hodgkin's lymphoma
.
BACKGROUND AND OBJECTIVES: Although doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is considered the standard chemotherapy regimen for
Hodgkin's lymphoma
(HL), information on the results of this therapy in human immunodeficiency (HIV)-
related
HL is scarce.
We analyzed the results of the ABVD regimen and highly active antiretroviral therapy (HAART) in patients with advanced stage, HIV-
related
HL.
The histologic subtype of HL was nodular sclerosis in 17 patients (27%), mixed cellularity in 25 (41%), lymphocyte depletion in 10 (16%) and
non
-specified in the remaining 10 (16%).
INTERPRETATION AND CONCLUSIONS: In patients with advanced stage, HIV-
related
HL, treatment with ABVD together with HAART is feasible and effective.
This supports the concept that patients with HIV-
related
HL should be treated in the same way as immunocompetent patients if HAART, adequate supportive therapy and anti-infectious prophylaxis are given concomitantly.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy.
Hodgkin
Disease / drug therapy.
Hodgkin
Disease / virology.
Lymphoma
,
AIDS
-
Related
/ drug therapy
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
Hazardous Substances Data Bank.
BLEOMYCIN
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
DACARBAZINE
.
Hazardous Substances Data Bank.
VINBLASTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17296568.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Chemical-registry-number]
11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
57.
Tisdale G, Mahadevan A, Matthews RH:
T-cell lymphoma of the rectum in a patient with AIDS and hepatitis C: a case report and discussion.
Oncologist
; 2005 Apr;10(4):292-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
T-cell
lymphoma
of the rectum in a patient with
AIDS
and hepatitis C: a case report and discussion.
Primary T-cell
non
-
Hodgkin's lymphoma
(
NHL
) occurring in the context of acquired immune deficiency syndrome (
AIDS
) is uncommon.
Although typical in some respects, the case is, in other ways, somewhat unusual for an
AIDS
-
related
NHL
(ARL); ARL tends to be B cell and advanced stage and our case was T cell and stage IE.
In addition, the patient suffered from concomitant cirrhosis
related
to hepatitis C.
Chemotherapeutic options for ARL were limited early in the
AIDS
epidemic due to poor tolerability.
Although this has largely been mitigated by the advent of highly active antiretroviral therapy, our patient eventually suffered complications of chemotherapy, apparently
related
more to his liver disease than to either his
lymphoma
or
AIDS
, that ultimately brought about his demise.
[MeSH-major]
AIDS
-
Related
Opportunistic Infections / complications. Hepatitis C / complications.
Lymphoma
,
AIDS
-
Related
/ diagnosis.
Lymphoma
, T-Cell / diagnosis. Rectal Neoplasms / diagnosis
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - Hepatitis
.
MedlinePlus Health Information.
consumer health - Hepatitis C
.
MedlinePlus Health Information.
consumer health - HIV/AIDS and Infections
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15821249.001).
[ISSN]
1083-7159
[Journal-full-title]
The oncologist
[ISO-abbreviation]
Oncologist
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
58.
Stebbing J, Mandalia S, Palmieri C, Nelson M, Gazzard B, Bower M:
Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphoma.
J Clin Oncol
; 2005 Nov 20;23(33):8538-40; author reply 8540-1
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Burkitt's
lymphoma
and previous
AIDS
-defining illnesses are not prognostic factors in
AIDS
-
related non
-
Hodgkin's lymphoma
.
[MeSH-major]
Antiretroviral Therapy, Highly Active. Burkitt
Lymphoma
/ drug therapy. Burkitt
Lymphoma
/ mortality.
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
,
AIDS
-
Related
/ mortality
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - Burkitt's Lymphoma
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
J Clin Oncol. 2005 Jul 1;23(19):4430-8
[
15883411.001
]
(PMID = 16293885.001).
[ISSN]
0732-183X
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
United States
59.
Spina M, Tirelli U:
Rituximab for HIV-associated lymphoma: weighing the benefits and risks.
Curr Opin Oncol
; 2005 Sep;17(5):462-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Rituximab for HIV-associated
lymphoma
: weighing the benefits and risks.
PURPOSE OF REVIEW: This review discusses the potential benefits and risks of using the anti-CD20 monoclonal antibody rituximab for the treatment of HIV-associated B-cell
non
-
Hodgkin's lymphoma
.
RECENT FINDINGS: Studies have consistently demonstrated that rituximab improves response and survival when combined with standard chemotherapy compared with chemotherapy alone in immunocompetent patients with intermediate-grade
non
-
Hodgkin's lymphoma
.
Several recently reported phase II and III trials have evaluated the use of rituximab plus chemotherapy for HIV-associated B-cell
non
-
Hodgkin's lymphoma
.
A phase III trial comparing CHOP with CHOP-plus rituximab (R-CHOP) demonstrated a lower risk from progression of the
lymphoma
, but a higher risk of early and late infectious-
related
death in patients with a low CD4 count (< 50/microL).
[MeSH-major]
Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use.
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
, B-Cell / drug therapy
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
Hazardous Substances Data Bank.
RITUXIMAB
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16093796.001).
[ISSN]
1040-8746
[Journal-full-title]
Current opinion in oncology
[ISO-abbreviation]
Curr Opin Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
[Number-of-references]
19
60.
Khan F, Bauer F, Gazi G, Bilgrami S:
Regression of large B-cell non-Hodgkin's lymphoma of stomach with HAART: case report and review.
Leuk Lymphoma
; 2006 Apr;47(4):750-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Regression of large B-cell
non
-
Hodgkin's lymphoma
of stomach with HAART: case report and review.
[MeSH-major]
Antiretroviral Therapy, Highly Active.
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
, Large B-Cell, Diffuse / drug therapy.
Lymphoma
,
Non
-
Hodgkin
/ drug therapy. Stomach Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16886274.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
England
61.
Uriarte-Duque J, Hernández-Riverab G:
[Treatment of non-Hodgkin's lymphoma associated with acquired immnodeficiency syndrome (AIDS) at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán].
Gac Med Mex
; 2006 Mar-Apr;142(2):99-102
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Treatment of
non
-
Hodgkin's lymphoma
associated with acquired immnodeficiency syndrome (
AIDS
) at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán].
[Transliterated title]
Tratamiento de pacientes con linfomas no
Hodgkin
asociados a SIDA: experiencia del Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.
BACKGROUND: Survival in patients with acquired immunodeficiency syndrome (
AIDS
)
related non
-
Hodgkin's Lymphoma
has improved with the use of High Active Antiretroviral Therapy (HAART) and less toxic chemotherapy.
MATERIAL AND METHODS: Clinical characteristics and outcome among patients treated for
AIDS related non
-
Hodgkin's Lymphoma
are described.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
,
Non
-
Hodgkin
/ drug therapy
Genetic Alliance.
consumer health - AIDS-HIV
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16711542.001).
[ISSN]
0016-3813
[Journal-full-title]
Gaceta médica de México
[ISO-abbreviation]
Gac Med Mex
[Language]
spa
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Mexico
62.
Heise W:
GI-lymphomas in immunosuppressed patients (organ transplantation; HIV).
Best Pract Res Clin Gastroenterol
; 2010 Feb;24(1):57-69
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Gastrointestinal
lymphoma
plays a major role complicating different diseases presenting with immunosuppression, both primary and acquired immunodeficiency (incl.
Lymphoma
in diseases with immunosuppression are clinically and pathologically heterogeneous, but share some features such as frequent involvement of extranodal sites, diffuse aggressive histology, B-cell lineage derivation, viral association with EBV and clinically aggressive courses.
While gastrointestinal
lymphoma
in congenital immunodeficiency disorders seems to be a rare event inspite of higher prevalences, in post-transplant lymphoproliferative disorders (PTLD) the gastrointestinal tract is one of the most important organs of
lymphoma
.
In HIV-associated
non
-
Hodgkin's lymphoma
, gastrointestinal lesions as the most frequent extranodal localisation occur in 30-50% of
lymphoma
patients, are late events of HIV infection with severe immunosuppression and are mainly diagnosed with advanced disease stages Ann Arbour III or IV.
With the introduction of highly active antiretroviral therapy (HAART) in the therapeutic concept in
AIDS
, a decrease of
AIDS
-
related
GI
lymphoma
was noted with improved survival rates and prognosis of
lymphoma
.
[MeSH-major]
Gastrointestinal Neoplasms / immunology. HIV Infections / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects.
Lymphoma
/ immunology.
Lymphoma
,
AIDS
-
Related
/ immunology. Organ Transplantation
Genetic Alliance.
consumer health - Transplantation
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
MedlinePlus Health Information.
consumer health - Organ Transplantation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2010 Elsevier Ltd. All rights reserved.
(PMID = 20206109.001).
[ISSN]
1532-1916
[Journal-full-title]
Best practice & research. Clinical gastroenterology
[ISO-abbreviation]
Best Pract Res Clin Gastroenterol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
[Number-of-references]
84
63.
Rafaniello Raviele P, Pruneri G, Maiorano E:
Plasmablastic lymphoma: a review.
Oral Dis
; 2009 Jan;15(1):38-45
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Plasmablastic
lymphoma
: a review.
Plasmablastic
lymphoma
(PBL) has been recently characterised as an aggressive subtype of
non
-
Hodgkin's lymphoma
, most frequently arising in the oral cavity of HIV-infected patients.
Similar to other types of
AIDS
-
related
lymphomas, there is evidence that Epstein-Barr virus and Kaposi-sarcoma associated Human Herpes Virus 8 may play a relevant role in the pathogenesis of PBL.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ pathology.
Lymphoma
, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Oral Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18939960.001).
[ISSN]
1601-0825
[Journal-full-title]
Oral diseases
[ISO-abbreviation]
Oral Dis
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Denmark
[Chemical-registry-number]
0 / SDC1 protein, human; 0 / Syndecan-1
[Number-of-references]
54
64.
Bower M, Palmieri C, Dhillon T:
AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.
Curr Opin Infect Dis
; 2006 Feb;19(1):14-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
AIDS
-
related
malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.
PURPOSE OF REVIEW: Three cancers in people with HIV denote an
AIDS
diagnosis: Kaposi's sarcoma, high-grade B-cell
non
-
Hodgkin's lymphoma
and invasive cervical cancer.
In addition a number of other cancers occur at increased frequency in this population group but are not
AIDS
-defining illnesses.
This review discusses the impact of highly active antiretroviral therapy on the epidemiology and outcome of
AIDS
-defining cancers.
RECENT FINDINGS: The incidence of both Kaposi's sarcoma and
non
-
Hodgkin's lymphoma
has declined in the era of highly active antiretroviral therapy and the outcome of both tumours has improved.
As people with HIV live longer with highly active antiretroviral therapy, an increased incidence of other
non AIDS
-defining cancers that have no known association with oncogenic infections is becoming apparent.
SUMMARY: For those with access to highly active antiretroviral therapy, the good news from the
AIDS
-defining cancers - particularly Kaposi's sarcoma and
non
-
Hodgkin's lymphoma
- may be balanced by the increasing numbers of
non AIDS
-defining cancers.
[MeSH-minor]
Female. Humans.
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
,
AIDS
-
Related
/ epidemiology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16374212.001).
[ISSN]
0951-7375
[Journal-full-title]
Current opinion in infectious diseases
[ISO-abbreviation]
Curr. Opin. Infect. Dis.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
45
65.
Cáceres W, Cruz-Amy M, Díaz-Meléndez V:
AIDS-related malignancies: revisited.
P R Health Sci J
; 2010 Mar;29(1):70-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
AIDS
-
related
malignancies: revisited.
Since the first reports between the association of Human Immunodeficiency Virus (HIV) infection and neoplasia, there has been a dramatic change in the incidence and epidemiology of
AIDS
-
related
malignancies.
Kaposi sarcoma (KS),
non
-
Hodgkin's
lymphomas (
NHL
), and cervical cancer are classified by the Centers for Disease Control and Prevention (CDC) as
AIDS
-defining malignancies.
However, since the availability of highly active combination antiretroviral therapy (cART), especially protease inhibitors, there has been a steady increase in
non
-
AIDS
defining malignancies, such as
Hodgkin's lymphoma
(HL), lung cancer, hepatocellular cancer, anal cancer and others and a decline in
AIDS
-defining neoplasias.
Although the emergence of
non
-
AIDS
defining cancers could be a result of longer life expectancy and due to a better control of HIV, toxic habits and co-infection with other viruses such as hepatitis B, hepatitis C and human papilloma virus (HPV) could play an important role.
The interactions of cART and incomplete immune reconstitution could be other factors explaining the increase in
non
-
AIDS
defining cancers.
These emerging
non
-
AIDS
defining malignancies present a new challenge in the care of patients with HIV infection, and require optimal treatment protocols that take into consideration the interaction between cART and systemic chemotherapy.
We review the current status of
AIDS
-
related
malignancies, its pathophysiology, epidemiology and management with emphasis in the changing patterns of presentation.
[MeSH-minor]
Humans.
Lymphoma
,
AIDS
-
Related
/ epidemiology
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20222338.001).
[ISSN]
0738-0658
[Journal-full-title]
Puerto Rico health sciences journal
[ISO-abbreviation]
P R Health Sci J
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Puerto Rico
[Number-of-references]
51
66.
Navarro JT, Ribera JM, Oriol A, Xicoy B, Mate JL, Sirera G, Lloveras N, Millá F, Feliu E:
Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy.
Int J Hematol
; 2007 Nov;86(4):337-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-
related non
-
Hodgkin's Lymphoma
treated with CHOP and highly active antiretroviral therapy.
In the era of highly active antiretroviral therapy (HAART), the prognosis for acquired immunodeficiency syndrome-
related
lymphomas (ARL) seems to be similar to that for aggressive B-cell lymphomas in human immunodeficiency virus (HIV)-negative patients.
We evaluated the prognostic factors for response and survival in a series of HIV-infected patients with systemic
non
-
Hodgkin's lymphoma
(
NHL
) in the HAART era.
Forty patients with systemic
NHL
treated with a CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) and HAART were studied.
[MeSH-major]
Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / pathology. Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols.
Lymphoma
,
Non
-
Hodgkin
/ drug therapy.
Lymphoma
,
Non
-
Hodgkin
/ pathology
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Palliative Care of Patients with HIV
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISOLONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 1993 Sep 30;329(14 ):987-94
[
8141877.001
]
[Cites]
AIDS. 2001 Aug 17;15(12):1483-91
[
11504980.001
]
[Cites]
J Clin Oncol. 1999 Apr;17(4):1244
[
10561185.001
]
[Cites]
Biometrics. 1973 Sep;29(3):579-84
[
4793138.001
]
[Cites]
Blood. 2006 Jan 1;107(1):13-20
[
16099881.001
]
[Cites]
Ann Intern Med. 2005 Aug 16;143(4):265-73
[
16103470.001
]
[Cites]
N Engl J Med. 1997 Jun 5;336(23):1641-8
[
9171066.001
]
[Cites]
Blood. 2003 Jun 15;101(12):4653-9
[
12609827.001
]
[Cites]
Curr Opin Infect Dis. 2006 Feb;19(1):14-9
[
16374212.001
]
[Cites]
AIDS. 2003 Jul 4;17(10):1521-9
[
12824790.001
]
[Cites]
AIDS. 2002 Sep 27;16(14):1973-6
[
12351963.001
]
[Cites]
Leuk Lymphoma. 2002 Sep;43(9):1837-42
[
12685841.001
]
[Cites]
Blood. 2001 Dec 1;98(12):3406-12
[
11719381.001
]
[Cites]
Blood. 2005 Mar 1;105(5):1891-7
[
15550484.001
]
[Cites]
AIDS. 2000 Aug 18;14(12):1675-88
[
10985303.001
]
[Cites]
Leuk Lymphoma. 1995 Dec;20(1-2):91-6
[
8750628.001
]
[Cites]
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
[
1361652.001
]
[Cites]
Br J Haematol. 2001 Mar;112(4):909-15
[
11298585.001
]
[Cites]
Am J Med. 1993 Aug;95(2):188-96
[
7689296.001
]
[Cites]
Haematologica. 2003 Apr;88(4):445-53
[
12681972.001
]
[Cites]
Haematologica. 2005 May;90(5):704-6
[
15921395.001
]
[Cites]
Haematologica. 1998 Jun;83(6):508-13
[
9676023.001
]
[Cites]
Clin Infect Dis. 2004 Jan 1;38(1):142-4
[
14679461.001
]
[Cites]
Cancer Res. 1971 Nov;31(11):1860-1
[
5121694.001
]
[Cites]
J Clin Oncol. 2003 Dec 1;21(23):4423-7
[
14581441.001
]
[Cites]
J Clin Oncol. 2005 Nov 20;23(33):8477-82
[
16230675.001
]
(PMID = 18055341.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Japan
[Chemical-registry-number]
0 / Anti-Retroviral Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
67.
Corti M, Villafañe MF, Souto L, Schtirbu R, Narbaitz M, Soler Mde D:
Burkitt's lymphoma of the duodenum in a patient with AIDS.
Rev Soc Bras Med Trop
; 2007 May-Jun;40(3):338-40
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Burkitt's
lymphoma
of the duodenum in a patient with
AIDS
.
Non
-
Hodgkin's lymphoma
of B-cell type is the second most common neoplasm after Kaposi's sarcoma, among patients with human immunodeficiency virus infection.
Most
non
-
Hodgkin's lymphoma
cases that are associated with acquired immunodeficiency syndrome involve extranodal sites, especially the digestive tract and the central nervous system.
We report a case of primary
lymphoma
of the duodenum in a patient with
AIDS
.
A complete diagnostic study including histological, immunohistochemical and virological analyses showed high-grade B-cell Burkitt's
lymphoma
.
[MeSH-major]
Burkitt
Lymphoma
/ diagnosis. Duodenal Neoplasms / diagnosis.
Lymphoma
,
AIDS
-
Related
/ diagnosis
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - Burkitt's Lymphoma
.
MedlinePlus Health Information.
consumer health - Intestinal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17653472.001).
[ISSN]
0037-8682
[Journal-full-title]
Revista da Sociedade Brasileira de Medicina Tropical
[ISO-abbreviation]
Rev. Soc. Bras. Med. Trop.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Brazil
68.
Krause J:
AIDS-related non-Hodgkin's lymphomas.
Microsc Res Tech
; 2005 Nov;68(3-4):168-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
AIDS
-
related non
-
Hodgkin's
lymphomas.
This work reviews the current status of
non
-
Hodgkin's lymphoma
(
NHL
) in HIV infected patients.
HIV infection remains at significantly increased risk for the development of
NHL
.
A number of genetic abnormalities have been found but additional studies are necessary to understand the etiology and pathogenesis of
NHL
in the setting of HIV infection.
[MeSH-major]
Acquired Immunodeficiency Syndrome / complications.
Lymphoma
,
AIDS
-
Related
/ pathology.
Lymphoma
,
Non
-
Hodgkin
/ etiology
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2005 Wiley-Liss, Inc.
(PMID = 16276515.001).
[ISSN]
1059-910X
[Journal-full-title]
Microscopy research and technique
[ISO-abbreviation]
Microsc. Res. Tech.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
50
69.
Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M:
[Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients].
Acta Gastroenterol Latinoam
; 2006 Dec;36(4):190-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Non
-
Hodgkin's
lymphomas of the digestive tract and anexal glands in
AIDS
patients].
BACKGROUND:
Non
-
Hodgkin's lymphoma
(
NHL
) is the second most common neoplasm among patients with
AIDS
.
One of the major clinical characteristics of
AIDS
-associated
NHL
is the high frequency of extra-nodal involvement, including the gastrointestinal tract, at initial presentation.
METHODS: From January 1997 to December 2004, 8 cases of
NHL
of the digestive tract and anexal glands (liver and parotid gland) were observed at the HIV/
AIDS
division of the Infectious Diseases FJ Muñiz Hospital from Buenos Aires, Argentina.
No patient was receiving highly active antiretroviral therapy (HAART) at
lymphoma
diagnosis.
The global incidence of
AIDS
-associated lymphomas (central nervous system lymphomas,
non
-
Hodgkin
lymphomas and
Hodgkin
lymphoma
) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic
NHL
; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary
NHL
of high grade and "B" phenotype.
Primary duodenal
lymphoma
was the only Burkitt
lymphoma
of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic
lymphoma
.
CONCLUSION:
NHL
of the gastrointestinal tract is a severe complication of advanced HIV/
AIDS
disease.
[MeSH-major]
Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis.
Lymphoma
,
AIDS
-
Related
/ diagnosis.
Lymphoma
,
Non
-
Hodgkin
/ diagnosis. Parotid Neoplasms / diagnosis
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
HIV InSite.
treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17225446.001).
[ISSN]
0300-9033
[Journal-full-title]
Acta gastroenterologica Latinoamericana
[ISO-abbreviation]
Acta Gastroenterol. Latinoam.
[Language]
spa
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Argentina
70.
Gingues S, Gill MJ:
The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.
HIV Med
; 2006 Sep;7(6):369-77
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The impact of highly active antiretroviral therapy on the incidence and outcomes of
AIDS
-defining cancers in Southern Alberta.
OBJECTIVES: To determine the impact of highly active antiretroviral therapy (HAART) on the incidence and outcomes of Kaposi's sarcoma (KS),
non
-
Hodgkin's lymphoma
(
NHL
) and invasive cervical cancer/dysplasia in a well-defined geographical HIV-infected population between 1984 and 2005.
METHODS: A clinic database search, chart review and verification with public health records were undertaken for all
AIDS
-defining cancers diagnosed in Southern Alberta before and after the introduction of HAART.
One hundred and forty-three cases of KS, 64 cases of
NHL
and 11 cases of invasive cervical cancer/dysplasia were identified.
KS and
NHL
together accounted for 15% of clinical presentations with an
AIDS
-defining illness that led to the HIV diagnosis.
Following the introduction of HAART, the reduced number of severely immunocompromised patients was associated with 92 and 84% reductions in new diagnoses of KS and
NHL
, respectively, which were seen mainly in clinic patients declining or failing HAART.
Crude reductions of 94 and 65% in mortality from KS and
NHL
, respectively, were also seen.
The prevalences of KS,
NHL
and invasive cervical cancer/dysplasia have recently stabilized at 3, 1 and 5% of the population, respectively.
CONCLUSIONS: The introduction of HAART has dramatically reduced the incidence of KS and
NHL
and improved survival from these cancers for most patients in HIV care.
However, patients still present with KS and
NHL
leading to their HIV diagnosis.
[MeSH-major]
Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy.
Lymphoma
,
AIDS
-
Related
/ epidemiology.
Lymphoma
,
Non
-
Hodgkin
/ epidemiology. Sarcoma, Kaposi / epidemiology. Uterine Cervical Dysplasia / epidemiology. Uterine Cervical Neoplasms / epidemiology
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
MedlinePlus Health Information.
consumer health - Kaposi's Sarcoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16903981.001).
[ISSN]
1464-2662
[Journal-full-title]
HIV medicine
[ISO-abbreviation]
HIV Med.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
71.
Ho SF, Fink C, Murray PI:
Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma.
Ocul Immunol Inflamm
; 2005 Dec;13(6):471-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for
AIDS
-associated
lymphoma
.
The finding of Epstein Barr virus (EBV) DNA at a > 1-log greater concentration in the vitreous compared to blood raised the possibility of a primary CNS
non
-
Hodgkin's lymphoma
, which was subsequently confirmed on brain biopsy.
[MeSH-major]
DNA, Viral / genetics. Herpesvirus 4, Human / genetics.
Lymphoma
,
AIDS
-
Related
/ diagnosis
Genetic Alliance.
consumer health - AIDS-HIV
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Ophthalmic Manifestations of HIV
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16321894.001).
[ISSN]
0927-3948
[Journal-full-title]
Ocular immunology and inflammation
[ISO-abbreviation]
Ocul. Immunol. Inflamm.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / DNA, Viral
72.
Stern JI, Raizer JJ:
Primary central nervous system lymphoma.
Expert Rev Neurother
; 2005 Nov;5(6 Suppl):S63-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary central nervous system
lymphoma
.
Primary central nervous system
lymphoma
is a stage 1E
non
-
Hodgkin's lymphoma
confined to the nervous system.
Primary central nervous system
lymphoma
can affect the brain, leptomeninges, spinal cord or eyes.
[MeSH-major]
Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / therapy.
Lymphoma
/ pathology.
Lymphoma
/ therapy
[MeSH-minor]
Diagnostic Imaging / methods. Drug Therapy / methods. Expert Testimony. Humans.
Lymphoma
,
AIDS
-
Related
. Prognosis. Radiotherapy / methods. Salvage Therapy / methods. Stem Cell Transplantation / methods. Steroids / therapeutic use
Genetic Alliance.
consumer health - Central Nervous System Lymphoma, Primary
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Expert Rev Neurother. 2005 Nov;5(6 Suppl):1-2
[
16274264.001
]
(PMID = 16274272.001).
[ISSN]
1744-8360
[Journal-full-title]
Expert review of neurotherapeutics
[ISO-abbreviation]
Expert Rev Neurother
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Steroids
[Number-of-references]
76
73.
Visani G, Isidori A:
Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.
Expert Rev Anticancer Ther
; 2009 Mar;9(3):357-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nonpegylated liposomal doxorubicin in the treatment of B-cell
non
-
Hodgkin's lymphoma
: where we stand.
Anthracyclines, including doxorubicin, are widely used in the treatment of B-cell
non
-
Hodgkin's lymphoma
(
NHL
).
Nonpegylated liposomal doxorubicin produced a promising response rate when substituted for conventional doxorubicin in the cyclophosphamide, doxorubicin, vincristine and prednisolone regimen in the treatment of patients with
NHL
either at diagnosis or at relapse.
The ability of nonpegylated liposomal doxorubicin to overcome excessive drug efflux due to P-glycoprotein (MDR-1) overexpression in
NHL
might confer on this drug a curative potential for patients with a bad prognosis (e.g., MDR-1 overexpressing, the elderly or frail).
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage.
Lymphoma
, B-Cell / drug therapy
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Humans. Liposomes.
Lymphoma
,
AIDS
-
Related
/ drug therapy. Middle Aged. Prednisolone / administration & dosage. Vincristine / administration & dosage. Vincristine / therapeutic use
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISOLONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19275512.001).
[ISSN]
1744-8328
[Journal-full-title]
Expert review of anticancer therapy
[ISO-abbreviation]
Expert Rev Anticancer Ther
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Liposomes; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
[Number-of-references]
31
74.
Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, Klein D, Quesenberry CP Jr, Towner WJ, Abrams DI:
HIV infection and the risk of cancers with and without a known infectious cause.
AIDS
; 2009 Nov 13;23(17):2337-45
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Adult HIV-infected and matched HIV-uninfected members of Kaiser Permanente followed between 1996 and 2007 for incident
AIDS
-defining cancers (ADCs), infection-
related non
-
AIDS
-defining cancers (NADCs; anal squamous cell, vagina/vulva,
Hodgkin's lymphoma
, penis, liver, human papillomavirus-
related
oral cavity/pharynx, stomach) and infection-unrelated NADC (all other NADCs).
HIV-infected persons experienced 552 ADC, 221 infection-
related
NADC, and 388 infection-unrelated NADC.
HIV-uninfected persons experienced 179 ADC, 284 infection-
related
NADC, and 3418 infection-unrelated NADC.
The rate ratio for infection-
related
NADC was 9.2 (95% CI: 7.7-11.1), also with decreases in the rate ratio over time (P < 0.001).
These results were largely influenced by anal squamous cell cancer and
Hodgkin's lymphoma
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Prog Exp Tumor Res. 1970;13:1-27
[
4921480.001
]
[Cites]
AIDS. 2009 Jan 2;23(1):41-50
[
19050385.001
]
[Cites]
Lancet. 1998 Jun 20;351(9119):1833-9
[
9652666.001
]
[Cites]
AIDS. 1998 Aug 20;12(12):1459-64
[
9727566.001
]
[Cites]
J Natl Cancer Inst. 1999 Feb 3;91(3):226-36
[
10037100.001
]
[Cites]
AIDS. 1999 May 7;13(7):839-43
[
10357384.001
]
[Cites]
J Natl Cancer Inst. 2005 Mar 16;97(6):425-32
[
15770006.001
]
[Cites]
AIDS. 2009 Jan 28;23(3):385-93
[
19114864.001
]
[Cites]
HIV Clin Trials. 2009 May-Jun;10(3):153-9
[
19632954.001
]
[Cites]
J Hepatol. 2004 Jul;41(1):156-66
[
15246224.001
]
[Cites]
JAMA. 2001 Apr 4;285(13):1736-45
[
11277828.001
]
[Cites]
Int J Cancer. 2001 Dec 1;94(5):753-7
[
11745473.001
]
[Cites]
J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8
[
11744829.001
]
[Cites]
AIDS. 2002 May 3;16(7):993-1001
[
11953465.001
]
[Cites]
AIDS. 2002 May 24;16(8):1155-61
[
12004274.001
]
[Cites]
Clin Infect Dis. 2002 Oct 1;35(7):873-9
[
12228825.001
]
[Cites]
J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85
[
15220706.001
]
[Cites]
J Clin Oncol. 2006 Mar 20;24(9):1383-8
[
16549832.001
]
[Cites]
Int J Cancer. 2006 Jun 15;118(12):3030-44
[
16404738.001
]
[Cites]
Blood. 2006 Dec 1;108(12):3786-91
[
16917006.001
]
[Cites]
AIDS. 2007 Jan 11;21(2):207-13
[
17197812.001
]
[Cites]
Am J Epidemiol. 2007 May 15;165(10):1143-53
[
17344204.001
]
[Cites]
Clin Infect Dis. 2007 Jul 1;45(1):103-10
[
17554710.001
]
[Cites]
Lancet. 2007 Jul 7;370(9581):59-67
[
17617273.001
]
[Cites]
AIDS. 2007 Sep 12;21(14):1957-63
[
17721103.001
]
[Cites]
Curr Opin Oncol. 2007 Sep;19(5):446-51
[
17762569.001
]
[Cites]
Eur J Cancer. 2007 Sep;43(14):2117-23
[
17764927.001
]
[Cites]
J Clin Oncol. 2008 Feb 1;26(4):612-9
[
18235120.001
]
[Cites]
Int J Cancer. 2008 Jul 1;123(1):187-94
[
18435450.001
]
[Cites]
Ann Intern Med. 2008 May 20;148(10):728-36
[
18490686.001
]
[Cites]
AIDS. 2008 Jun 19;22(10):1203-11
[
18525266.001
]
[Cites]
Antivir Ther. 2008;13(3):455-60
[
18572759.001
]
[Cites]
Curr HIV/AIDS Rep. 2008 Aug;5(3):140-9
[
18627663.001
]
[Cites]
N Engl J Med. 1998 Apr 2;338(14):948-54
[
9521982.001
]
(PMID = 19741479.001).
[ISSN]
1473-5571
[Journal-full-title]
AIDS (London, England)
[ISO-abbreviation]
AIDS
[Language]
ENG
[Grant]
United States / NIAAA NIH HHS / AA / R01 AA016893; United States / NIAID NIH HHS / AI / K01 AI071725; United States / NIAID NIH HHS / AI / U01 AI069918-04; United States / NIAID NIH HHS / AI / K01 AI071725-03; United States / NIAID NIH HHS / AI / AI069918-04; United States / NIAID NIH HHS / AI / U01-AI069918; United States / NIAID NIH HHS / AI / K01AI071725; United States / NIAID NIH HHS / AI / AI071725-03; United States / NIAID NIH HHS / AI / U01 AI069918
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ NIHMS198381; NLM/ PMC2863991
75.
Kristinsson SY, Goldin LR, Björkholm M, Koshiol J, Turesson I, Landgren O:
Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.
Haematologica
; 2009 Nov;94(11):1581-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Genetic and immune-
related
factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.
There are data to support a role for genetic and immune-
related
factors in the pathogenesis of lymphomas and plasma cell diseases.
In this paper, we review our published large population-based studies and other relevant studies in
Hodgkin's
and
non
-
Hodgkin's
lymphomas, multiple myeloma, and the precursor condition monoclonal gammopathy of undetermined significance.
We discuss the overlap in risk factors between
related
malignancies and explore the underlying mechanisms.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Clin Pract Rheumatol. 2007 Oct;3(10):561-9
[
17906611.001
]
[Cites]
Blood. 2007 Nov 1;110(9):3326-33
[
17687107.001
]
[Cites]
Br J Haematol. 2007 Dec;139(5):717-23
[
18021086.001
]
[Cites]
Br J Haematol. 2007 Dec;139(5):762-71
[
18021089.001
]
[Cites]
Mayo Clin Proc. 2007 Dec;82(12):1468-73
[
18053453.001
]
[Cites]
Arthritis Rheum. 2008 Mar;58(3):657-66
[
18311836.001
]
[Cites]
Blood. 2008 Apr 1;111(7):3388-94
[
18239085.001
]
[Cites]
Blood. 2008 Apr 15;111(8):4029-38
[
18263783.001
]
[Cites]
J Natl Cancer Inst. 1993 Feb 17;85(4):307-11
[
8426374.001
]
[Cites]
Cancer Causes Control. 1993 Jul;4(4):361-8
[
8347786.001
]
[Cites]
Leukemia. 1993 Sep;7(9):1363-9
[
8371587.001
]
[Cites]
Cancer Res. 1994 May 1;54(9):2378-85
[
8162584.001
]
[Cites]
Scand J Immunol. 1994 Aug;40(2):195-200
[
8047841.001
]
[Cites]
J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8
[
7932824.001
]
[Cites]
J Clin Oncol. 1996 Jun;14(6):1943-9
[
8656264.001
]
[Cites]
J Rheumatol. 1996 Jun;23(6):1095-7
[
8782146.001
]
[Cites]
Eur J Cancer. 1996 Sep;32A(10):1753-7
[
8983286.001
]
[Cites]
Haematologica. 2005 Jan;90(1):66-71
[
15642671.001
]
[Cites]
Nat Rev Microbiol. 2005 Feb;3(2):182-7
[
15685227.001
]
[Cites]
Blood. 2005 Jul 15;106(2):668-72
[
15811955.001
]
[Cites]
J Med Genet. 2005 Jul;42(7):595-601
[
15994882.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6
[
16214923.001
]
[Cites]
Arch Intern Med. 2005 Nov 14;165(20):2337-44
[
16287762.001
]
[Cites]
Am J Epidemiol. 2005 Dec 15;162(12):1153-61
[
16251389.001
]
[Cites]
J Natl Cancer Inst. 2006 Jan 4;98(1):51-60
[
16391371.001
]
[Cites]
Blood. 2006 Feb 1;107(3):904-6
[
16210333.001
]
[Cites]
N Engl J Med. 2008 Jul 10;359(2):152-7
[
18614782.001
]
[Cites]
Lupus. 2008 Jul;17(7):613-4
[
18625632.001
]
[Cites]
Arch Intern Med. 2008 Sep 22;168(17):1903-9
[
18809818.001
]
[Cites]
Nat Genet. 2008 Oct;40(10):1204-10
[
18758461.001
]
[Cites]
Blood. 2008 Oct 15;112(8):3052-6
[
18703425.001
]
[Cites]
N Engl J Med. 2008 Oct 16;359(16):1734-5; author reply 1735
[
18923179.001
]
[Cites]
N Engl J Med. 2009 Feb 12;360(7):659-67
[
19213679.001
]
[Cites]
J Clin Oncol. 2009 Feb 20;27(6):904-10
[
19114699.001
]
[Cites]
Am J Med. 1985 Jan 21;78(1A):29-32
[
3970037.001
]
[Cites]
Br J Haematol. 1985 Jul;60(3):551-4
[
3925983.001
]
[Cites]
J Natl Cancer Inst. 1986 Aug;77(2):371-8
[
3461199.001
]
[Cites]
Br J Cancer. 1987 Jan;55(1):85-90
[
3814482.001
]
[Cites]
Cancer Res. 1987 Jun 1;47(11):2978-81
[
3567914.001
]
[Cites]
Leuk Res. 1988;12(1):81-8
[
3357350.001
]
[Cites]
Am J Pathol. 1988 Oct;133(1):173-92
[
2845789.001
]
[Cites]
Nouv Rev Fr Hematol. 1988;30(5-6):353-7
[
3222144.001
]
[Cites]
Am J Epidemiol. 1991 Jul 1;134(1):22-8
[
1853857.001
]
[Cites]
Cancer Causes Control. 1992 Jan;3(1):63-7
[
1536915.001
]
[Cites]
Haematologica. 2009 May;94(5):647-53
[
19286886.001
]
[Cites]
Int J Cancer. 2009 Jul 15;125(2):398-405
[
19365835.001
]
[Cites]
Br J Haematol. 2009 Jun;146(1):91-4
[
19438470.001
]
[Cites]
Blood. 2009 Jul 23;114(4):785-90
[
19179466.001
]
[Cites]
Blood. 2009 Jul 23;114(4):791-5
[
19182202.001
]
[Cites]
Haematologica. 2009 Aug;94(8):1179-81
[
19546435.001
]
[Cites]
Int J Cancer. 2009 Nov 1;125(9):2147-50
[
19582882.001
]
[Cites]
Hum Genet. 2000 May;106(5):553-6
[
10914686.001
]
[Cites]
Int J Cancer. 2000 Nov 1;88(3):497-502
[
11054684.001
]
[Cites]
Nat Immunol. 2001 Sep;2(9):793-5
[
11526388.001
]
[Cites]
Blood. 2001 Sep 15;98(6):1979-81
[
11535538.001
]
[Cites]
APMIS. 2001 Nov;109(11):797-800
[
11900061.001
]
[Cites]
Blood. 2002 Jun 1;99(11):3909-15
[
12010788.001
]
[Cites]
Arthritis Rheum. 2003 Apr;48(4):963-70
[
12687538.001
]
[Cites]
Blood. 2003 Nov 15;102(10):3759-64
[
12881316.001
]
[Cites]
Cancer. 2004 May 1;100(9):1902-8
[
15112271.001
]
[Cites]
Int J Cancer. 2004 Aug 10;111(1):76-80
[
15185346.001
]
[Cites]
Curr Opin Pharmacol. 2004 Aug;4(4):347-54
[
15251127.001
]
[Cites]
Blood. 2004 Sep 15;104(6):1850-4
[
15161669.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21
[
15342441.001
]
[Cites]
Blood. 1966 Apr;27(4):435-48
[
5327005.001
]
[Cites]
Nature. 1970 Dec 12;228(5276):1056-8
[
4320657.001
]
[Cites]
N Engl J Med. 1977 Feb 3;296(5):248-50
[
831107.001
]
[Cites]
Scand J Haematol. 1977 Oct;19(4):396-404
[
562530.001
]
[Cites]
Cancer. 1977 Nov;40(5):2094-101
[
336182.001
]
[Cites]
Acta Med Scand. 1982 May;211(3):237-9
[
6805257.001
]
[Cites]
J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7
[
1512794.001
]
[Cites]
Cancer Causes Control. 1992 Sep;3(5):449-56
[
1525326.001
]
[Cites]
Ann Oncol. 2006 Mar;17(3):488-94
[
16357024.001
]
[Cites]
Int J Cancer. 2006 Jun 15;118(12):3095-8
[
16395700.001
]
[Cites]
Blood. 2006 Jul 1;108(1):292-6
[
16527887.001
]
[Cites]
AIDS. 2006 Aug 1;20(12):1645-54
[
16868446.001
]
[Cites]
Semin Immunol. 2006 Oct;18(5):305-17
[
16916610.001
]
[Cites]
Am J Hum Genet. 2006 Oct;79(4):695-701
[
16960805.001
]
[Cites]
J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30
[
16985251.001
]
[Cites]
Haematologica. 2006 Dec;91(12):1697-700
[
17145609.001
]
[Cites]
Arthritis Rheum. 2006 Dec;54(12):3774-81
[
17133544.001
]
[Cites]
Int J Cancer. 2007 Mar 1;120(5):1099-102
[
17131330.001
]
[Cites]
Blood. 2007 Mar 1;109(5):2198-201
[
17082317.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4
[
17337646.001
]
[Cites]
Int J Cancer. 2007;120 Suppl 12:40-61
[
17405120.001
]
[Cites]
Int J Cancer. 2007;120 Suppl 12:1-39
[
17405121.001
]
[Cites]
JAMA. 2007 May 9;297(18):2010-7
[
17488966.001
]
[Cites]
Cell. 2007 Jul 13;130(1):25-35
[
17632054.001
]
[Cites]
Ann Oncol. 2007 Jul;18(7):1260-7
[
17426058.001
]
[Cites]
Expert Opin Pharmacother. 2007 Sep;8(13):2089-107
[
17714062.001
]
(PMID = 19586941.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
ENG
[Grant]
United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Italy
[Number-of-references]
93
[Other-IDs]
NLM/ PMC2770969
76.
Cheung MC, Pantanowitz L, Dezube BJ:
AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
Oncologist
; 2005 Jun-Jul;10(6):412-26
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
AIDS
-
related
malignancies: emerging challenges in the era of highly active antiretroviral therapy.
Human immunodeficiency virus (HIV)-infected patients are at increased risk of developing cancer, particularly in the later stages of acquired immune deficiency syndrome (
AIDS
).
Kaposi's sarcoma (KS) and
AIDS
-
related non
-
Hodgkin's lymphoma
(ARL) are the most common
AIDS
-defining malignancies.
AIDS
-
related
KS varies from minimal to fulminant disease.
Treatment decisions for
AIDS
-
related
KS are guided largely by the presence and extent of symptomatic disease.
Novel therapies that have become available to treat
AIDS
-
related
KS include angiogenesis inhibitors and antiviral agents.
HIV-infected patients also appear to be at increased risk for developing certain
non
-
AIDS
-defining cancers, such as
Hodgkin's lymphoma
and multiple myeloma.
Although the optimal treatment of these neoplasms is at present uncertain, recent advances in chemotherapy, antiretroviral drugs, and supportive care protocols are allowing for more aggressive management of many of the
AIDS
-
related
cancers.
This article provides an up-to-date review of the epidemiology, pathogenesis, clinical features, and treatment of various
AIDS
-
related
malignancies that are likely to be encountered by an oncologist practicing in the current HAART era.
[MeSH-major]
Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active.
Hodgkin
Disease / drug therapy.
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
,
Non
-
Hodgkin
/ drug therapy. Medical Oncology / trends. Sarcoma, Kaposi / drug therapy
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
MedlinePlus Health Information.
consumer health - Kaposi's Sarcoma
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15967835.001).
[ISSN]
1083-7159
[Journal-full-title]
The oncologist
[ISO-abbreviation]
Oncologist
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Number-of-references]
157
77.
Phatak UA:
Immune reconstitution inflammatory syndrome in AIDS-related non-hodgkin's lymphoma.
Indian J Med Paediatr Oncol
; 2009 Oct;30(4):153-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immune reconstitution inflammatory syndrome in
AIDS
-
related non
-
hodgkin's lymphoma
.
Immune Reconstitution syndrome following antiretroviral therapy is common in HIV/
AIDS
patients due to boosting of immunity.
A case is reported here wherein
AIDS
-
related Non
-
Hodgkin's lymphoma
patient received CHOP regimen and antiretroviral therapy.
HIV InSite.
treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20838562.001).
[ISSN]
0975-2129
[Journal-full-title]
Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
[ISO-abbreviation]
Indian J Med Paediatr Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Other-IDs]
NLM/ PMC2930308
[Keywords]
NOTNLM ; AIDS-related lymphoma / HIV-IRIS / IRIS
78.
Bongiovanni M, Cappelletti A, D'Arminio Monforte A, Bini T:
Cutaneous B-cells non-Hodgkin's lymphoma in a HIV-infected female.
Scand J Infect Dis
; 2005;37(1):78-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cutaneous B-cells
non
-
Hodgkin's lymphoma
in a HIV-infected female.
[MeSH-major]
HIV Infections / physiopathology.
Lymphoma
,
AIDS
-
Related
/ physiopathology. Skin / pathology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
HIV InSite.
treatment guidelines - Non-ARV Adverse Events
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15764197.001).
[ISSN]
0036-5548
[Journal-full-title]
Scandinavian journal of infectious diseases
[ISO-abbreviation]
Scand. J. Infect. Dis.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Sweden
79.
Corti M, Villafañe MF, Trione N, Schtirbu R, Narbaitz M:
Primary pulmonary AIDS-related lymphoma.
Rev Inst Med Trop Sao Paulo
; 2005 Jul-Aug;47(4):231-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary pulmonary
AIDS
-
related lymphoma
.
Extranodal involvement is common in lymphomas associated with human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (
AIDS
).
However, primary pulmonary
AIDS
-
related non
-
Hodgkin's lymphoma
is very rare and only few reports were published in the medical literature.
Primary pulmonary
lymphoma
associated with
AIDS
is generally a high-grade B-cell
non
-
Hodgkin
lymphoma
and Epstein-Barr virus is strongly associated with the pathogenesis of these tumors.
We report a patient with
AIDS
and primary pulmonary
lymphoma
which clinical presentation was a total atelectasis of the left lung.
[MeSH-major]
Lung Neoplasms / diagnosis.
Lymphoma
,
AIDS
-
Related
/ diagnosis. Pulmonary Atelectasis / etiology
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - Collapsed Lung
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16138208.001).
[ISSN]
0036-4665
[Journal-full-title]
Revista do Instituto de Medicina Tropical de São Paulo
[ISO-abbreviation]
Rev. Inst. Med. Trop. Sao Paulo
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Brazil
80.
Krentz HB, Kliewer G, Gill MJ:
Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.
HIV Med
; 2005 Mar;6(2):99-106
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
AIDS
deaths were reconciled with Public Health Reports.
In the pre-HAART era, 90% of all deaths were
AIDS related
whereas only 67% were
AIDS related
in the current HAART era.
The leading causes of
AIDS
deaths were
AIDS
multiple causes (31%), Mycobacterium avium complex (18%), Pneumocystis pneumonia (10%) and
non
-
Hodgkin's lymphoma
(7%).
The proportion of
non
-
AIDS related
deaths increased from 7% pre-HAART to 32% in the current HAART era.
Accidental deaths, including drug overdose (29%), suicide (7%) and violence (3%), hepatic disease (19%),
non
-
AIDS related
malignancies (19%), and cardiovascular disease (16%) accounted for the majority of
non
-
AIDS related
deaths.
A total of 14% of patients dying from
AIDS
were ARV-naive in contrast to 35% dying from
non
-HIV
related
conditions.
Of all those dying from
AIDS
, 23% died<3 months after their initial diagnosis, reflecting late presentation.
In the current HAART era, 87% of patients who died from
AIDS
were extensively treated, reflecting HAART treatment failures due mostly to multiclass drug resistance (42%), inexorable disease progression despite ARV (32%), lack of ability or interest to be maintained on a lifelong HAART programme (21%) and, rarely, drug intolerance (<1%).
CONCLUSIONS: Deaths from
AIDS
-
related
causes have decreased significantly, but deaths from
non
-
AIDS related
conditions have increased, both as an absolute number of deaths and as a proportion of all deaths in HIV-infected patients.
[MeSH-minor]
Acquired Immunodeficiency Syndrome / mortality. Alberta. Antiretroviral Therapy, Highly Active. Antiviral Agents / therapeutic use. Cause of Death / trends. Disease Progression. Drug Resistance, Multiple, Viral. Humans.
Lymphoma
,
Non
-
Hodgkin
/ mortality.
Lymphoma
,
Non
-
Hodgkin
/ virology. Mycobacterium avium-intracellulare Infection / mortality. Mycobacterium avium-intracellulare Infection / virology. Pneumonia, Pneumocystis / mortality. Pneumonia, Pneumocystis / virology. Socioeconomic Factors. Substance Abuse, Intravenous. Treatment Refusal
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Mycobacterium avium Complex and Atypical Mycobacterial Infections in the Setting of HIV Infection
.
HIV InSite.
treatment guidelines - Coinfection with Hepatitis Viruses and HIV
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15807715.001).
[ISSN]
1464-2662
[Journal-full-title]
HIV medicine
[ISO-abbreviation]
HIV Med.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antiviral Agents
81.
Lanjewar DN, Dongaonkar DD:
HIV-associated primary non-Hodgkin's lymphoma of ovary: a case report.
Gynecol Oncol
; 2006 Sep;102(3):590-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HIV-associated primary
non
-
Hodgkin's lymphoma
of ovary: a case report.
BACKGROUND: Although there have been few case series of primary
non
-
Hodgkin's lymphoma
(
NHL
) of ovary, no patient with
AIDS
-
related
primary ovarian
lymphoma
has been described in the literature.
CASE: We report a case of human immunodeficiency virus infected female with primary ovarian
NHL
for which she could not receive standard
NHL
combination chemotherapy and standard HIV highly active antiretroviral therapy (HAART) and succumbed to death within 7 months after diagnosis.
CONCLUSIONS: Primary ovarian
lymphoma
is rare as compared with other ovarian tumors and has similar presentation to other common ovarian malignancies.
The patients from developing countries cannot afford standard
NHL
combination chemotherapy and HAART as these drugs are expensive and are not provided freely to all patients, in state government run public hospitals.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ diagnosis.
Lymphoma
,
Non
-
Hodgkin
/ complications. Ovarian Neoplasms / complications
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16697449.001).
[ISSN]
0090-8258
[Journal-full-title]
Gynecologic oncology
[ISO-abbreviation]
Gynecol. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
82.
Keszler A, Piloni MJ, Paparella ML, Soler Mde D, Ron PC, Narbaitz M:
Extranodal oral non-Hodgkin's lymphomas. A retrospective study of 40 cases in Argentina.
Acta Odontol Latinoam
; 2008;21(1):43-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Extranodal oral
non
-
Hodgkin's
lymphomas. A retrospective study of 40 cases in Argentina.
A retrospective study was conducted of extranodal oral
Non
-
Hodgkin's
Lymphomas diagnosed at the Surgical Pathology Laboratory of the School of Dentistry at Buenos Aires University, Argentina, between 1985 and 2004.
The most common histological type was Diffuse Large Cell
Lymphoma
.
[MeSH-major]
Jaw Neoplasms / pathology.
Lymphoma
, B-Cell / pathology.
Lymphoma
,
Non
-
Hodgkin
/ pathology. Mouth Neoplasms / pathology
[MeSH-minor]
Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Argentina. Child. Child, Preschool. Female. Humans.
Lymphoma
,
AIDS
-
Related
/ pathology. Male. Middle Aged. Retrospective Studies. Sex Distribution. Young Adult
MedlinePlus Health Information.
consumer health - Oral Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18841745.001).
[ISSN]
0326-4815
[Journal-full-title]
Acta odontológica latinoamericana : AOL
[ISO-abbreviation]
Acta Odontol Latinoam
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Argentina
83.
Foschi D, Rizzi A, Corsi F, Trabucchi E, Corbellino M:
Chylous ascites secondary to B-cell non Hodgkin's lymphoma in a patient with the acquired immune deficiency syndrome (AIDS).
Dig Liver Dis
; 2008 Jun;40(6):481-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chylous ascites secondary to B-cell
non Hodgkin's lymphoma
in a patient with the acquired immune deficiency syndrome (
AIDS
).
In the present article we describe a patient with
AIDS
and chylous ascites secondary to B-cell
non Hodgkin's lymphoma
.
The final pathology report was of diffuse, CD20-positive, CD3-negative, Epstein Barr Virus-negative, large B-Cell
non Hodgkin's lymphoma
.
Five months after the initial diagnosis of
lymphoma
, the patient relapsed and was treated with high-dose BEAM (carmustine, etoposide, cytosine, arabinoside, melphalan) chemotherapy followed by CD34 stem-cell transplantations salvage therapy.
[MeSH-major]
Acquired Immunodeficiency Syndrome / complications. Chylous Ascites / etiology.
Lymphoma
,
AIDS
-
Related
/ complications.
Lymphoma
, B-Cell / complications
Genetic Alliance.
consumer health - Chylous Ascites
.
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17997372.001).
[ISSN]
1878-3562
[Journal-full-title]
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
[ISO-abbreviation]
Dig Liver Dis
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Netherlands
84.
Jablonowski H:
[Diagnostics of the HIV infection].
MMW Fortschr Med
; 2005 Apr 25;147 Spec No 1:5-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Above all, the presence of
non
-
Hodgkin's lymphoma
is characteristic of the complete clinical picture of
AIDS
.
[MeSH-major]
AIDS
Serodiagnosis. HIV Infections / diagnosis
[MeSH-minor]
AIDS
-
Related
Opportunistic Infections / diagnosis. Diagnosis, Differential. Early Diagnosis. Germany. HIV Seroprevalence. Humans
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16385861.001).
[ISSN]
1438-3276
[Journal-full-title]
MMW Fortschritte der Medizin
[ISO-abbreviation]
MMW Fortschr Med
[Language]
ger
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Germany
85.
Navarro JT, Vall-Llovera F, Mate JL, Morgades M, Feliu E, Ribera JM:
Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART.
Haematologica
; 2008 Jan;93(1):149-50
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Decrease in the frequency of meningeal involvement in
AIDS
-
related
systemic
lymphoma
in patients receiving HAART.
We evaluated the frequency of primary central nervous system
lymphoma
and leptomeningeal involvement in systemic
non
-
Hodgkin's lymphoma
(
NHL
) in HIV-infected patients.
Those receiving highly active antiretroviral therapy (HAART) showed a decrease in leptomeningeal involvement in systemic
NHL
(0/30 vs. 12/87; p=0.023).
Therefore HAART could prevent CNS involvement in systemic
NHL
.
[MeSH-major]
Acquired Immunodeficiency Syndrome / diagnosis. Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active.
Lymphoma
,
AIDS
-
Related
/ diagnosis.
Lymphoma
,
AIDS
-
Related
/ prevention & control. Meninges / pathology
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18166804.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Letter; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
86.
Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R:
Cancer biomarkers in HIV patients.
Curr Opin HIV AIDS
; 2010 Nov;5(6):531-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PURPOSE OF REVIEW: In this review, we update investigations
related
to cancer biomarkers in HIV-infected populations.
RECENT FINDINGS: CD4 lymphocyte count is associated with primary central nervous system
lymphoma
(PCNSL), systemic
non
-
Hodgkin's lymphoma
(
NHL
) (except perhaps for Burkitt
lymphoma
), Kaposi's sarcoma, cervical cancer, and anal cancer.
HIV load is associated with Burkitt
lymphoma
and systemic
NHL
(but not PCNSL), with Kaposi's sarcoma and with anal cancer.
CD40 ligand incorporated into the HIV envelope and expression of activation-induced cytidine deaminase may help explain the relationship between HIV load and Burkitt
lymphoma
.
Genetic polymorphisms have been identified that are linked to
lymphoma
in HIV patients.
B-cell activation as manifest in immunoglobulin light chain production may be an important marker for
NHL
risk.
Cytokines and
related
molecules (IL10, sCD30) may identify patients at high risk for
NHL
.
EBV and Kaposi's sarcoma-associated herpesvirus (KSHV) have not yet emerged as especially promising markers of risk for either
lymphoma
or Kaposi's sarcoma.
SUMMARY: CD4 lymphocyte count, HIV load, germline genetic polymorphisms, cytokine and
related
molecules, and immunoglobulin light chains all show increasing promise as biomarkers of malignancy in HIV patients.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
AIDS. 2000 Jan 28;14(2):133-40
[
10708283.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84
[
10566552.001
]
[Cites]
Clin Immunol. 2003 Nov;109(2):119-29
[
14597210.001
]
[Cites]
J Clin Oncol. 2004 Jun 1;22(11):2177-83
[
15169806.001
]
[Cites]
Clin Infect Dis. 2004 Nov 1;39(9):1396-7; author reply 1397-8
[
15494920.001
]
[Cites]
Blood. 1999 Mar 15;93(6):1838-42
[
10068655.001
]
[Cites]
Cancer Res. 1999 Aug 1;59(15):3561-4
[
10446961.001
]
[Cites]
Clin Immunol. 1999 Sep;92(3):293-9
[
10479534.001
]
[Cites]
Gynecol Oncol. 2005 Mar;96(3):760-4
[
15721423.001
]
[Cites]
Tumour Biol. 2006;27(4):187-94
[
16651853.001
]
[Cites]
J Clin Virol. 2006 Aug;36(4):258-63
[
16762591.001
]
[Cites]
Blood. 2006 Dec 1;108(12):3786-91
[
16917006.001
]
[Cites]
Int J Infect Dis. 2007 Mar;11(2):172-8
[
16931088.001
]
[Cites]
Clin Infect Dis. 2007 Jul 1;45(1):103-10
[
17554710.001
]
[Cites]
J Natl Cancer Inst. 2007 Jun 20;99(12):962-72
[
17565153.001
]
[Cites]
PLoS Med. 2007 Mar 27;4(3):e96
[
17388662.001
]
[Cites]
J Clin Virol. 2008 Aug;42(4):433-6
[
18455472.001
]
[Cites]
J Clin Oncol. 2009 Feb 20;27(6):884-90
[
19114688.001
]
[Cites]
J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):427-9
[
19322036.001
]
[Cites]
PLoS One. 2009;4(4):e5360
[
19390683.001
]
[Cites]
J Clin Oncol. 2009 May 20;27(15):2496-502
[
19349542.001
]
[Cites]
Haematologica. 2009 Jun;94(6):875-80
[
19336735.001
]
[Cites]
J Infect Dis. 2009 Jul 1;200(1):79-87
[
19476437.001
]
[Cites]
Blood. 2009 Jun 4;113(23):5737-42
[
19336755.001
]
[Cites]
J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30
[
19648510.001
]
[Cites]
Blood. 2009 Sep 10;114(11):2354; author reply 2354-5
[
19745076.001
]
[Cites]
Blood. 2009 Sep 24;114(13):2730-2
[
19638620.001
]
[Cites]
J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22
[
19770804.001
]
[Cites]
Lancet Oncol. 2009 Dec;10(12):1152-9
[
19818686.001
]
[Cites]
Am J Epidemiol. 2010 Feb 1;171(3):267-76
[
20047977.001
]
[Cites]
J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9
[
19654554.001
]
[Cites]
Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91
[
19835968.001
]
[Cites]
J Clin Oncol. 2010 Feb 10;28(5):773-9
[
20048176.001
]
[Cites]
Leuk Lymphoma. 2010 Mar;51(3):497-506
[
20038229.001
]
[Cites]
J Clin Oncol. 2010 Mar 20;28(9):1514-9
[
20177022.001
]
[Cites]
AIDS. 2010 Apr 24;24(7):1025-33
[
20299965.001
]
[Cites]
Cancer Causes Control. 2010 May;21(5):759-69
[
20087644.001
]
[Cites]
J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84
[
20418723.001
]
[Cites]
Sex Transm Dis. 2010 May;37(5):311-5
[
20065890.001
]
[Cites]
J Natl Cancer Inst. 2010 Jun 2;102(11):784-92
[
20442214.001
]
[Cites]
BMC Cancer. 2010;10:278
[
20537184.001
]
[Cites]
Clin Infect Dis. 2010 Aug 1;51(3):342-9
[
20572760.001
]
[Cites]
PLoS One. 2010;5(7):e11448
[
20625427.001
]
[Cites]
Blood. 2000 Oct 15;96(8):2730-4
[
11023505.001
]
(PMID = 20978397.001).
[ISSN]
1746-6318
[Journal-full-title]
Current opinion in HIV and AIDS
[ISO-abbreviation]
Curr Opin HIV AIDS
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U01 CA121947-05; United States / NCI NIH HHS / CA / CA096888-05S2; United States / NCI NIH HHS / CA / UO1 CA 121947; United States / NCI NIH HHS / CA / P50 CA096888-05S2; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
[Other-IDs]
NLM/ NIHMS274983; NLM/ PMC3055562
87.